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1. INTRODUCTION
1.1. Back ground of the proposed work
Kidney receives rich blood flow of 525 mL/min and plays a prominent role in the
filtration, concentration, excretion and detoxification of drug, chemicals or their
metabolites.  This makes kidney, a major organ vulnerable to drug-related toxic responses
and also become a routinely assessed organ during the preclinical safety evaluations or in
toxicological studies. Drug-induced kidney injury is a common condition present even
among the infants, young children, often require multiple interventions, hospitalization
and exert financial burden.1 Previous literature has prescribed that the concurrent
administration of nephroptotective herbal drugs along with different nephrotoxic agents
may reduce its toxicity.2 Several research studies have proved that various chemical and
natural substances with antioxidant activity reduce the toxic response of drug having
nephrotoxic potential and  enhance its efficacy.3
1.2. The Kidney
1.2.1. Structure of the kidney
Adult human kidney weighs about 160 g, 11.25 cm long, 2.5 cm thick and 5.5-7.7
cm wide. This retroperitoneal organ are paired, bean shaped, reddish brown, located  at
the level of the twelfth thoracic and third lumbar vertebrae on either sides of the vertebral
column. It is protected by three layers of tissue.  These layers consists of (1) renal
capsule, an innermost strong fibrous layer which protects kidney from shock and
infections  (2)  the adipose capsule, middle layer of  fatty tissue which keeps kidney in
right position (3) the renal fascia, outermost fibrous connective tissue which bind kidney
with the abdominal wall. Cut surface of a bisected kidney shows two anatomically
Introduction
Page 2
distinct regions: the pale outer region called renal cortex and the inner dark region known
as renal medulla. 4, 5
Figure 1: Structure of kidney & nephron
Table 1:  Kidney structure and functions based on different parts
Parts of the kidney Functions
Hilus Renal vein and ureter exit and the renal artery enters the kidney
Renal capsule Maintain the kidney's shape and  protect the kidney from damage
Renal cortex Bowman's capsules, glomeruli, proximal and distal convoluted tubules
and blood vessels are found.
Renal medulla Loop of Henle  and collecting ducts are found
Renal  pyramids Transport urine from the cortical or outer part of the kidney where urineis produced to the calyces in which urine collects.
Renal pelvis Receives urine drained from the nephrons through the collecting ducts
and papillary ducts
Renal artery Blood vessel that carry oxygen-rich blood to the kidney
Renal vein Blood vessel that collects deoxygenated blood from the kidney
Interlobular artery Blood vessel that delivers oxygen-rich blood to the glomerular
capillaries
Interlobular vein Blood vessel that receives deoxygenated blood from the glomeruli andthe loops of Henle
Nephrons Functional units where the kidney's main functions are performed
Collecting duct Collects urine and drains finally into the ureter and urinary bladder
Ureter Structure which conveys urine from the kidney to the urinary bladder.
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1.2.2. Functions of the kidney
Table 2:  Major functions of the kidney6
Basic functions  of kidney
Excretory
functions
Excretion of nitrogenous waste products of protein metabolism
Excretion of most drugs or toxins
Regulation of extracellular fluid volume and blood pressure by altering
sodium excretion.
Regulation of osmolality by altering water excretion
Regulation of plasma electrolyte concentration within normal range
Regulation of  plasma pH by eliminating excess hydrogen and
bicarbonate ions
Non-excretory
functions
Synthesis and activation of hormones
Erythropoietin which stimulate red blood cell synthesis by bone marrow
Renin which control blood pressure, salt and water balance.
Prostaglandins which act as vasodilators and prevent renal ischemia.
1,25-dihydroxyvitamin D3, potent form of vitamin D which maintain
bone health
Degradation of polypeptide hormones
Antidiuretic hormone, gastrin, glucagon, growth hormone, insulin,
parathormone, prolactin, vasoactive intestinal poly peptide
1.3. Nephrotoxicity
Kidney plays a prominent role in the metabolism and excretion of many
exogenously administered drugs, diagnostic agents and their metabolites. Nephrotoxins
are drugs or chemicals that produce toxic effect on kidney.7, 8 Through renal arteries
nephrotoxins reach the functional units of kidney known as nephrons.  Hence cells of
nephrons are more susceptible to drug related toxic responses as it is exposed to high
concentration of drug and metabolites. Previous research studies have reported that the
acute kidney injury have been a serious adverse effect of various drugs, compounds used
in industries and diagnostic agents like radio contrast media.9
Kidney injury associated with certain drug administration may cause either
cumulative dose-dependent toxicity or idiosyncratic dose-independent toxicity. The
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morphological examination of the kidney biopsy due to nephrotoxic insult exhibited
alterations in the normal structures of the nephron, indicating damage to the renal
infrastructure. Drug induced renal failure can be further classified based upon the renal
compartments principally affected with toxicity as acute tubular necrosis, interstitial
nephritis, glomerulonephritis, renal vascular damage and intrarenal obstruction. Acute
tubular necrosis is the most common form of intrarenal failure associated with prolonged
exposure of kidney to nephrotoxin or due to ischaemia, sepsis, diabetes and
artherosclerosis.10 Interstitial nephritis is related with nephrotoxin-induced
hypersensitivity reaction or inflammation affecting interstitium. Common cause of
glomerular nephritis is inflammatory response due to the deposition of immune
complexes (exogenous or endogenous antigens) in glomerulus.11 Damage to the visceral
layer of the Bowman’s capsule-podocytes may cause a disorder known as nephritic
syndrome, which further leads to glomerulonephritis. Occlusion of renal artery or vein
also causes alterations in intrarenal vasculature. Deposition of debris provoke intrinsic
renal damage.
Lithium chloride, usually indicated for psychotic disturbances like bipolar
disorder causes nephrogenic diabetes insipidus, due to the decreased expression of
aquaporin-2 channels on the apical surfaces of the proximal convoluted tubule. The
prolonged administration of lithium containing drugs also promote development of
chronic tubular interstitial nephritis and tubular microcysts. Most of the analgesics are
available in combination dosage forms. The large cumulative doses of analgesics may
lead to a more serious form of nephrotoxicity known as analgesic nephropathy. Pre-renal
failure also occurs due to diminished cardiac output related to heart diseases and
Introduction
Page 5
alterations in fluid volume distribution associated with sepsis or burns.12 Urolithiais,
prostatic hypertrophy, blood clots and neoplasm are the various mechanism associated
with obstruction of urinary tract resulting in post renal failure. Certain nephrotoxic drugs
induce tubular injury, interstitial inflammation and obstruction due to the formation of
crystal like substances in the kidney. Most common type is calcium-containing stones
(75-90%), followed by magnesium ammonium phosphate or struvite stones (10-15%),
uric acid crystals (3-10%) and cystine stones (0.5-1%).  Other types of stones include
silicate stones, protease related stones and dihydroxy adenine crystals.13
1.3.1. Epidemiology of drug induced nephrotoxicity
Drug-induced acute kidney injury accounted for 20% of all acute renal failure
cases in an Indian study.14 Prospective cohort studies have reported that the incidence
of drug related kidney toxicity is about  14-16% of adult population.15,16
Nephrotoxicity linked with the administration of aminoglycoside  antibiotics elevated
from 3% in 1969 to 10-20%  in 2010.9,17 Another study reported that 27 million
persons are suffering from chronic kidney disease. Drastic increase in drug related
nephrotoxicity (about 30%) has been observed over the last 10 years.18 Drug related
renal injury is a common condition present even in children and estimated about 16%
of hospitalized acute renal failure events.19 Incidence and prevalence of chronic
kidney disease and end-stage renal disease is dramatically increasing globally.20
Kidney stones is a painful disorder and still it remain as common worldwide problem.
Recurrent rate is high, more than 50% in 5-10 years. It is accounted that 12% of the
world population is affected by kidney stones and male/female ratio is 3:1. Relapse
rate is more in male (70 to 80%) than in females (47 to 60%).21
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1.3.2. Etiology
Various factors are involved which enhance the drug induced nephrotoxicty. An
easiest approach to know about the vulnerability of kidney nephrotoxins entails the
classification of risk factors into three major categories  as patient-specific, kidney-
related, and drug-related factors. Usually, more than one risk factors are involved in drug
related renal injury affecting all renal compartments and cause one or more renal
syndromes.
Table 3: Risk factors of drug induced nephrotoxicity
Major  risk factors of drug induced nephrotoxicity22
Patient-related
factors
Sex- female
Age - children and age over 65 years
Co-morbidities and polypharmacy
Volume depletion
Reduced glomerular filtration rate
Increased  proximal tubular toxin reabsorption
Decreased distal tubular urine flow rates
Metabolic perturbations
Alkaline or acid urine pH
Immune  response genes
Gene mutations in hepatic and renal P450 system
Gene mutations in renal transporters and transport proteins
Acute/Chronic kidney disease
Nephrotic syndrome
Cirrhosis/obstructive jaundice
Kidney-related
factors
High perfusion rate
Enhanced toxin level
Biotransformation of substances to reactive oxygen species
Elevated  metabolic rate of tubular cells
Proximal  tubular absorption of toxins
Drug-related
factors
Prolonged dosing periods
Potent  direct nephrotoxic effects of the drug or compound
Combinations of toxins/drugs promoting enhanced nephrotoxicity
Competition between endogenous and exogenous toxins for
transporters
Increasing  toxin accumulation within the tubular cell
Intratubular crystal precipitation of insoluble parent compound or
metabolite.
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Table 4:  Risk factors of drug induced urolithiasis
Major  risk factors of drug-induced urolithiasis 23
Patient-related
factors
Sex- Male
Age-age over 40 years
Co-morbidities and polypharmacy
Family history
Volume depletion
High concentration of minerals and chemicals within the urine
Living  in warm climate
Drinking  insufficient amount of water or excess sweating
High dietary intake of animal protein, sodium, refined sugars,
fructose
High body mass index (BMI), large waist size and weight gain
Alkaline or acid urine pH
Increased  calculi-induced  toxin reabsorption
Hyperparathyroidism, hypercalcemia and hyperuricosuria
Insulin resistant states,  surgical menopause,  history of gout,
urinary tract infections, cystic fibrosis, hypertension, gastric
bypass surgery, inflammatory bowel disease or chronic
diarrhoea, Crohn's disease
Kidney-related
factors
High perfusion rate
Enhanced drug level which induce calculi
Biotransformation of substances to reactive oxygen species
Decreased  urine volume
Increased  excretion of stone-forming components
Changes  in the acid-base balance (pH)
Decrease  in urinary citrate levels
Excess  vitamin D, deficiency of vitamins A or C
Intratubular  crystal precipitation of  insoluble  dug or metabolite
Drugs-related
factors
Prolonged dosing periods
Combinations of toxins/drugs promoting kidney stone formation
Increase  toxin accumulation within the tubular cell
Urinary supersaturation of drug or its metabolite
Drug-Induced metabolic calculi
1.3.3. Mechanism of drug induced nephrotoxicity
Most of the drug exert nephrotoxicity through more than one pathogenic
mechanism but some drugs exert toxicity through direct effect or their accumulation in
renal tubule.24 Renal blood flow is  disproportionately higher in renal cortex (90%)
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compared to renal medulla (6-10%) or papillae (1-2%), hence concentration of blood
borne toxins are more in this region. Mechanism involved in urine formation and
reabsorption process of nephron also promote accumulation of nephrotoxins and often
causes precipitation of poorly soluble substances. High permeability and active transport
increase the possibility of drug accumulation in proximal tubule of kidney than in the
distal tubular region.5, 25 Therefore, most  research works related to drug induced kidney
injury is focusing mainly on proximal tubular part of kidney.26 Sometimes, kidney
metabolically convert protoxicants to nephrotoxicants.4
Changes in glomerular hemodynamics, tubular cell toxicity, inflammation, crystal
nephropathy, rhabdomyolysis, and thrombotic microangiopathy are the general
mechanisms leading to renal dysfunction following the exposure to nephrotoxins.27, 28
Kidney  maintain constant glomerular filteration rate (120 mL per min) and urine output
by adjusting intraglomerular pressure and regulating blood flow in afferent and efferent
arteries Prolonged administration of nonsteroid anti-inflammatory drugs (anti-
prostaglandin drugs)  angiotensin converting enzyme inhibitors, angiotensin receptor
blockers may induce changes in glomerular hemodynamics and thereby induce toxicity in
glomerulus.29.
Proximal tubular cell toxicity is associated with mitochondrial damage, disturbed
tubular transport system and oxidative stress by free radical generation.30 Gentamicin
(aminoglycoside antibiotics), cisplatin and foscarnet (anticancer) drugs, amphotericin B
(antifungal agents), adefovir (anti-retroviral) are the common drugs which induce tubular
cell toxicity.26,30
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Certain nephrotoxic drug often produce inflammation in the kidney tissue
inducing acute interstitial nephritis, chronic interstitial nephritis or/and
glomerulonephritis. Gold, penicillin, phenytoin are certain drugs which induce
inflammation in glomerulus (glomerulonephritis). Prolonged use of non-steroid anti-
inflammatory drugs and rifampicin may induce acute interstitial nephritis, where as
administration of calcineurin inhibitors, lithium, anticancer drugs or analgesics causes
chronic interstitial nephritis.31, 32
Administration  of certain drugs  ampicillin (antibiotics), acyclovir (antiviral
agents)  or chemicals (ethylene glycol) cause crystal nephropathy (crystallisation of stone
forming constituents in human urine).26,30 Alcoholism  or prolonged intake of  heroin,
methadone, methamphetamine and statins  induce rhabdomyolysis or disintergration of
renal muscle cell which causes release of myoglobin and serum creatine kinase into the
blood.33
Some drugs including cyclosporin, mitomycin-C and quinine have potential to
induce drug-induced thrombotic microangiopathy through inflammation or direct toxic
effect in renal epithelial cells.34
1.3.3.1. Gentamicin-induced nephrotoxicity
Degree of renal damage varies from one drug to another. Gentamicin (GM) is a
typical aminoglycoside antibiotic which provides an effective treatment against life-
threatening infections caused by gram-negative organisms.35 However, it has been
reported that nephrotoxicity was observed in 30% of patients treated with GM, for more
than 7 days.36 Possibility of developing nephrotoxicity increases with duration of therapy,
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as 50% of patient treated with genatmicin for more than 14 days exhibited acute kidney
injury symptoms.37 GM-induced nephrotoxicity related to the clinical features of acute
tubular necrosis such as proximal tubular dysfunction, enzymuria, proteinuria, glycosuria,
hypokalemia, hypocalcemia and hypomagnesemia. Still this drug is widely used because
of its low cost and efficacy, even though less nephrotoxic antibiotics are available.38
The usual dose of aminoglycoside antibiotic like gentamicin is less than 80 to 100 mg/kg
for about 5 days.  At physiological pH, this aminoglycoside antibiotic become highly
charged, water soluble and impermeable through biological membranes. These factors
causes the accumulation of high amount of drug in the renal cortex,39 then  filtered
through glomeruli, reabsorbed actively via lysosomes in the brush border membrane of
proximal tubular cells resulting in the formation of myeloid bodies/secondary lysosomes.
The gentamicin drug molecules enter the tubular cells by absorptive/ receptor mediated
endocytosis after binding to acidic phospholipids and megalin receptors. Rats
administered even with less and therapeutic doses of gentamicin exhibited
phospholipidosis and apoptosis in proximal tubular cells.40 Prolonged administration of
gentamicin causes alterations in structural architecture of lysosomes, followed by the
release of lysosomal enzymes from the proximal convoluted tubule. This also causes
lowering absorption of protein, electrolytes (potassium, magnesium, calcium, sodium),
phospholipid urea, fall in creatinine clearance, glucose wasting, and appearance of casts
(solidification of protein) in the urine.41
The histopathological examination of the kidney tissue exposed to gentamicin in
animals exhibited signs of focal necrosis and apoptosis in the tubular epithelium. This
supports that the aminoglycoside exerts its toxicity due to its high concentration in the
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tissues. Metabolic alterations are observed within the tubular cells due to the
accumulation and release of excess aminoglycosides from the lysosomes. This causes
lipid peroxidation, decreased rate of mitochondrial respiration or cell death.42
The aminoglycoside released from lysosomes of the tubular cells act indirectly as
nephrotoxic. GM-induced hydrogen peroxide production causes the release of iron from
mitochondrial membranes. The gentamicin chelates with iron forming oxidant molecule,
the ferric-gentamicin complex which causes necrosis of tubular hair cells in the proximal
convoluted tubule.  The changes in the sodium-glucose symporters and sodium-hydrogen
antiporters in tubular cells of  the nephrons is mainly due to fluidity of the membrane
caused by gentamicin. Gentamicin also causes the direct inhibition on sodium-potassium-
ATPase of proximal convoluted tubule.41
1.3.3.2. Cisplatin-induced nephrotoxicity
Cisplatin is chemically known as cis-diamine dichloro platinum  (II), CDDP. It is
the  most potent, highly  effective and currently available alkylating agent used in the
treatment of solid tumours like breast cancer, head cancer, neck cancer, testes and ovarian
cancers etc.43 However, clinical  utilization of this heavy metal complex is restricted due
to the adverse reactions including ototoxicity, gastrotoxicity, myelosuppression, allergic
reaction and nephrotoxicity.44 Cisplatin induced nephrotoxicity occurs in about 20-30%
of patients.45 Factors which promote cisplatin induced nephrotoxicity include high
perfusion rate, drug uptake of free-form cisplatin in the proximal kidney tubule,
metabolism and disproportionate accumulation of platinum concentrations in the kidneys
greater than other organs.46 Major clinical manifestations of cisplatin induced
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nephrotoxicity include erythropoietin deficiency, proteinuria, renal salt wasting,
hyperuricemia, renal concentrating defect, hypocalcemia, hypomagnesemia and
hypokalemia.
Through glomeruli cisplatin enter the tubular lumen of the nephron either by
passive process or facilitated transport mechanism. Cisplatin administration may
precipitate acute renal failure as it causes vasoconstriction of afferent arterioles, leading
to the decreased blood flow to the Bowman’s capsule. Cisplatin stimulates various
signaling pathways (mitogen-activated protein kinase, tumor protein p53, reactive oxygen
species) of the tubular cells and induces  tumor necrosis factor-alpha formation  which
leads to inflammatory response, tubular cell injury or necrosis. The intrinsic
mitochondrial and extrinsic death receptor may also gets activated which further leads to
caspase-dependent  or  independent apoptosis.  Inequilibrium between cyclin-dependent
kinase (CDK2) or cyclin-dependent kinase inhibitor proteins (p21) is the major causative
factor which induce cell apoptosis and acute renal failure. Cisplatin administration
causes  induction  of inhibitory protein p21 and the activation of CDK2 protein which
results in renal tubular cell toxicity. DNA injury stimulate ATR  (ataxia telangiectasia
and Rad3-related protein) which leads to stimulation of inhibitory protein p53 and
phosphorylation. This inhibitory protein further causes transcription of p53 upregulated
modulator of apoptosis (PUMA) and  p53-inducible death-domain-containing protein,
(PIDD, apoptosis genes) in the neuron cells. PIDD genes promote caspase-2 activation
and secretion of apoptosis-inducing factor (AIF) from the mitochondria of the tubular
cells and causes caspase-independent apoptosis. The PUMA-alpha translocates to the
cellular power house, interacts with cellular components, neutralizes anti-apoptotic
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protein called B-cell lymphoma-extra large (Bcl-XL) and  form oligomer  pores on the
outer surface of the mitochondria. This process is followed by the release of cytochrome
c into the cytoplasm and stimulates the caspases leading to caspase-dependent
apoptosis.47
1.3.3.3. Ethylene glycol-induced urolithiasis
Drugs can cause renal stone formation either by raising excretion rates of
naturally occurring stone forming components or by directly precipitating within the
urinary tract. Urinary supersaturation of the agent may also lead to metabolic
abnormalities that facilitate the formation of stones and eventually grow large enough to
cause problems.  Ureteral obstruction causes post renal azotemia, hydronephrosis and
spasm of the ureter. This leads to renal colic pain (most commonly felt in the flank, lower
abdomen, and groin), nausea, vomiting, fever, hematuria, pyuria, painful urination and
secondary infections.
Urolithiasis can be induced by using variety of agents like ethylene glycol,
sodium oxalate, ammonium oxalate, glyolic acid etc. Accumulation of glycolic acid, a
metabolite of ethylene glycol in the body is responsible for the toxicity.
Alcohol dehydrogenase converts ethylene glycol initially into glycoaldehyde
which is then metabolized by acetaldehyde dehydrogenase, producing glycolic acid.
Cytochrome P450 2E1 (CYP2E1) metabolize glycoaldehyde to glyoxal. Glyoxal is then
further metabolized into glycolic acid or glyoxylic acid. Glycolate oxidase or lactate
dehydrogenase convert  glycolic acid into glyoxylic acid. Glyoxylic acid is further
converted into oxalic acid either by the action of lactate dehydrogenase or glycolate
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oxidase. Oxalic acid can form crystals with calcium, producing calcium oxalate, which is
the most common type of kidney stone causing renal injury.
Urolithiasis or crystallisation of the calcium oxalate is a multifaceted process
involving several physicochemical events which begins with increased urinary super
saturation with one or more  calculogenic (crystal-forming) substances. Supersaturation
of the urine with respect to a calculogenic compound depends on urinary pH, ionic
strength, solute concentration and complexations. Driving force for crystallization is a
reduction in the potential energy of the atoms or molecules that bonds to each other. This
is followed by formation of seed crystal by which stone-forming salts in supersaturated
urinary solution coalesce into clusters (nucleation) and attaches to cell surface of renal
papilla. Growth of insoluble particles and agglomeration is the next major step of stone
formation. A seed crystal can grow by combining with other crystals in solution,
ultimately retained and accumulated in the kidney.48 Crystal retention promotes renal
injury and the development of a stone nidus on the renal papillary surface and further
supports crystal nucleation even at lower supersaturation levels.
In most individuals, the crystallization inhibition capacity of urine prevent stone
formation whereas, this natural inhibition is lacking in stone formers.49 When  inhibitors
of stone formation  fall below their normal proportions, urolithiasis can occur. Normal
urine contains chelating agents such as citrate, magnesium and orthophosphate which
inhibit the nucleation, growth and aggregation of calcium-containing crystals. Other
endogenous inhibitors include calgranulin , Tamm–Horsfall protein, glycosaminoglycans,
uropontin (a form of osteopontin), nephrocalcin (an acidic glycoprotein), prothrombin F1
peptide, and bikunin (uronic acid-rich protein).50 Sufficient dietary intake of magnesium
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and citrate also inhibit the formation of calcium oxalate and calcium phosphate stones.
Nephrolithiasis causes a variety of changes in the renal epithelial cells, such as an
increase in free radical production and a decrease in antioxidant status, followed by
inflammation, cell injury and cell death.
1.3.4. Assessment of kidney function
Periodic assessment of renal function is a part of health care especially for
chronically sick patients.51 Conventional parameters widely employed for assessing
kidney function and monitoring progression and treatment of renal disease are serum
blood urea nitrogen and creatinine level.52 Urea is the waste product of protein catabolism
produced in the liver from ammonia, dissolved in the blood and finally excreted by renal
tubules. Creatinine is waste product of metabolism formed from a high energy molecule
known as creatinine kinase used by skeletal muscles.53 However these parameters are
nonspecific to kidney injury as various non-renal related factors exhibit alteration from
normal serum level of these nitrogenous waste products without producing any negative
effect on kidney. Other parameters that indicate renal dysfunction include lowered
glomerular filtration rate (<60%), proteinuria, hematuria, increased renal excretion and
serum level of uric acid, altered enzymes, urinary and serum electrolytes from normal
level.54 Reabsorption power for endogenous components like small proteins, sugars or
metabolites is highly diminished and  the presence of  low molecular weight proteins (β2-
microglobulin, α1-macroglobulin and retinol binding protein) in urine indicate tubular
injury.55 Presence of high molecular weight proteins like albumin,56 transferrin and
immunoglobulin G in urine represent renal dysfunction.57 Imaging tests  like X-ray,
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computed tomography, ultrasound etc are used to confirm the size and location of the
kidney stone.
1.3.5. Prevention and treatment strategies
Close monitoring of renal function and vital signs is important especially when
administering nephrotoxic drug to patients at risk. Age, co-morbidities and polypharmacy
are the major risk factors. Gentamicin, cisplatin, polyethylene glycol etc cause acute
tubular necrosis, predominantly in early or late segments of the proximal tubule. Initial
therapy for drug-induced nephrotoxicity  is basically supportive which  include
examining of  serum drug levels and renal  function twice or thrice per week, extended-
interval dosing or prefer once-daily doses, using lowest effective dose of causative drug,
limit duration of therapy or stopping the causative drug, avoid drug combination having
nephrotoxic  potential, maintaining fluid and electrolyte balance, and controlling sepsis .
Hemodialysis may be required in certain occasions.58 It is reported that the hydration
(intravenous saline-about 150 to 250 mL/hr  before, during and after chemotherapy) and
intravenous mannitol decreases the appearance of cisplatin induced nephrotoxicity. It acts
by decreasing the uptake of cisplatin into the renal tubular cells. However, there is still
significant incidence of renal insufficiency despite routine hydration and frequent use of
mannitol before cisplatin administration. Urine alkalinization, adequate hydration,
establishing  high urine flow and reducing dose of nephrotoxic drug may prevent
crystalluria. Diuretics such as hydrochlorothiazide, potassium citrate are used to decrease
calcium excretion. Allopurinol decreases high blood uric acid levels. In most cases, renal
function slowly recovered within 7 days after stopping the offending drug. Steroid
therapy (oral prednisone, 1 to 2 mg/kg/day for 4 to 6 weeks) is suggested if renal failure
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persists.59 If renal dysfunction persist even after steroid therapy, immune suppressive
agents such as cyclophosphamide can be indicated.  However, no randomized trial data is
available supporting the efficiency of use of these drugs in this situation.
1.4. Importance of herbs in nephroprotection
Plant drugs have been used for treating numerous health problems all over the
world as it is generally considered to be free from side effects due to their natural origin.
The trend of using herbal products has increased and the active plant extracts are
frequently screened for new drug discoveries. It has been observed that modern medicine
used for the treatment of many diseases like kidney diseases, liver disorders,
cardiovascular diseases, arthritis, asthma and skin diseases associated with serious
adverse effects. Hence in recent years numerous research works have been carried out on
medicinal plants for their claimed activities.
Several research studies confirmed that the generation of free radicals and
diminished antioxidant activity are implicated in development of several life limiting
chronic diseases and xenobiotics-induced nephrotoxicity.60,61 Inhibition of protein
synthesis, DNA damage, mitochondrial injury, apoptotic cell death are the various
mechanism associated with oxidative stress in drug induced nephrotoxicty. Endogenous
antioxidant defense system of body generally provide insufficient protection against the
generation of reactive oxygen species, hence antioxidant are needed to supplement from
external sources.
Most synthetic drugs used for the treatment of nephrotoxicity associate with
higher incidence of adverse drug reactions. Currently, there is no satisfactory drug for the
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treatment, prevention or recurrence of kidney stone formation.62 Invasive procedures
including extracorporeal shock wave lithotripsy (ESWL), ureteroscopy, nephro-lithotomy
etc, are effective but they are costly and may reduce renal functions. It also causes acute
renal injury, infections and recurrence of kidney stone formation.63
Prolonged exposure of kidney to drugs (gentamicin, cisplatin, NSAIDs and
cyclosporine), chemical reagents  (ethylene glycol, carbon tetra chloride, sodium oxalate)
and heavy metals (lead, mercury, arsenic and cadmium) lead to renal injury.
Nephrotoxicity is a multifactorial process linked with various  etiological  factors, hence
the treatment is aimed at multiple targets. Medicinal plants have curative properties on
nephrotoxicity due to the presence of various chemical constituents aiming at multiple
targets and may offer effective, inexpensive and safe remedy. Early literatures have
prescribed numerous herbal drugs for the treatment of renal disorders and also reported that
concurrent administration along with different nephrotoxic agents reduced the toxic effects.
Many herbs have been proven to be effective as nephroprotective agents while many more
are claimed to be nephroprotective but there is lack of scientific evidence to support such
claims.
1.4.1. Various mechanism of action of nephrocurative plant drugs
Research conducted on multiple species of Lespedeza capitata rich with phenolic
and polyphenolic compounds like flavonoids, proanthocyanidins exhibited improvement in
renal function.64 Lespedeza virgata attenuated kidney damage due to doxorubicin
injection.65 Glabridin, a flavonoid from Glycyrrhiza glabra showed protective effect
against proteinuria in a mice model of glomerulonephritis.66
Moringa oleifera and Rubia cordifolia significantly lowered serum levels of
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accumulated waste products blood urea nitrogen and creatinine and enhanced glomerular
filtration rate.67 Berginia ciliate possessed diuretic, antioxidant, hypermagnesuric effect
and also showed highest dissolution of both calcium oxalate and calcium phosphate
stones.68 Phyllanthus niruri, Solanum xanthocarpum (Solanaceae), decreased the stone
forming constituents such as calcium in urine along with an increase in
glycosaminoglycans (crystallization inhibitors) concentration.69
Presence of flavonoids, quercitrin and afzelin, the major components in Copaifera
langsdorffii leaves showed protective effect against nephrotoxicity due to their
antioxidant properties.70 Pomegranate (Punica granatum) juice was found to be
nephroprotective which increased inducible nitric oxide synthase  (iNOS) and nuclear
factor , NF-kappa-B (transcription factor 65) expression emphasizing its antioxidant
potential. These plant drugs also showed inhibition on crystal growth.71 Orthosiphon
stamineus showed  good diuretic, antiseptic and litholytic properties and its flavonoids
were found to possess adenosine A1 receptor binding activity, which promote diuresis
and sodium excretion.72
Tribulus terrestris rich with saponin exhibited a significant decrease in peristaltic
movements of rabbit jejunum preparation in a dose-dependent manner. This effect may
be useful for colic pain or smooth muscle spasms.73 Patients  treated with  Cystone
showed  a symptomatic relief from abdominal pain, dysuria, urinary tract infection and
infective stones.74
Rubia cordifolia, Aerva lanata, Moringa oleifera and Cystone (polyherbal
formulation) maintain crystalloid-colloid balance by decreasing excretion of urinary
calcium, oxalate, uric acid, phosphorus and protein in urolithiasis.
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Phytoconstituents khellin and visnagin isolated from Ammi visnaga fruits are
found to be effective against hyperoxaluria. The mechanism of action of Crataeva
nurvala produce a reduction in glycolate oxidase, with hypermagnesuric effect.75
‘Pashanabheda’ is the Sanskrit  term  used  for  a group  of  plants with  diuretic
and  antiurolithic activities  (Pashana = stone;  Bheda = break). The term has been
indicated in various literature in indigenous system of medicine. During the last two
decades extensive research has been carried out to elucidate the chemistry, biological
activities, and medicinal application of Biophytum sensitivum (B. sensitivum). The flower
of this plant is considered as one of the ten sacred plants which is called as Dasapushpam
in tradition and culture of Kerala state in India.76 This  drug is commonly  known as
‘Nagbeli,’ a folk medicine against ‘Madhumeha’  (diabetes mellitus), particularly in
Eastern Nepal. Tracing the history of traditional practice of B. sensitivum reveals its key
action; the plant is bitter tonic, expectorant and stimulant in Ayurveda. It has been used
as traditional medicine for various ailments. Specifically, the leaves of B. sensitivum
showed diuretic effect and the powdered form is indicated for urolithiasis. Extract of
these bioactive compound have been known to possess various pharmacological activities
mainly antioxidant and anti- inflammatory and the phytochemical analysis have shown
the presence of beneficial compounds which include bioflavonoids like amentoflavone,
cupressoflavone and isorientin. Aforementioned reasons suggests that this plant may have
some therapeutic effect as nephroprotective and antiurolithic. Currently, the search for
nephroprotective and antiurolithic drug possessing significant antioxidant activities from
natural sources has gained immense potential. Hence, in this  study an attempt has been
made to investigate these activities and this  could  serve  as  a  source  of information  on
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the  present  trends  in  research  on plants accredited with nephroprotective and
antiurolithic activity.
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2. AIM AND OBJECTIVES
In the present scenario, most of the people above sixty years of age, have higher
incidence of co-morbidities, and are exposed more to diagnostic or therapeutic
procedures having nephrotoxic potential.77-79 Prolonged exposure of kidney to
nephrotoxic drugs, chemical reagents and heavy metals lead to renal injury. Gentamicin
and cisplatin, still widely prefered in clinical practice because of its high efficacy, but
limits their clinical relevance due to their nephrotoxicity.
Various etiological factors are involved in nephrotoxicty and hence effective
treatment mainly focus on drugs acting on multiple targets. However, satisfactory
synthetic drugs for the treatment of kindey injury are not available in the market.
Currently available allopathic medicines for the treatment of nephrotoxicity and
urolithiasis associates with higher incidence of adverse drug reactions. Accumulation of
nephrotoxic drug or chemicals at higher concentration in renal tubule may induce
apoptosis, necrosis and oxidative stress.80 Lipid peroxidation mediated by reactive
oxygen species has been suggested as a major causative agent of cell death.81
Globally, the use of medicinal plants for the prevention and treatment of various
diseases is constantly developing owing to their natural origin, low cost, easy
accessibility and minimal side effects. Large volumes of preclinical research studies have
been carried out on herbal drugs for their claimed activities. World health organisation
reported that 80% of the world’s population still depends exclusively on traditional
medicine for their primary health care, despite the advancement in allopathic medicines.
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Early literatures have prescribed many herbal drugs for the treatment of
nephrotoxicity and urolithiasis.  The  curative properties of these medicinal plants are
mainly due to the presence of various complex chemical substances aiming at multiple
targets such as antispasmodic, anti-inflammatory, diuretics, antibiotics, muscle relaxants,
analgesics and anti-oxidant activities. Research studies also confirmed that co-therapy
with nephroprotective herbal drugs along with nephrotoxic agent may reduce its toxicity.
Traditionally many more herbal plants are claimed to be nephroprotective but there is
lack of scientific evidence to support such claims.  Previous research works also
confirmed that the presence of high content of phenolic and polyphenolic compounds
(flavonoids, proanthocyanidins) in medicinal plants preserved renal function.64, 82
Among polyphenols, phenolic and flavonoids are naturally occuring aromatic compounds
which have excellent antioxidant and free radical scavenging activity, thereby reducing
the nephrotoxic effect. Plants rich with saponins possess anti-crystallisation properties by
disaggregating the suspension of mucoproteins, the promoters of crystallization.83
Biophytum senitivum is a well known medicinal plant widely used in traditional
Ayurvedic and Siddha systems. This auspicious herbs is also included in the group of
“Dasapushpam”, an Ayurvedic formulation. Phytochemical investigations of this plant
had revealed the presence of large amount of phenolic and poly phenolic compounds,
saponins, polysaccharides, pectin and essential oils. The principle bioactive constituents
are bioflavonoids like amentoflavone with trace amounts of cupressoflavone, luteolin,
isoorientin and isovitexin.84, 85 Grounded leaves exhibited diuretic effect and powdered
form is indicated for urolithiasis.86 This plant was investigated for various
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pharmacological properties which include antidiabetic, anti-inflammatory,
hypocholesterolemic, antibacterial, antiulcer, antioxidant, anthelmintic and many more.
However none of the studies have compared the combined nephroprotective,
antiurolithic and antioxidant activities with ethanol extract of B. sensitivum. Presently, the
search for nephroprotective and antiurolithic drug possessing significant antioxidant
activities from natural sources has gained immense potential. Hence, this study was
designed to investigate nephroprotective activity of B. sensitivum on gentamicin and
cisplatin-induced nephrotoxicity and antiurolithic activity on ethylene glycol-induced
urolithiasis in Wistar albino rats.
The specific objectives of the study were to determine the following:
1. Various  phytoconstituents present in the ethanol extract of B. sensitivum (EEBS)
2. In vitro antioxidant and free radical scavenging activity of EEBS.
3. In vitro antiurolithic activity of EEBS
4. In vitro cytoprotective activity of EEBS on kidney cell lines
5. Nephroprotective activity of EEBS on gentamicin-induced nephrotoxicity in rats.
6. Nephroprotective  activity of EEBS on cisplatin-induced nephrotoxicity in rats
7. Antiurolithic activity of EEBS on ethylene glycol-induced urolithiasis in rats
8. In vivo enzymatic and non-enzymatic antioxidant studies in kidney homogenate
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3. REVIEW OF LITERATURE
3.1. Plant Profile
3.1.1. Botanical description
Biophytum sensitivum (Linnaeus) DC (B. sensitivum), within the Biophytum
genus belongs to the Oxalidaceae family and have been used as traditional medicine in
Ayurvedic  and Siddha system to alleviate various ailments. This plant is considered as
one among ten sacred plants, known as ‘Dasapushpam’ in tradition and culture of
Kerala.76, 87 Life  plant, little tree plant are the common name used for this plant. This
auspicious herb is also known as sensitive plant and in Sanskrit as ‘Lajjaluka,’ due to an
interesting nastic movement in leaves in response to touch, similar to touch-me- not
plant. In Eastern Nepal, this plant is commonly known as “Nagbeli,” which is used as a
folk medicine for the treatment of “Madhumeha” (Diabetes mellitus). In Ayurveda,
powdered form of this drug is indicated for urolithiasis, gonorrheal infection and
grounded leaves with water exhibited diuretic activity. Ayurveda also recommends
decoction of this plant for amenorrhea and dysmenorrhea. In Siddha system, this plant is
advised for diarrhea, cough, epilepsy and wound healing.88
3.1.2. Geographical distribution
This genus is commonly found in wetlands, under shades of trees, at low and
medium altitude. Most of the species occur in plains of tropical Africa and Asia, mainly
Philippines. In Asia, this plant is widely distributed throughout the hotter parts of Nepal,
Thailand, Malaysia, Indonesia, Sri Lanka and India.89 B. sensitivum is abundantly seen in
South India , especially in Eastern and Western Ghats.90
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3.1.3. Common names of Biophytum sensitivum (Linn.) DC 91, 92
Language Name
French : Alleluya
Bengal : Jhalai
Hindi : Lajalu, Lajjaalu, Lakshmana, Zarer
Indo-China : Chua me
Kannada : Haramuni, Jalapushpa
Marathi : Jharera, Lajwanti, Lahanmulaka
Sanskrit : Jhullipuspa, Lajjaluka, Panktipatra, Pitapushpa
Telugu : Attapatti, Chumi, Jala pupa
Malayalam : Mukkutti
Tamil : Nilaccurunki, Tintaanaalee
3.1.4. Scientific classification of Biophytum sensitivum92
Kingdom : Plantae
Phylum : Tracheophyta
Class : Magnoliposida
Order : Oxalidales
Family : Oxalidaceae
Genus : Biophytum
Species : sensitivum
Botanical name : Biophytum sensitivum (L.) DC
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Figure 2: Pictorial presentation of Biophytum sensitivum (Linn.) DC
3.1.5. Morphology93
This is a slender, erect, annual herb, looks like a miniature palm. Plants can grow
upto to 25 cm.
B. sensitivum leaves: The leaves are  sensitive, compound, abruptly pinnate, crowded
into rosette on top of stem, total length less than 5- 12 cm with short petiole, rachis
slender,  glabrous or hairy with 6-12 pairs of leaflets. The leaflets are opposite, oblong,
obliquely rounded, apiculate at apex, subsessile, glabrous with short petiole, measure
upto 4-5 mm and 1.5 cm long, the terminal pair the biggest and the pairs becoming
smallest downwards.
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B. sensitivum flowers: The flowers are dimorphic, many and crowded, 8 mm across
yellow peduncle, length varies up to 10 cm, slender, pubescent or glabrous, pedicles
many, bracts lanceolate, crowded beneath the pedicles. Sepals are 5, subulate-lanceolate,
striate, about 7 mm long, imbricate, and acute with parallel nerves. Petals are 5, yellow
with red marking in the centre of petals, corolla connate into salver shaped exceeding the
sepals, lobes rounded, spreading. Stamens are 10, distinct filament free, the five inner
ones are longer and styles 5. Fruits are ellipsoidal capsule, apiculate, exceed the sepals.
Seeds are ovoid and transversely striate.
B. sensitivum stem: The stems are short, unbranched, erect, glabrous or hairy stems,
cylindrical, woody, apical part greenish and basal part usually brownish, ligneous when
old.
B. sensitivum root: Typical tap root with few root nodules in the lateral branches, hard
and woody, cylindrical, external surface brown.
3.1.6. Ethnomedicinal /traditional uses
B. sensitivum is a well known auspicious medicinal plant and the ethno-medicinal
values of this plant has been recommended in various indigenous system of medicine.
This plant has been used for the treatment of various diseases in Ayurveda and Siddha
system.
The whole plant of this plant has been used traditionally in the treatment of
urinary calculi, gonorrhea, asthma, pthisis, stomachalgia, chest complaints, hyperdipsia in
bilious fever, wound, inflammatory-tumours, burns, cramps, snake bite, stangury and in
abcesses.94 It is also used as bitter tonic, stimulant, thermogenic, expectorant,
suppurative, diuretic and lithonotriptic.92 Leaf extract of this plant has been used as
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traditional folk medicine for various diseases, such as diabetes, ashma, pthisis and
decoction of leaf for tuberculosis.95 Leaf extract also applied on wound to arrest bleeding,
also act as bitter tonic, antiseptic, astringent, diuretic, styptic, expectorant and stangury.93
Powdered form of seed is used as antiseptic and also to arrest bleeding, hence used to
apply on wounds. Decoction of root of this plant is used in gonorrhea, fever, styptic in
pthisis and lithiasis.94, 95
3.1.7. Phytochemistry
Major group of phytoconstituents present in B. sensitivum include phenolic and
polyphenolic compounds, saponin, essential oil, polysaccharides and pectin.96
Methanolic extract of the leaves showed the presence of phenolic compounds
including isoorientin, orientin, isovitexin, isoorientin-7-O-glucoside, isoorientin-2”-O-
rhamnoside.85Ariel part of this plant has been reported to contain three  flavonoids,
luteolin-7-methyl ether, isoorientin and 3'-methoxyluteolin-7-o-glucoside, and two acids,
4-caffeoylquinic acid and 5-caffeoylquinic acid.84
Methanolic extract of roots, stems and leaves revealed the presence of two
bioflavonoid, amentoflavone which is the main bioactive constituent  with small amount
of cupressoflavone.97
Highest amount of epicatechin and epicatechin-(4β-8)-epicatechin
(proanthocynidin B2, condensed form of tannins) were found in roots and leaves possess
C-glycosyl flavones.85 Around 69 compounds were identified in the essential oil of air
dried plant. Major constituents are benzene derivatives including  1,4-dimethoxy
benzene, 1,2-dimethoxy benzene,  2-methoxy-4-methyl phenol, the monoterpenes (Z)-
linalool oxide, (E)-linalool oxide,  linalyl acetate , 1-octen-3-ol and isophorone.86
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Aqueous extract of aerial parts confirmed the presence of a bioactive
polysaccharide, BP100 III which is composed of galacturonic acid and rhamnose.98
Figure 3: Chemical structures of some of the phytochemicals present in
B. sensitivum
Amentoflavone Cupressoflavane Isoorientin
Luteolin 7-methyl ether 4-Caffeoylquinic acid 5-Caffeoylquinic acid
1,4-dimethoxy benzene 1,2-dimethoxy benzene 2-methoxy-4-methyl phenol
3.2. Review of published literature on B. sensitivum
B. sensitivum is a very popular and a sacred plant in Indian medical system and
has been used for the prevention or treatment of wide spectrum of diseases. Scientifically
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unproven  pharmacological activities of this plant helped researchers to investigate the
validity of these traditional claims.  This species were investigated for multifarious
pharmacological activities including antidiabetic, anti-inflammatory,
hypocholesterolemic, antibacterial, antiulcer, antioxidant, anthelmintic, antiangiogenic,
chemoprotective, apoptotic, larvicidal, immuno- modulatory and antitumour activities.
Some compounds have been isolated and characterized from this plant species.
Inngjerdingen KT et al., (2006)98 isolated polysaccharide fractions, BP100 III, from the
aqueous extract of aerial parts of B. petersianum [syn. Biophytum sensitivum (L.) DC].
This fraction was then degraded by endo-alpha-d-(1-->4)-polygalacturonase and
collected three fractions by gel filtration. BP100 III.1, highest molecular weight fraction
which consists of galacturonic acid and rhamnose showed  dose-dependent complement
fixating activity,  compared to other two lower molecular weight fractions.
Bucar F et al., (1998)97 isolated amentoflavone from the roots of B. sensitivum DC and
showed a selective inhibition on cycloxygenase (COX)-1 catalyzed prostaglandin
biosynthesis, indicating anti-inflammatory activity of B. sensitivum.
Guruvayoorappan C et al., (2007)99 demonstrated antitumour activity of
amentoflavone, a biflavonoid from B. sensitivum. Intraperitoneal injection of Ehrlich
ascites carcinoma cells to BALB/c mice resulted in tumour formation and by
administration of amentoflavone significantly elevated the natural killer cell activity and
antibody-dependent cellular cytotoxicity  in tumour bearing animals, compared to
untreated tumour-bearing control animals.
Guruvayoorappan C et al., (2008)100 displayed that amentoflavone showed significant
reduction in  the production of various endogenous factors such as interleukin-1 beta,
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interleukin-6, tumour necrosis factor-alpha, granulocyte-macrophage colony-stimulating
factor, and vascular endothelial growth factor that control the process of angiogenesis.
3.2.1. Antidiabetic activity of B. sensitivum
Puri D et al., (1998)101 investigated antidiabetic activity of leaf extract of B. sensitivum
in alloxan induced hyperglycemia in male rabbits  which were categorized into three
groups based on the severity of disease as sub-diabetic, mild-diabetic and severe-diabetic.
Hypoglycaemic activity was assessed based on the improvement in the oral glucose
tolerance test and fasting plasma glucose (FPG) lowering effect.  FPG lowering was
observed in 1 hour and 2.5 hour showing glucose values by 25.9% and 27.4%
respectively in the subdiabetic rabbits, and by 36.9% and 37.7% in the mild diabetic
rabbits.  Improvement in glucose tolerance test (GTT) response was also observed in the
subdiabetic rabbits and mild diabetic rabbits. These results support the use of this plant
as an antidiabetic agent.
Prabu et al., (2012) 102 investigated the effect of aqueous solution of B. sensitivum leaf
extract on normal and streptozotocin-nicotinamide-induced diabetic models. Diabetic rats
were treated with extract (200 mg/kg) for 28 days. Antidiabetic effect of extract was
assessed by evaluating the blood glucose, plasma insulin, total haemoglobin, glycosylated
haemoglobin, liver glycogen and carbohydrate metabolism regulating enzymes of liver.
The study concluded that this plant  possessed significant antidiabetic activity as it
showed reduction in blood glucose,  glycosylated haemoglobin levels, glucose-6-
phosphatase, fructose-1,6-bisphosphatase activities and significant  elevation in total
haemoglobin, plasma insulin and liver glycogen levels and the hexokinase activity in
diabetic rats.
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3.2.2. Anti-inflammatory activity of B. sensitivum
Chandrasekharan et al., (2008)103 examined the methanolic extract of B. sensitivum for
its anti- inflammatory activity and the findings revealed that the plant extract could
suppress the inducible nitric oxide synthase,  cyclo-oxygenase-2 mRNA expression and
production of proinflammatory cytokines in lipopolysaccharide (LPS) or Concanavalin
(Con) A-stimulated primary macrophages. Hence this plant may provide beneficial effect
for the treatment of endotoxic shock or sepsis.
Jachak SM et al., (1999)104 assessed  the anti-inflammatory activity of aqueous and
methanol extracts of aerial parts and  aqueous and ultrafiltration fractions of methanol
extract of roots of B. sensitivum in carrageenan-induced rat paw edema. The test extracts
significantly suppressed edema except the methanol extract of aerial parts. This study
confirmed that the aqueous extract of B. sensitivum exhibited better anti-inflammatory
effect compared to methanol extract.
3.2.3. Hypocholesterolemic activity of B. sensitivum
Puri D, (2003)105 demonstrated  hypocholesterolemic effect of aqueous extract of leaves
of B. sensitivum in  male albino rabbits. Animals were divided into three groups,
containing six animals each, designated as Group I, II, III.  Group I served as healthy
control, group II of untreated hypercholesterolemic rabbits and group III of
hypercholesterolemic rabbits co-treated with the aqueous extract.  The result suggested
that animals co-administered with the extract lowered the elevated serum triglycerides,
very low density lipoprotein plus low density lipoprotein cholesterol and the ratios of
total cholesterol to high density lipoprotein cholesterol level.
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3.2.4. Antibacterial activity of B. sensitivum
Natarajan D et al., (2010)106 demonstrated that the leaves extract of B. sensitivum can be
used as an anti-infective agent.  Antibacterial activity of petroleum ether, chloroform,
acetone and methanol extract of B. sensitivum were evaluated against human pathogenic
bacterial strains (Bacillus subtillis, Staphylococcus aureus, Streptococcus pneumonia,
Klebsiella pneumonia, Salmonella typhi, Proteus vulgaris and Escherichia coli).
Antibacterial activity was remarkably higher with acetone extract compared to other
extracts. Methanol and chloroform extracts were found to be better than petroleum ether
extract.
3.2.5. Anthelmintic activity of B. sensitivum
Rajanikant TK et al., (2013)107 evaluated the anthelmintic activity of B. sensitivum
leaves and stems by  extracting with petroleum ether, ethyl acetate and methanol. All the
extracts were evaluated for anthelmintic activity with Indian earthworm (Pheretima
posthuma). This study concluded that the ethyl acetate extract showed excellent
anthelmintic activity (at concentration of  25 mg/mL, 50 mg/mL, 100 mg/mL with
paralysis time 85.0±1.9, 66.0±1.3, 40.8±1.0 and death time 91.3±1.1, 81.2±1.7, 50.5±0.8
respectively), compared to other extracts and this may be  due to presence of
bioflavonoids and tannins.
3.2.6. Antioxidant activity of B. sensitivum
Guruvayoorappan C et al., (2006)108 investigated vitro and in vivo antioxidant potential
of B. sensitivum. The study result suggested that the plant extract scavenged  superoxide
radicals,  hydroxyl radicals,  nitric oxide radicals and inhibit lipid peroxidation  with an
IC50 value of 50, 95, 100, and 120 μg/mL respectively. Administration of B. sensitivum to
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mice significantly  inhibited superoxide generation in macrophages  and increased the
catalase activity, glutathione-S transferase and glutathione reductase levels, thereby
clearly indicated its antioxidant potential.
3.2.7. Immunomodulatory  and antitumour activity of B. sensitivum
Guruvayoorappan  C et al., (2007)109 assessed immunomodulatory and antitumour
activity of alcoholic extract of B.  sensitivum. This study fortifies  that  extract  was found
to be cytotoxic at a concentration of 0.1 mg/mL to L929 cells lines and  100%  toxic at a
concentration of 0.5 mg/mL to Dalton’s lymphoma ascites (DLA) and Ehrlich ascites
carcinoma (EAC) cells. Co-administration of extract (500 μg/dose/animal) to mice
induced with DLA cells, inhibited tumour development. Life span of mice bearing
Ehrlich ascites carcinoma tumours was increased.  Moreover, extract significantly
(p<0.001) lowered the tumour cell glutathione levels, serum gamma glutamyl
transpeptidase (GGT) and nitric oxide (NO) levels in ascites tumour bearing animals. The
total WBC count, bone marrow cellularity and β esterase positive cells were increased by
the administration of B. sensitivum extract. This study provided evidences   suggesting its
immunomodulatory and  antitumour potential.
Bhaskar et al., (2010)110 investigated the possible antitumour effects of aqueous extract
of B. sensitivum leaves against Dalton’s Ascitic lymphoma bearing Swiss albino mice.
Study concluded that B. sensitivum exhibited significant antitumour activity.
3.2.8. Antiulcer activity of B. sensitivum
Sakthivel KM et al., (2014)111 demonstrated antiulcer activity of methanol extract of
aerial parts of B. sensitivum in Wistar rats. Ulcerative colitis was induced by
intracolonic injection of 3% acetic acid.  The study result confirmed the antiulcer activity
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of extract (50 mg/kg) as it  inhibited colitis by lowering macroscopic score (up to
3.66±0.77) and reducing (p<0.01) colonic tumor necrosis factor-α (TNF-α), interleukin-
1-β (IL-1β) and IL-6 levels. The expression of inducible nitric oxide synthase (iNOS) and
cyclooxygenase-2 (COX-2) were lowered in extract treated animals, compared with rats
in disease control group. Significant reduction (p<0.01) in lactate dehydrogenase,
myeloperoxidase activities and lipid peroxidation (LPO) were also observed.
Anindya B et al., (2014)112 communicated  the anti-ulcer profile of  ethanolic extract of
leaves of B. sensitivum in aspirin induced  peptic ulcer model. This study offered anti-
ulcer activity in comparison with the rats treated with standard drug Omeprazole.
3.2.9. Anti-angiogenic activity of B. sensitivum
Guruvayoorappan C et al., (2007)113 investigated  antiangiogenic effect of B.
sensitivum using B16-F10 melanoma cell-induced capillary formation in C57BL/6 mice.
Intraperitoneal administration of the extract at a concentration of 50 mg/kg controlled the
production of proinflammatory cytokines such as interleukin-1 beta, interleukin-6, tumor
necrosis factor-α, granulocyte macrophage-colony stimulating factor and vascular
endothelial growth factor involved in angiogenesis, thereby indicated its anti-angiogenic
activity.
3.2.10. Chemoprotective activity of B. sensitivum
Guruvayoorappan C et al., (2006)114 demonstrated that alcoholic extract of B.
sensitivum could diminish  cyclophosphamide induced intestinal damage in  Swiss albino
mice. This study result showed significant improvement in relative organ weight of the
spleen and thymus and elevation of total WBC count, bone marrow cellularity and α-
esterase positive cells in animals treated with extract and cyclophosphamide, in
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comparison with control mice treated with cyclophosphamide alone. Administration of B.
sensitivum extract also reduced pro-inflammatory cytokine, tumor necrosis factor-alpha
and elevated cytokines interferone-gamma, interleukin-2 and granulocyte macrophage-
colony stimulating factor.
3.2.11. Cytotoxicity and larvicidal potential of B. sensitivum
Johnson M et al., (2015) 115 assessed cytotoxicity, larvicidal, and antioxidant activity of
various extract of B. sensitivum. Total phenolics were maximum  in methanolic extracts
of B. sensitivum (1399.84 ± 215.79 mg of gallic acid equivalent/g) and showed strongest
phosphomolybdenum reduction (202.24 ± 11.44 g of ascorbic acid/100 g).  Excellent
DPPH radical scavenging activity was observed in acetone extracts (IC50 value 30.12
μg/mL). The methanolic extracts of B. sensitivum exhibited highest larval mortality
against Culex quinquefasciatus with LC50= 215.34 mg/mL and brine shrimp nauplii with
LC90= 66.34 mg/mL. This study report confirmed that extracts showed good antioxidant,
larvicidal and cytotoxic activity.
3.2.12. Wound healing activity of B. sensitivum
Saritha1 B et al., (2015) 116 investigated  the wound healing potentials of methanolic
extracts of B. sensitivum at dose level of  1g and 2g in excision wound models. The
wound treated with  plant extract demonstrated better wound contraction, elevated level
of hydroxy proline, hexosamine content, superoxide dismutase and diminished lipid
peroxidation. On 15th day, complete wound healing activity was observed in animals
treated with 2g of plant extract.
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3.2.13. Apoptotic effect of B. sensitivum
Guruvayoorappan C et al., (2007)117 have evaluated apoptotic effect and  regulatory
effect of B. sensitivum on nitric oxide and cytokine production in B16F-10 cells, tumour-
associated macrophages, and peritoneal macrophages. This result suggested that extract
induced apoptosis in B16F-10 melanoma cells by reducing the production of
proinflammatory cytokines.
3.2.14. Radioprotective activity of B. sensitivum
Guruvayoorappan C et al., (2008)118 demonstrated radioprotective effect of methanolic
extract of B. sensitivum in mice models.  Animals were pretreated with B. sensitivum
(50 mg/kg body wt.), before exposing whole body to gamma irradiation and observed
protection against radiation-induced hemopoietic damage and  free radical scavenging
activity.
3.2.15. Antiurolithic activity of B. sensitivum
Anil TP et al., (2015)119 reported the antiurolithic activity of standardized methanolic
extract of whole plant of B. sensitivum in rats.  Kidney stone formation was induced by
surgical implantations of zinc disc in the urinary bladders of rats, followed by the
administration of various doses (100, 200, and 400 mg/kg; p.o.) of plant extract for a
period of 7 days. Stone size and various biomarker levels were estimated in urine and
serum. Extract administration caused significant improvement in glomerular filtration
rate and also altered the elevated levels of nitrogenous waste product, indicating its
antiurolithic activity.
Anil TP et al., (2016) 120 also evaluated antiurolithic activity of some fractions of
methanolic extract of whole plant of B. sensitivum, by extracting with dichloromethane,
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ethyl acetate, ethanol and water.  Rats were treated with 20 & 40 mg/kg. p.o. of the
fractions and after 1 hr urolithiasis was induced by injecting  sodium oxalate (70 mg/kg,
i.p.) for 7 days. Histological changes and various biochemical changes in urine, serum
and kidney homogenate were observed. Ethyl acetate fraction exhibited significant
antiurolithic activity compared to other two fractions.
Anil TP et al., (2015)121 also investigated methanolic extract of whole plant of B.
sensitivum at three dose level (100, 200, 400 mg/kg) against calcium oxalate induced
urolithiasis in rats. The study assessed antiurolithic c activity by evaluating histological and
biochemical changes in urine, serum and kidney and the result confirmed that the extract
attenuated drug induced urolithiasis.
3.2.16. Nephroprotective activity of B. sensitivum
Sachin C et al., (2017)122 evaluated nephroprotective activity of whole plant B.
sensitivum by extracting with dichloromethane, ethyl acetate, ethanol and water. Rats
were treated with gentamicin (40mg/kg. i.p) for seven days. Serum level of urea and
creatinine were determined. Study concluded that this medicinal plant showed excellent
nephroprotective activity.
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4. MATERIALS AND METHODS 
4.1. Phytochemical studies 
4.1.1. Collection of plant materials and authentication 
Well grown whole plant, Biophytum sensitivum were collected between the 
months of December   2015 and February 2016 from Shevaroy Hills, Salem District, 
Tamil Nadu. The plant was taxonomically identified and authenticated by Dr. A. 
Balasubramanian, Executive Director, ABS Botanical conservation, Research and 
Training Centre, Kaaripatti, Salem. The authentication number is T.N. (Ref. No.-
AUT/JKK/095). 
4.1.2. Preparation of crude ethanol extract of Biophytum sensitivum (EEBS) 
After authentication, the collected whole plants of B. sensitivum were washed and 
dried in shadow for about three weeks. Dried plants were crushed in to coarse powder, 
passed through pharmaceutical sieve No. 40 and stored in air tight container at room 
temperature. For defatting the drug, 500 gms of powdered plant material was sequentially 
extracted with 2L of petroleum ether using Soxhlet apparatus for 36 hrs at a temperature 
of 60-80
º
C with occasional shaking and filtered. The marc was again dried in hot air oven 
below 50
º
C and extracted using 70% v/v ethanol for 72 hrs at a temperature of 50
º
C using 
Soxhlation method. The extracted solvents were concentrated by vacuum distillation and 
evaporated to dryness in a water bath. After weighing, the final extract obtained from this 
procedure were stored in air tight container and kept in refrigerator for further 
phytochemical and pharmacological studies.
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4.1.3. Qualitative analysis of phytochemicals present in whole plant B. sensitivum 
Crude EEBS was subjected to various qualitative tests for screening the presence 
of phytochemical constituents.  The extract was analyzed for carbohydrate, alkaloids, 
steroids, saponins, proteins, aminoacids, flavonoids, glycosides, terpenes, tannins and 
phenolic compounds according to the standard testing procedures.
93, 124
 
4.1.3.1. Tests for carbohydrates and reducing sugars 
Small quantity of extract (about 50 mg) was dissolved in 5 mL of distilled water. 
After filtration the solution was subjected to the following procedures. 
a. Molisch’s test (General test): Two mL of the filtrate was subjected to Molisch’s test 
by adding three drops of alcoholic solution of alpha napthol, shaken well and added 1 mL 
of concentrated sulphuric acid through the sides of test tube. Formation of violet colour 
ring at the junction of two liquids indicates the presence of carbohydrates. 
b. Fehling’s test: Boiled 1 mL of Fehling’s solution A and Fehling’s solution B taken in 
test tube for 1 min. Added I mL of the filtrate and heated the solution further for 5-10 
mins by keeping it in boiling water. Formation of yellow colour, followed by brick red 
precipitate indicates the presence of reducing sugar. 
c. Benedict’s test: Mixed thoroughly 5 mL of Benedict’s reagent and 1 mL of the filtrate 
in a test tube and heated in a boiling water bath for 2 mins. Appearance of green or 
yellow colour, followed by the formation of red precipitate upon cooling indicates the 
presence of reducing sugar.  
d. Barfoed’s test: Mixed thoroughly equal volume  (2 mL)  of Barfoed’s reagent and the 
filtrate in a boiling water bath and heated for 2 mins. Formation of red precipitate after 
cooling indicates the presence of monosaccharides.    
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e. Tollen’s test: Added one mL of the filtrate to 2 mL of Tollen’s reagent and boiled. 
Formation of silver colour on the inner walls of the test tube indicates the presence of 
aldose sugar. 
f. Seliwanoff’s test: About one mL of the filtrate was heated with 1 mL of hydrochloric 
acid and resorcinol.  Formation of red colour indicates the presence of glucose.  
g. Bromine water test: Small quantity of the filtrate was mixed with bromine water. 
Decolorization indicates the presence of aldose sugar.  
4.1.3.2. Tests for alkaloids 
A small portion of the solvent free extract (50 mg) was mixed with few drops of 
dilute hydrochloric acid and filtered. The filtrate was tested carefully with various 
alkaloid reagents such as:  
a. Mayer’s reagent: One mL of the filtrate was treated with 1 mL of Mayer's reagent 
(potassium mercuric iodide solution). Appearance of cream colour precipitate indicates 
the presence of alkaloids. 
b. Dragendorff’s reagent: One mL of the filtrate was treated with 1 mL of Dragendroff's 
reagent (potassium bismuth iodide solution). Appearance of reddish brown or orange 
precipitate indicates the presence of alkaloids. 
c. Hager’s reagents: One mL of the filtrate was treated with 3 mL of Hager's reagent 
(aqueous solution of picric acid). Appearance of yellow colour precipitate indicates the 
presence of alkaloids. 
d. Wagner’s reagent: One mL of the filtrate was mixed with 1 mL of Wagner's reagent 
(iodine and potassium iodide solution). Appearance of reddish brown colour precipitate 
indicates the presence of alkaloids. 
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e. Tannic acid test: One mL of filtrate was mixed with 1 mL of 10% tannic acid 
solution. Appearance of buff colour indicates the presence of alkaloids. 
4.1.3.3. Tests for saponins 
a. Foam test: Small amount of the extract was shaken vigorously with 20 mL distilled 
water in a graduated cylinder for 15 mins. Formation of foam layer (about 1 cm) indicates 
the presence of saponins. 
b. Hemolytic test: Few drops of the extract solution  was mixed thoroughly with a drop 
of blood placed on glass slide. Formation of hemolytic zone indicates the presence of 
saponins. 
c. Lead test: One mL of the filtrate was mixed with 1% lead acetate solution. 
Appearance of white precipitate indicates the formation of saponins. 
4.1.3.4. Tests for flavonoids 
Small quantity of the extract was shaken with few mL of water and the resulting mixture 
was subjected to the following tests: 
a. Shinoda's test: A small quantity of test sample was dissolved in 5 mL of alcohol 
(95%) and treated with 2-3 pieces (0.5 gm) of magnesium metal. Development of pink 
colour within two mins  after the addition of few drops of concentrated hydrochloric acid 
indicates the presence of flavonoids.  
b. Alkaline reagent test: Small quantity of the filtrate was mixed with sodium 
hydroxide. Appearance of yellow colour indicates the presence of flavonoids.  
c. Lead acetate test: Small quantity of the filtrate was treated with lead acetate solution. 
Appearance of yellow colour which further decolorized on addition of acid indicates the 
presence of flavonoids.  
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d. Sulphuric acid test: Appearance of yellow colour on treating an aliquot quantity of 
crude extract with concentrated sulphuric acid indicates the presence of flavonoids.  
4.1.3.5. Tests for phenolic compounds  
a. Ferric chloride test: Dissolved about 50 mg of extract in distilled water and added 3-4 
drops of neutral 5% ferric chloride solution. Appearance of green colour indicates the 
presence of phenols.  
b. Lead acetate test: Small quantity of extract dissolved in distilled water was mixed 
with 3 mL of 10% lead acetate solution. Appearance of white precipitate indicates the 
presence of phenols. 
4.1.3.6. Tests for tannins 
a. Ferric chloride test: Dissolved about 50 mg of extract in distilled water and to this 
added 3-4 drops of neutral 5% ferric chloride solution. Appearance of bluish black colour 
which disappears on addition of few drops of concentrated sulphuric acid without the 
formation of yellow or brown precipitate indicates the presence of tannins. 
b. Gelatin test: One mL of the filtrate was treated with 1% gelatin solution containing 
10% sodium chloride. Appearance of cream precipitate indicates the presence of tannins. 
c. Lead acetate test: Small amount of the filtrate was treated with 10% lead acetate 
solution. Appearance of white precipitate indicates the presence of tannins. 
4.1.3.7. Tests for glycosides 
a. Keller-killiani test:  An aliquot quantity of extract was dissolved in 2 mL of ethanol 
and 0.5 mL of strong lead acetate solution. Filtered and then the filtrate was further 
mixed thoroughly with chloroform. Chloroform layer was separated and solvent was 
evaporated. Residue was dissolved in 2 mL of glacial acetic acid and few drops of 5% 
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ferric chloride solution were added. This solution was then transferred to a test tube 
containing concentrated sulphuric acid.  Formation of red ring at the junction of two 
liquids indicates the presence of glycosides. 
b. Baljet’s test: One mL of the filtrate was mixed with 1 mL of sodium picrate solution. 
Yellow colour changing to orange colour indicates the presence of glycosides.  
c. Legal's test: A small portion of the extract was hydrolyzed with dilute hydrochloric 
acid for few minutes on a heating water bath. To the hydrolysate, 1 mL of pyridine and 
few drops of sodium nitroprusside solution were added and then made alkaline with 
sodium hydroxide solution. Appearance of pink to red colour indicates the presence of 
cardenolide glycosides. 
d. Borntrager's test: Boiled 3 mL of extract with 2 mL dilute sulphuric acid and   
filtered. To the filtrate added equal volume of chloroform. Shaken well and the 
chloroform layer was separated. To this added equal quantity of dilute ammonia solution. 
Appearance of rose pink colour in the ammoniacal layer indicates the presence of 
anthraquinone glycoside. 
4.1.3.8. Tests for steroids 
a. Libermann Burchard test: Two mL of the extract was treated with chloroform 
solution and 2 mL of acetic anhydride. Mixed well and then added two drops of 
concentrated sulphuric acid through the sides of the test tube. Appearance of bluish green 
color indicates the presence of steroids. 
b. Salkowski test: Two mL of the extract was dissolved in 2 mL of chloroform solution  
and the resulting solution was then shaken with 2 mL of concentrated  sulphuric acid. 
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Appearance of red colour in chloroform layer and greenish yellow flouresence in acid 
layer indicates the presence of phytosterol. 
4.1.3.9. Tests for proteins and amino acids 
Small quantity of the extract was shaken with few mL of water and the resulting mixture 
was subjected to the following tests:   
a. Biuret test: Two mL of test sample was treated with 3 drops of 4% of sodium 
hydroxide solution and few drops of 1% copper sulphate solution. Appearance of pink to 
purple colour indicates the presence of proteins.  
b. Ninhydrin test: Two mL of test sample was heated with 3 drops of  5% of ninhydrin 
solution in boiling water bath for 10 mins. Appearance of violet, blue or purple colour 
indicates the presence of proteins or amino acid. 
c. Xanthoprotein test: One mL of concentrated nitric acid was added to 2 mL of test 
sample. After heating and cooling, sodium hydroxide (40% w/v) was added to make the 
solution alkaline. Formation of white  precipitate initially, then on boiling changed to 
yellow and then to orange colour indicates the presence of amino acids. 
d. Millon’s test: One mL of the test sample was heated with 3 drops of Millon's reagent 
(mercuric nitrate solution), appearance of pink or dark red colour indicates the presence 
of protein. 
e. Lead acetate test: Three mL of the filtrate was mixed with 10% lead acetate and 40% 
sodium hydroxide solution. Formation of black precipitate indicates the presence of 
amino acids. 
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4.1.3.10. Tests for terpenoids 
a. Hirschonn reaction: Two mL of the filtrate was added with 2 mL of tetra nitro 
methane. Appearance of a yellow color indicates the presence of triterpenoids. 
b. Knoller’s test: To a small quantity of the extract taken in a dry test tube, added few tin 
granules and 1 mL of thionyl chloride and shaken well.  Appearance of a pink color 
indicates the presence of triterpenoids. 
4.1.3.11. Tests for fixed oil and fat  
a. Spot test: Small quantity of the extract was pressed between two filter papers. 
Appearance of oil stains on the filter paper indicates the presence of fixed oil. 
b. Saponification test: Few drops of 0.5 N alcoholic potassium hydroxide were mixed 
with 2 mL of the extract along with a drop of phenolphthalein. The mixture was heated 
on a water bath for 1-2 hrs. Formation of soap or partial neutralization of alkali indicates 
the presence of fixed oils and fats. 
c. Solubility test: Oils are soluble in benzene, ether and chloroform but insoluble in 
water and 90% ethanol. 
4.2. Quantitative estimation of total phenolic and flavonoid content of EEBS   
After phytochemical screening, EEBS was subjected to quantitative analyses of 
total phenolic content and flavonoids. 
4.2.1. Estimation of total phenolic content
125
 
Total phenolic content was estimated by calibration curve method using gallic 
acid (standard), Folin- Ciocalteu reagent and 20% sodium carbonate solution. 1mL of 
crude extract was mixed with 1mL of 10% Folin-Ciocalteu reagent.  After keeping it for 
3 mins in darkness, 1mL of sodium carbonate (7.5% w/v) was added and adjusted to 10 
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mL with distilled water. Incubated for  90 mins  in darkness . Absorbance was measured 
at 725 nm by using Shimadzu UV-1700 spectrophotometer. Standard calibration curve of 
absorbance against gallic acid concentration was prepared and used for estimation of total 
phenolic content in test sample. Assays were carried out in triplicate and the results were 
mean values ± standard deviation, expressed as gallic acid equivalents. 
4.2.2. Estimation of total flavonoid content
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Flavonoid content present in EEBS were evaluated according to 
spectrophotometric method. Test sample and rutin (standard) were prepared with the 
methanol to make a final concentration of 100 mg/mL. One mL of test solution was 
treated with 1 mL of 2% aluminium chloride in ethanol, taken in a 10 mL volumetric 
flask and volumes were made up to 10 mL with methanol.  After keeping this solution for 
an hr at room temperature, absorbance was measured at 415 nm using spectrophotometer. 
Assays were conducted in triplicate and the mean value of absorbance were obtained. 
Calibration curve was constructed using standard solution of rutin by following the same 
assay procedure.  Based on the measured absorbance the concentration of flavonoid was 
estimated from the calibration line. The content of flavonoids in extract were expressed in 
terms of rutin equivalents.  
4.3. Assessment of in vitro antioxidant activity of EEBS 
4.3.1. DPPH (1,1-Diphenyl-2-picryl hydrazine) radical scavenging activity 
DPPH free radical scavenging activity was evaluated using the method described 
by Blois.
127
 Various concentrations of EEBS and ascorbic acid (standard) ranging (10-
100 µg/mL)  were mixed with 1 mL of freshly prepared 0.3 mM DPPH ethanol solution 
and 2 mL of 0.1M acetate buffer. Incubated at room temperature for 30 mins and the 
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Absorbance of resulting solutions were then measured colorimetrically at 517 nm. DPPH 
solution (1.0 mL, 0.3 mM) treated with 1mL ethanol, served as negative control. 
Ascorbic acid was used as positive control under the same assay condition. Samples were 
prepared in triplicate for each analysis and the mean value of absorbance was obtained. 
The antioxidant activity of the extract was expressed as IC50. Higher absorbance indicates 
lower free radical scavenging activity. The percentage of DPPH radical scavenging 
activity of extract was calculated from decrease in absorbance in comparison with control 
by using formula: 
Percentage inhibition (%) = [(Abs control – Abs test) / Abs control] X 100 
4.3.2. Ferric reducing antioxidant power (FRAP) assay 
The antioxidant capacity of EEBS was determined using method described by 
Benzie and Strain.
128
  0.5 mL  of  EEBS at different concentration (10-100 μg/mL) was 
mixed with 900 µL of  FRAP reagent,  incubated for 6 mins  at room temperature and the 
absorbance was measured at 593 nm.  Methanol solution of ferrous sulphate ranging from 
100 to 2000 𝜇M were prepared and used for the preparation of the calibration curve of 
known Fe
2+
 concentration. The antioxidant capacity based on the ability to reduce ferric 
ions of sample was calculated from the linear calibration curve and expressed as mmol 
ferrous sulphate equivalents per gram of sample. Ascorbic acid at various concentrations 
were used as standard. Increased absorbance of reaction mixture indicates increase in 
reducing power.  
 
 
  
                                                                              Materials and Methods 
 
 Page 50 
 
4.3.3. ABTS [2, 2’-azino-bis (3-ethylbenzo-thiazoline-6-sulphonic acid) diammonium 
          salt] radical scavenging assay   
Total antioxidant potential of extract was determined based on the procedure 
described by Re et al.
129
 5 mL of 4.9 mM ammonium  per sulphate  solution was mixed 
with 5 mL of 14 mM ABTS stock  solution and kept for 16 hrs in dark at room 
temperature that resulted in the formation of fresh ABTS radical. The resultant ABTS
*+
 
solution was diluted with ethanol (99.5%) until an absorbance of 0.70 ± 0.02 at 734 nm 
was obtained. One mL of different concentration of EEBS or standard ascorbic acid (10-
100 μg/mL) were allowed to react with 900 µL of ABTS radical solution. Reaction 
mixture was vortexed for 10 secs and after 6 mins, the absorbance was recorded at 734 
nm. Negative control was prepared without adding extract or standard.  Mean values  
were obtained from triplicate analysis. The extract concentration providing 50% 
inhibition (IC50) was obtained by plotting inhibition percentage versus extract 
concentration. 
4.3.4. Hydroxyl radical scavenging activity  
Scavenging activity of the extract on hydroxyl radical was determined according 
to the 2-deoxyribose assay reported by Halliwell and Gutteridge. 
130 
 Hydroxyl radical 
was generated from Fe
3+ 
-ascorbate, EDTA-hydrogen peroxide system.  0.4 mL of EEBS 
at concentration ranging (10-100 μg/mL) were treated with 2-deoxy-D- ribose (1.4 mM), 
ferric chloride (100 µM), EDTA (1.04 mM) and hydrogen peroxide (1 mM).  Volume 
was made upto 1.6 mL using potassium  phosphate buffer (10 mM,  pH 7.4). Incubated  
the solution for 10 mins at 37ºC.  0.4 mL of 0.2 mM phenyl hydrazine hydrochloride  was 
added, incubated for 1hr and then 1 mL each of 2.8% tricarboxylic acid (TCA) and 
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thiobarbituric acid (0.5% TBA in 0.025 M sodium hydroxide containing 0.02% butylated 
hydroxyanisole) were added to 0.5 mL of the reaction mixture.  Reaction  mixture was 
then heated in a water bath at 95ºC for  15 mins. The reaction mixture was centrifuged at 
5000 rpm for 15 mins, after cooling by keeping the mixture on ice.  Absorbance of the 
supernatant was measured at 532 nm. The hydroxyl radical scavenging capacity of the 
extract was compared with that of ascorbic acid which was used as positive control under 
the same assay condition. Negative control was prepared without adding extract or 
standard and was considered as 100% deoxy oxidation. The percentage hydroxyl radical 
scavenging activity of extract was determined in terms of IC50 value, in comparison with 
negative control. 
4.3.5. Superoxide radical scavenging activity 
Super oxide anion radical scavenging assay was determined according to the 
method described by Nishimiki et al.,
131 
with slight modification. 0.1 mL of 
EEBS/standard at different concentrations  (10-100 μg/mL) were mixed with 1 mL of 156 
µM nitroblue tetrazolium (NBT) solution in phosphate buffer  (100 mM, pH 7.4) and 1 
mL  468 µM nicotinamide adenine dineucleotide hydrogen (NADH) in phosphate buffer  
(100 mM, pH 7.4). The reaction was started by adding 100 mL of 60 mM phenazine 
methosulphate (PMS) in phosphate buffer (100 mM, pH 7.4), then incubated the reaction 
mixture at 25ºC for 5 mins and the absorbance was measured at 560 nm against the 
standard solution (ascorbic acid). Radical scavenging activity of the extract concentration 
providing 50% inhibition (IC50) was obtained by plotting inhibition percentage versus 
extract concentration. 
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4.3.6. Nitric oxide radical scavenging activity 
This assay was done according to the method of Garatt et al
 
.
132
 Griess Ilosovy 
reagent was modified by using naphthyl ethylenediamine dihydrochloride  (0.1% w/v) 
instead of the use of 1-naphthyl amine (5%). 2mL of 10 mM sodium nitroprusside 
prepared in 0.5 mM phosphate buffer saline (pH 7.4) was added to 0.5 mL of sample at 
various concentration (10-100 μg/mL). The solution was incubated at 25ºC  for  2.5 hrs. 
Then 1.5 mL of mixture was mixed with 1.5 mL of  Griess reagent (1% sulphanilamide,  
2% phosphoric acid, 0.1% of naphthyl ethylenediamine di-hydrochloride) and incubated 
at room temperature for 5 mins. The absorbance was read at 546 nm. Ascorbic acid was 
taken as standard. Percentage inhibition was calculated. 
4.3.7. Reducing power activity 
The reducing power activity was estimated according to the method of Oyaizu.
133
 
2.5 mL of various concentrations of EEBS (10-100 μg/mL) were mixed with sodium 
phosphate buffer (2.5 mL, pH 6.6) and 1% potassium ferricyanide (2.5 mL).  Incubated at 
50ºC for 20 mins and 2.5 mL of 10% trichloroacetic acid (w/v) was added and then 
centrifuged for 10 mins. The upper layer of solution 5 mL was treated with 5 mL 
deionized water and 1mL of 0.1% ferric chloride.. Reducing ability of extract was 
compared with that of ascorbic acid which was used as positive control.  A blank was 
prepared without adding extract or standard. Absorbance was measured at 700 nm. 
Assays were carried out in triplicate and the results were expressed as mean values ± SD. 
Increased absorbance of reaction mixture indicates increase in reducing power. 
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4.4. Assessment of in vitro antiurolithic activity of EEBS 
Chemicals: Calcium chloride dihydrate, Tris-buffer, Sodium oxalate (Sisco Research 
Laboratories Pvt. Ltd., Mumbai, India). 
Stock calcium chloride and sodium oxalate solutions (respectively 20x10
-3
M and 
1.0x10
-3
M) were buffered at pH 5.5 with 9 mM sodium di-methyl arsinate and brought to 
an ionic strength of 0.15 M. 
4.4.1. Nucleation assay 
Inhibition capacity of plant extract on calcium oxalate (CaOx) crystallization was 
determined according to the classical method described by Hennequin et al.
134
 1 mL of 
0.025 M calcium chloride solution, 2 mL of 0.05 mol/L Tris-buffer, 1 mL of EEBS/ 
standard compound cystone at various concentrations (10-100 mg/mL) were added to test 
tube and then 1 mL of 0.025 M sodium oxalate was added. Solution was transferred to a 
beaker and then constantly stirred at room temperature. Procedure was repeated for six 
duplicates for each sample. The rate of nucleation was determined by comparing 
appearance of crystals that reached critical or optically detectable size in the presence of 
extract and that of control with no extract.
 135
 The absorbance was recorded at 620 nm 
and the percentage inhibition was calculated by using the formula:  
Percentage inhibition (%) = Abs test /Abs control  X 100 
4.4.2. Aggregation assay 
Aggregation of CaOx crystals was determined by following the method of Atmani 
et al.
136 
The CaOx crystals were prepared by mixing 1 mL of 0.025 M calcium chloride 
and 1mL of 0.025 M sodium oxalate. Both solutions were then equilibrated at 60ºC in a 
water bath for 1 hr and then cooled to 37ºC overnight.  The formed crystals were 
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harvested by centrifugation for 5 mins and then evaporated at 37ºC. The crystals were 
used at final concentration of 0.8 mg/mL, buffered with Tris-hydrochloride 0.05 mol/L 
and sodium chloride 0.15 mol/L at pH 6.5. Experiments were conducted at 37ºC by 
adding 1mL of EEBS or cystone (standard) at various concentrations (10-100 mg/mL). 
The rate of aggregation was estimated by comparing turbidity in presence of 
EEBS/standard with that of control. The absorbance at 620 nm was recorded 
spectrophotometrically. The percentage inhibition rate (Ir) was calculated by the 
following formula:
69
 
Percentage inhibition (Ir) = 1- (Turbidity test / Turbidity control)  X 100 
4.4.3. Image analysis of calcium oxalate (CaOx) crystal morphology (Microscopic 
          assay) 
Incubation of metastable solutions of calcium chlorie and sodium oxalate resulted 
in the formation of CaOx crystals. The harvested crystals were centrifuged and placed on 
a petriplate glass slide. Various concentration of EEBS (20, 40, 80, 160 µg/mL) and 
control were then applied directly to the crystals. Change in structure of CaOx crystals 
were compared with the control by observing under microscope after 30 mins to 
determine how crystals were dissolved by extract. Crystal size was observed under Leica 
stereo zoom dissecting microscope with digital imaging system at 4X and the 
photographs were taken.135  
4.5. In vitro pharmacological studies 
 4.5.1. Assessment of cytotoxic  activity of EEBS  on kidney cell lines 
Therapeutic usefulness of plant drugs for various diseases were normally based on 
accidental discovery. Hence cytotoxicity testing with herbal extracts are vital for the 
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safety evaluation. Prior to in vivo pharmacologic studies, cell viability or cell toxicity of 
EEBS were determined by Trypan blue dye exclusion aasay and MTT assay method. 
Lactate dehydrogenase (cytosolic enzyme) levels  were also determined which is an 
important  indicator of cellular cytotoxicity. Additionally, DNA fragmentation assay was 
also done for further evaluating the nature of cell death. 
The percentage cell viability of EEBS was determined on human embryonic 
kidney 293 (HEK 293) cell line by using Trypan blue dye exclusion and MTT assay 
method. 
Chemicals: Trypan blue, 3-(4, 5 dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT), fetal bovine serum (FBS), phosphate buffered saline (PBS), bovine serum 
albumin (BSA), Dulbecco’s  modified eagle’s medium (DMEM), Trypsin (Sigma Aldrich 
Co., St Louis, USA) ethylenediaminetetraacetic acid (EDTA), antibiotics, isopropanol 
and dimethyl sulphoxide (DMSO)   
Cell line 
The human embryonic kidney cell line (HEK 293) was obtained from National 
Centre for Cell Science  (NCCS), Pune and were grown in DMEM containing 10% 
inactivated FBS, penicillin (100 IU/mL), streptomycin (100 µg/mL) and amphotericin B 
(5 µg/mL). The cells were maintained at 37ºC, 5% CO2, 95%  air  and 100% relative 
humidity. Maintenance cultures were passaged weekly and the culture medium was 
changed twice a week. Stocks were maintained in 25-cm
2
 tissue culture flasks at 37ºC in 
5% CO2 incubator. Each experimental culture was performed with a culture density of 
1×10
6
 cells in 96 microtitre plates (Tarsons India Pvt. Ltd., Kolkata, India).  
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Preparation of test solutions 
For cytotoxicity studies, different concentrations of EEBS (12.5, 25, 50,100, 200 
μg/mL) were separately dissolved in distilled DMSO and volume was made up with 
DMEM supplemented with 2% inactivated FBS to obtain a stock solution of 1 mg/mL 
concentration and sterilized by filtration. A serial of two fold dilution of different 
concentration of plant extracts were prepared and added to the culture medium.  All 
preparations were sterilized by passing through the membrane filter 0.45 μm (Schleicher 
& Schuell, Germany).  
4.5.1.1. Determination of cell viability by trypan blue exclusion assay 
137, 138 
 
Trypan blue is an essential blue acid dye, consist of two azo chromophore groups 
used in determining viability of cells. For the determination of cell viability, HEK 293 
cells were plated at a density of (1×10
6
 cells/well) in 96 well tissue culture plates and 
cultured for 48 hrs at 37ºC. Cells were then treated with various concentrations of EEBS 
(12.5, 25, 50, 100 and 200 μg/mL) for 48 hrs. The cultures were harvested, washed twice 
with PBS and then cell pellets were  suspended in 0.5 mL PBS. 50 µL of cell suspension 
was mixed thoroughly with an equal volume of 0.4% trypan blue in sterile microfuge 
tube. Washed hemacytometer and coverslip with 70% isopropanol, dried and transferred 
10 μL mixture of the cell culture/trypan blue mixture from microfuge tube using 
micropipette into a notch of the haemacytometer and covered it with a cover slip. Placed 
the haemocytometer on the stage of an inverted microscope. Focused light on the 
haemocytometer grid using 100X magnification and observed live cells which appeared 
as clear.  The medium without samples were served as control and triplicate was 
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maintained for all concentrations. Calculated the percentage of cell viability by using 
following formula: 
Percentage cell viability (%) = Viable cell count / Total cell count X 100 
4.5.1.2. Determination of cell viability by MTT assay
139-141
 
Procedure 
The monolayer cells were detached with Trypsin phosphate Versene Glucose 
(TPVG) solution (0.1% trypsin, 0.02% EDTA, 0.05% glucose in PBS)  to make single 
cell suspensions (HEK 293 cells) and one hundred microlitres per well of cell suspension 
were seeded into 96-well plates at plating density of 10,000 cells/well. Incubated for cell 
attachment at 37º C, 5% CO2, 95% air and 100% relative humidity. Aliquots of 100 µL of 
serial concentrations of the test sample (12.5, 25, 50, 100, 200 μg/mL), which was 
initially dissolved in dimethyl sulfoxide were added to the appropriate wells already 
containing 100 µL of medium, resulting in the required final sample concentrations. 
Following sample addition, the plates were incubated for an additional 24 hrs  at 37ºC, 
5% CO2, 95% air and 100% relative humidity. The viable cells were counted using 
hemocytometer. The medium containing no samples were served as control and triplicate 
were maintained for all concentrations. After 48 hrs of incubation, 15 µL of MTT (5 
mg/mL) in phosphate buffered saline (PBS) were added to each well and incubated at 
37ºC for 4 hrs. The plates were wrapped in aluminum foil. The medium with MTT was 
then flicked off and the formed formazan crystals were solubilized in 100 µL of DMSO 
and absorbance was measured at 570 nm using micro plate reader. The percentage cell 
growth was then calculated with respect to control. 
Percentage cell growth (%) =  Abs test / Abs control  X 100 
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4.5.1.3. Determination of cytotoxicity of EEBS by lactate dehydrogenase (LDH) 
             assay  
[LDH, EC 1.1.1.27] 
Chemicals: Sodium pyruvate, NADH, foetal bovine serum, RPMI (Roswell Park 
Memorial Institute medium), penicillin (100 IU/mL), streptomycin (100 µg/mL). 
Cell lines and culture medium 
The human kidney adenocarcinoma cell line (A498) was obtained from National 
Centre for Cell Science (NCCS), Pune. Cell culture A498 cells were cultured in RPMI-
1640 medium supplemented with 10% foetal bovine serum and penicillin (100 IU/mL), 
streptomycin (100 µg/mL). Cultures were maintained in a humidified incubator 
containing 21% O2 and 5% CO2 in air. 
Procedure 
Lactate dehydrogenase assay was carried out according to the method of 
Wroblewski and Ladue.
142  
The LDH leakage assay is a simple reliable and fast 
cytotoxicity assay based on the measurement of lactate dehydrogenase activity in the 
extracellular medium. A498 cells (1×10
6
 cells/well) were plated in 100 μL of 
medium/well in 96-well plates and were allowed to attach to the plate for 24 hrs. After 
cell attachment, cells were treated with various concentrations of EEBS (5, 10, 20, 40, 
80,160, 320 μg/mL). Following treatment, the culture medium was aspirated and 
centrifuged at 3000 rpm for 5 mins in order to obtain a cell free supernatant. The activity 
of LDH in the medium was determined by adding 100 μL of cell free supernatant of the 
control and EEBS treated A 498 cells to 1-mL cuvette containing 0.9 mL of the reaction 
mixture of pyruvate, 0.15 mmol/L NADH and 104 mmol/L phosphate buffer (pH 7.4).  
                                                                              Materials and Methods 
 
 Page 59 
 
After thorough mixing, the absorbance of the solution was measured at 340 nm. LDH 
activity was expressed as μ moles of NADH used per minute per well. All experiments 
were repeated for three duplicates for each sample.  
LDH activity (U/L) = (Abs.@ 340 nm/min) X 16030. 
4.5.1.4. Determination  of nature of cell death by DNA fragmentation assay
143
 
Chemicals: Lysis buffer, Tris-EDTA (TE)  buffer, Trypsin, ethanol, Sodium acetate,  
Ribo- nuclease A (RNase A), Isopropanol 
Procedure 
A498 cells were seeded at a concentration of 10
6
 per 35 mm dish incubated at 
37
o
C/ 5 % CO2 for 24 hrs. The confluent cells grown after 24 hrs of incubation were 
treated with EEBS extract at 160 and 320 µg/mL. After treatment, cells were trypsinized 
and both adherent and floating cells were collected by centrifugation at 2000 rpm for 5 
mins. The cell pellet was suspended in 0.5 mL lysis buffer [Tris-HCl 10 mM, pH 8; 
EDTA 20 mM, pH 8.0; Triton X-100 (0.2%), 4M NaCl], vortexed vigorously and 
incubated at 50°C for 5 mins. To the lysate, 0.5 mL of phenol-chloroform-isoamylalcohol 
were added and mixed for 2-3 mins. It was centrifuged at 10000 rpm for 15 mins at 4
o
C. 
The upper aqueous layer was taken in a tube, to which double the volume of cold 100% 
ethanol and 3M sodium acetate were added and incubated for 5-10 mins at room 
temperature. The supernatant was removed, the DNA pellet was air dried and was finally 
dissolved in TE buffer (Tris-HCl 10 mM, pH 7.4, EDTA 1 mM, pH 8.0), and separated 
by 2% agarose gel electrophoresis at 100 V for 50 mins.  
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4.6. Pharmacological studies 
4.6.1. Experimental animals 
Adult male albino rats of Wistar strain, weighing between 150‐200 gms were used 
for the nephroprotective and antiurolithic studies. They were obtained from Sree 
Venkateswara Enterprises Pvt. Ltd., Bangalore and housed in clean polypropylene cages 
covered with stainless steel filter tops under standard laboratory condition of 12 hr 
light/12 hr dark cycle, 50% humidity and temperature 25±2ºC. They were fed with 
standard commercial rat feed pellets (SAI animal feed Ltd., Bangalore, India) and 
water ad libitum  throughout the study. The animals were acclimatized to laboratory 
condition before the commencement of experiments. 
4.6.2. Ethical committee approval 
All animal procedures in this study were performed after obtaining ethical 
clearance from Institutional Animals Ethics Committee (IAEC) of KMCH College of 
Pharmacy, Coimbatore,  (KMCRET/Ph.D/12/2015-16). The rats received human care 
according to the guideline of Committee for the Purpose of Control and Supervision of 
Experiments on Animals (CPCSEA). 
4.6.3. Acute toxicity studies 
Acute oral toxicity studies were not performed as studies of ethanolic extract of 
whole plant B. sensitivum have already been reported. Previous study by Anidya et al.,
112 
 
used 5000 mg/kg dose of  EEBS as higher  dose in albino rats. Hence, one tenth of this 
dose, 500 mg/kg (higher dose) and lower dose as 250 mg/kg have been selected for the 
present study. 
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4.7. Evaluation of nephroprotective activity of EEBS 
4.7.1. Animal grouping  
Thirty albino rats were used in each drug induced toxicity models. Animals were 
divided into five groups with 6 animals in each group, designated as Group I, II, III, IV 
and V. Animals in  group I served as control and  group II served as toxic control. Rats in 
Group II to V were treated with drugs which induce toxicity. Animals in group III, IV 
and V also received standard drug, low dose of EEBS (250 mg/kg) and high dose EEBS 
of (500 mg/kg) respectively. 
4.7.1.1. Gentamicin-induced nephrotoxicity 
144, 145 
Table 5: Grouping of animals in gentamicin (GM)-induced nephrotoxicity model 
 
 
 
 
 
 
 
 
  
 
 
 
 
Gentamicin (GM)-induced nephrotoxicity 
Group              Treatment 
Group I Normal saline1mL/day; for 8 days; i.p. 
Group II GM 100 mg/kg; for 8 days; i.p 
Group III GM+Quercetin 50 mg/kg; for 8 days; p.o. 
Group IV GM+Extract 250 mg/kg; for 8 days; p.o. 
Group V GM+Extract 500 mg/kg; for 8 days; p.o. 
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4.7.1.2. Cisplatin-induced nephrotoxicity 
146, 147  
Table 6: Grouping of animals in cisplatin (CDDP)-induced nephrotoxicity model 
 
 
 
 
 
 
 
 
4.7.1.3. Ethylene glycol-induced urolithiasis 
148-150 
Table 7: Grouping of animals in ethylene glycol (EG)-induced urolithic model 
 
 
.  
 
  
 
 
 
  
 
 
Cisplatin (CDDP)-induced nephrotoxicity 
Group              Treatment 
Group I Normal saline 1mL/day; for 9 days; i.p 
Group II CDDP  single dose of 8 mg/kg on fifth day; i.p. 
Group III CDDP+Quercetin 50 mg/kg; for 9 days; p.o. 
Group IV CDDP+Extract 250 mg/kg; for 9 days; p.o. 
Group V CDDP+Extract 500 mg/kg; for 9 days; p.o. 
Ethylene glycol (EG)-induced urolithiaisis 
Group Treatment 
Group I Normal control 
Group II EG (0.75% v/v) for 28 days; p.o. 
Group III EG+Cystone 750 mg/kg; from 15
th
 day till 28
th 
day; p.o. 
Group IV EG+Extract 250 mg/kg; from 15
th
 day till 28
th
 day; p.o. 
                          ( Curative regimen) 
Group V EG+Extract 500 mg/kg; from 1
st
 day till 28
th
 day; p.o. 
                           ( Preventive regimen) 
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4.8. Parameters studied in drug induced nephrotoxicity and urolithic models 
After treatment period, 24 hr urine samples were collected. Urine was then 
analyzed for total protein, albumin, sodium, potassium, calcium and magnesium in 
animals induced with nephrotoxicity, whereas in calculi-induced rats total protein, 
albumin, calcium, phosphate and magnesium levels were determined. After collecting the 
urine, the rats in all groups were anaesthetized with 80 mg/kg ketamine hydrochloride. 
Blood was collected from tail vein under mild anesthesia and determined various 
haematological parameters. For the estimation of different biochemical parameters, 
serum was separated and analyzed for total protein, albumin, sodium, potassium, calcium, 
magnesium, blood urea nitrogen (BUN), uric acid, and creatinine levels in CDDP and 
GM-induced nephrotoxicity models. Total protein, albumin, calcium, phosphate, 
magnesium, BUN, uric acid, and creatinine levels were determined in EG-induced 
urolithic rats.The rats were sacrificed after the administration of last dose of toxicant and 
separated kidneys were weighed, homogenized and used for the estimation of superoxide  
dismutase (SOD), catalase (CAT), glutathione  peroxidase (GPx), reduced glutathione 
(GSH) and malondialdehyde (MDA) levels.  
4.8.1. Assessment of general parameters 
 Body weight of all experimental animals were recorded at the beginning and 
end of the treatment schedule. After the last dose of drug administration, change in the 
body weight, kidney weight and water intake (mL/24 hr) were measured. Total urine 
volume (mL/24 hr) and the acidity of the urine were also recorded. 
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4.8.2. Assessment of hematological parameters 
After the treatment  period, experimental animals in drug induced toxicity models 
were fasted over night and blood was collected for the estimation of different 
hematological parameters including, red blood cells (RBCs), hemoglobin (Hb), packed 
cell volume (PCV), mean corpuscular hemoglobin (MCH), white blood corpuscles 
(WBC), lymphocyte, monocyte,  polymorphs and eosinophils. 
For determining red blood cells, EDTA anti-coagulated blood was drawn using a 
red blood cell pipette of haemocytometer and thoroughly mixed with RBC diluting fluid 
(Turks solution). The mixture was transferred onto the counting chamber (neubar 
chamber) and placed under the microscope. The total number of RBC (millions per cubic 
millimetre) were counted uniformly in the smaller four corner squares.
151  
Haemoglobin 
was converted into acid haematin by the action of dilute hydrochloric acid.  Blood drawn 
upto 20 µL in the Sahli’s pipette was mixed with 0.1 N hydrochloric acid taken up to the 
lowest marking in the haemoglobinometer.  Allowed the mixture to stand at room 
temperature for 10 mins.  The acid haematin solution was further diluted with distilled 
water until its colour matched exactly with that of permanent standard in the 
haemoglobinometer. The lower meniscus of the fluid was noted in g/100 mL. (Sahli’s 
acid hematin method). The total white blood cells were enumerated according to the 
method described by John,
152  
using Turk’s fluid  (WBC diluting fluid). Blood was 
collected using a white blood cell pipette of haemocytometer and mixed with WBC 
diluting fluid. The mixture was transferred onto the counting chamber (neubar chamber) 
placed under the microscope and  viewed under 10X objective. The total number of WBC 
in thousands per cubic millimeter were counted uniformly in the four larger corner 
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squares. The haematological parameters like PCV (%), MCH (Pg) and differential 
leukocytes (%) were measured using instrument celldyn 1700 haematology analyser 
(automated method).  
4.8.3. Determination of total protein and albumin level 
Total protein content in urine/serum were determined by the method of Lowry et 
al.
153  
Briefly, 4.5 mL of alkaline copper sulphate reagent and 0.5 mL of  Folin’s phenol 
reagent were added to all the test tubes containing 0.2 mL of test solution and 0.2-1 mL 
of Bovine serum albumin (working standard, 100 mg/mL). Volume of the sample and 
standard were made upto 1mL with distilled water, before adding the reagent. Distilled 
water of 1mL served as blank. Thoroughly mixed the reagent with sample or test solution  
and the blue colour developed was read at 640 nm. From the standard graph the amount 
of protein in the given unknown solution was calculated. Total protein present in the 
sample is expressed in g/dL.  
Albumin level was determined by Reinhold’s method using biuret reagent.154  
Pipetted out 0.2 mL of serum/urine in a centrifuge tube and added 5.8 mL sodium 
sulphite solution and 3 mL ether. Mixed well, kept for 5 mins and then centrifuged. 
Albumin appears in the bottom layer of the tube. 3 mL of biuret reagent was added to test 
tubes containing 3 mL globulin free test solution.  3 mL of biuret reagent was added to 
0.1 mL standard solution (albumin solution) mixed with 2.9 mL of distilled water. For 
blank, 3 mL of distilled water was mixed with 3mL of biuret reagent.  Mixed  well and 
kept all test tubes in a water bath for 10 mins at 37ºC.  Allowed to cool and observed 
readings of test and standard against the blank at 540 nm in a spectrophotometer. Total 
albumin content present in the sample is expressed in g/dL. 
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4.8.4. Determination of urinary and serum electrolyte level 
4.8.4.1. Determination of calcium level  
The serum/urine calcium levels  were  estimated based on method of Lorentz 
using a diagnostic kit supplied by  Clini chem calcium kit manufacturer, Robonik Pvt. 
Ltd., Mumbai, India.
155 
 24-hr collected urine sample was  diluted with distilled water 
(1:3). The pH-value of the urine was adjusted to pH 3-4 with dilute  hydrochloric acid. 
0.5 mL of buffer solution (2-amino-2-methyl-1-propanol,  400 mmol/L) mixed with 0.5 
mL of chromogen reagent (o-cresolphthalein 0.62 mmol/L,  8-Hydroxy quinoline 69 
mmol/L), served as working reagent. 1 mL of working reagent was added to each test 
tube containing 20 μL sample and 20 μL standard solution. 1 mL working reagent added 
to 20 μL distilled water was used as blank.  After mixing thoroughly incubated the 
reaction mixtures at room temperature for  5 mins. The absorbance of sample and 
standard were measured at 570 nm  against the blank reagent.  
Conc. of calcium (mg/dL) =  Abs sample / Abs blank X Conc. of sample 
4.8.4.2. Determination of phosphate level 
Phosphate levels  were  determined by the method of Fiske and Subbarow.
156
 5mL 
serum/urine or 5 mL standard containing 0.04 mg phosphate, were mixed with 1mL 
molybdic acid reagent, and added 0.4 mL amino-naphthoL-sulphonic acid (0.25%).  For 
blank , 1mL molybdic acid reagent was mixed with  5mL distilled water and added 0.4 
mL amino- naphthoL-sulphonic acid. Finally volume  was  made upto 10 mL mark with 
distilled water. The absorbance of sample and standard were  measured at 680 nm against 
the blank reagent after keeping the reaction mixtures at room temperature for 5 mins. 
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Conc. of Phosphate (mg/dL) = Abs test / Abs standard X 0.04 X 100 
4.8.4.3. Determination of magnesium level 
  Urinary and serum level of magnesium were determined according to the method 
of Heaton.
157 
1 mL serum/urine was mixed with 6 mL trichloroacetic acid (10%). 
Centrifuged after keeping the solution for 10 mins at room temperature. 0.5 mL polyvinyl 
alcohol (0.2%), 2.5 mL titan yellow (15mg%)  and 1 mL sodium hydroxide (20%) were 
added to the 2mL of supernatant, mixed the solution carefully and allowed to stand for 20 
mins at room temperature. For standard, 1 mL magnesium sulphate solution was used and 
followed same assay procedure of test solution.  1mL distilled water was used as blank. 
The absorbance of sample and standard were measured at 680 nm against the blank. 
Conc. of magnesium (mg/dL) = Abs sample – Abs blank  /  Abs std –Abs blank X Conc. of std 
4.8.4.4. Determination of sodium level 
Urinary and serum level of sodium was estimated by the modified method of 
Trinder and Maruna
158 
using a diagnostic reagent kit supplied by Lab care diagnostics pvt 
Ltd., Sarigam, Valsad, India. 1 mL filtrate reagent was added to each of sample (50 μL 
serum/urine) and 50μL sodium standard. Mixed well and allowed to stand for 5 mins at 
room temperature.  50 μL    supernatant of standard sodium solution or 50 μL supernatant 
of test solution, after centrifugation at high speed for 10 mins  was mixed with 1 mL  acid 
reagent and 2 drops of color reagent. 50 μL filtrate reagent mixed with 1 mL   acid 
reagent and 2 drops color reagent were used as blank. Absorbance  of standard and test 
against reagent blank were measured at 546 nm. 
Conc. of sodium (mmol/L) = Abs blank – Abs test  /  Abs blank – Abs std X 150 
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4.8.4.5. Determination of potassium level  
Potassium was estimated by the modified method of Trinder and Maruna
159
 using 
a diagnostic reagent kit supplied by Lab care diagnostics pvt Ltd, Sarigam, Valsad, India. 
1 mL  potassium reagent was added to each of the sample (20 μL  serum/urine), 
potassium standards (20 μL) and  blank (20 μL distilled water).  After incubating the 
mixture at room temperature for 15 mins absorbance of the standard and test were 
measured against reagent blank at 630 nm.  
Conc. of potassium (mmol/L) =  Abs test – Abs blank /  Abs std – Abs blank X 5 
4.8.5. Determination of nitrogenous waste product levels in serum 
4.8.5.1. Determination of serum blood urea nitrogen (BUN) level 
The blood urea was estimated by Berthelot method (Fawcett and Scott)
160 
using 
the commercially available kit  (Kamineni Life Sciences Pvt. Ltd., Hyderabad, India). 
1000 μL of working reagent-I containing urease reagent and a mixture of salicylate, 
hypochlorite and nitroprusside were added to each of the sample  (10 μL of serum), 
standard (10 μL of urea)  and  blank (10 μL of purified water). Mixed well and incubated 
at 37°C for 5 mins. Then 1000 μL of reagent-II containing alkaline buffer, was added to 
all the test tubes, which were incubated at 37°C for 5 mins. The intensity of blue-green 
colour produced is directly proportional to the concentration of urea in the sample and 
absorbance was measured spectrophotometrically at 578 nm. The blood urea was 
calculated using the following formula:  
Conc. of blood urea (mmol/L) = Abs test – Abs std  X 40 
   Blood urea nitrogen (mg/dL) = Serum urea X 0.467 
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4.8.5.2. Determination of serum uric acid level  
Uric acid content was estimated by following the method of Caraway.
161
 After  
centrifugation of serum,  0.6 mL of phosphotungstic acid and 0.6 mL of sodium 
carbonate  were  added to each of  2 mL  supernatant of sample and  standard.  Uric acid 
standards with graded volumes were also prepared.  A blank was setup with 3.0 mL of 
water. After 10 mins  the colour developed was measured at 640 nm 
spectrophotometrically.  
Conc. of uric acid (mg/dL) =  Abs sample /  Abs std X 0.02 
4.8.5.3. Determination of serum creatinine level  
The serum creatinine concentration was estimated using the commercially 
available kit (Cresent biosystems, Goa, India) by alkaline picrate method (Bonsnes and 
Taussky).
162  
2.0 mL of picric acid reagent was added to 0.2 mL of serum, mixed well and 
centrifuged at 3000 rpm to obtain a clear supernatant. 100 μL of buffer reagent was added 
to 1.1 mL of supernatant, 0.1 mL of standard creatinine and 0.1 mL of distilled water to 
prepare test, standard and blank, respectively. 1.0 mL of picric acid reagent was added to 
blank and standard. Mixed well and kept all solutions at room temperature for 20 mins. 
The intensity of orange colour formed was read at 520 nm spectrophotometrically. The 
serum creatinine concentration was calculated using the following formula: 
Conc. of creatinine (mg/dL) =  Abs test /  Abs std X 2 
4.8.6. Determination of antioxidant enzymes and lipid peroxidation 
Preperation of tissue homogenate 
The rats were sacrificed after the administration of last dose of toxicant by 
euthanasia method. Both the kidneys were removed immediately, washed with normal 
                                                                              Materials and Methods 
 
 Page 70 
 
saline and stored for 12 hrs to carry out in vivo antioxidant studies. The  separated left 
kidney was homogenized with a motor driven Teflon coated homogenizer with 0.1M 
Tris-hydrochloride  buffer (pH 7.4) to get 10%  w/v homogenate. The homogenate was 
centrifuged at 10,000 rpm for 10 mins at 5°C, then the collected clear supernatant was 
used for the estimation of superoxide dismutase, catalase activity,  glutathione 
peroxidase, reduced glutathione and lipid peroxidation. 
4.8.6.1. Estimation of superoxide dismutase (SOD) 
SOD  was estimated according to the modified  procedure described by Kakkar et 
al. 
163 
0.5 mL of  kidney homogenate was diluted with distilled water (0.5 mL) and 
treated with 0.25 mL of ethanol and 0.15 mL of chloroform. Supernatant of kidney 
homogenate was removed after centrifuging the mixture for 1 min. 1.5 mL of buffer was 
added to 0.5 mL of kidney homogenate and the reaction was started by adding 0.4 mL of 
epinephrine. Change in optical density per minute was determined at 480 nm in double 
beam UV-VIS spectrophotometer. Activity of SOD was expressed as unit/min/mg of 
protein. 
4.8.6.2. Estimation of catalase (CAT) 
The catalase activity was assayed by colourimetric method of Sinha.
164   
Kidney 
homogenate (0.1 mL) was mixed with 1.0 mL of phosphate buffer and 0.50 mL of 
hydrogen peroxide. 1 mL of the reaction mixture was withdrawn and 0.2 mL 
dichromate/acetic acid reagent was blown at the interval of 1 min to arrest the reaction.  
The standard hydrogen peroxide in the range of 4 to 20 µL were taken and treated 
similarly. The tubes were heated in a boiling water bath for 10 mins. The green color 
developed was read at 570 nm by using a double beam UV-VIS spectrophotometer. The 
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activity of catalase was expressed as µmol of hydrogen peroxide consumed/min/mg 
protein. 
4.8.6.3. Estimation of glutathione peroxidase (GPx) 
The glutathione peroxidase activity was measured according to the method of 
Rotruck et al.
165 
0.2 mL each of  EDTA, sodium azide, reduced glutathione, hydrogen 
peroxide,  0.4 mL of buffer and 0.1 mL of enzyme (kidney homogenate) were mixed and 
incubated at 37°C for 10 mins. The reaction was arrested by the addition of 0.5 mL of 
tricarboxylic acid and the tubes were centrifuged. To 0.5 mL of supernatant, 3mL of 
sodium hydrogen phosphate and 1 mL of 5,5′-dithiobis(2-nitrobenzoic acid) were added 
and the color developed was read at 412 nm immediately by using UV-VIS 
spectrophotometer. Glutathione peroxidase activity is expressed as µ moles of glutathione 
oxidized/min/mg protein. 
4.8.6.4. Estimation of reduced glutathione (GSH) 
GSH  was estimated by Ellman’s procedure.166  Tissue  homogenate (250 L)  was 
treated with 1 mL of  5% tricarboxylic acid in a 2 mL Eppendorf tube and precipitate was 
removed by centrifugation at 3000 rpm for 10 mins at room temperature. To 250 L of 
the above supernatant, 1.5 mL of 0.2 M phosphate buffer was added and mixed well. 250 
L of 0.6 mM of Ellman’s reagent  [5,5′-Dithiobis(2-nitrobenzoic acid) solution]  was 
added to the above mixture and the absorbance was measured at 412 nm within 10 mins. 
A standard graph was plotted using glutathione reduced (1.0 mg/mL) and GSH content 
present in sample was calculated by interpolation.  Amount of glutathione expressed as 
g/mg of protein. 
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4.8.6.5. Estimation of lipid peroxidation (LPO) 
Lipid peroxidation  (LPO) was estimated by thiobarbituric reaction method of 
Okhawa et al. 
167
 1 mL of kidney homogenate was mixed with 0.2 mL 4 % w/v  sodium 
dodecyl sulfate, 1.5 mL 20% acetic acid in 0.27 M hydrochloric acid (pH 3.5) and 15 mL 
of 0.8% thiobarbituric acid ( pH 7.4). The mixture was heated in a hot water bath at 85˚C 
for 1 hr. The intensity of the pink colour developed was read against a reagent blank at 
532 nm, followed by centrifugation at 1200 rpm for 10 mins. The concentration was 
expressed as n moles of malondialdehyde per mg of protein using 1,1,3,3-tetra-
ethoxypropane as the standard. 
4.9. Histopathological studies
168 
 
The right kidney of experimental animals from all groups were removed, washed 
with the normal saline and fixed in 10% neutral buffered formalin for 48 hrs. After 
washing for 1 hr in running tap water, dehydrated the tissue and cleaned the tissues with 
xylene.  Embedded cleaned tissues in melted paraffin wax at 56ºC. Longitudinal and 
transverse sections were taken and incubated the tissue sections  for  2 hrs at 40ºC. After 
rehydration, the sections were stained with haematoxylin and eosin (H and E) and 
observed under light microscope. Photographs were obtained to study the 
histopathological changes. 
4.10. Statistical analysis  
In vitro studies of EEBS: All results were expressed as mean value ± standard deviation 
(SD). Student’s t-test was used for comparison between values of samples and standards. 
Difference was considered statistically significant when P<0.05. 
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In vivo studies of EEBS: The results were expressed as mean ± standard error of mean 
(SEM). Statistical significance between means was analyzed by one-way analysis of 
variance (ANOVA) followed by “Dunnett’s test.” Pvalue<0.05 were considered 
statistically significant. The statistical program used was Graph Pad Prism 7.02 version 
for Windows (GraphPad Soft ware Inc., San Diego, California, USA).  
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5. RESULTS
5.1. Phytochemical studies
5.1.1. Preparation of crude EEBS Linn
The authenticated whole plant of B. sensitivum were washed, air dried, subjected
to size reduction and passed through sieve No. 40. Uniformly powdered plant material
was initially extracted with petroleum ether (60-80ºC) for defatting the drug and then
with 70% ethanol by using Soxhlation method. The obtained solvent extract was filtered,
evaporated to dryness and weighed. The percentage yield was calculated in terms of air
dried weight of the plant material subjected to the extraction process. The percentage
yield of petroleum ether and ethanolic extract of B. sensitivum were 4.92% w/w and
12.54% w/w respectively and are presented in table 8.
Table 8: Percentage yield of solvent extraction of B. sensitivum (Linn.) DC
Sl.No. Solvents Colour &
Consistency
Plant material
taken (gms)
Weight of
extract (gms)
% yield
(w/w)
1 Petroleum
ether
Greenish yellow
Sticky solid
500 24.6 4.92
2 Ethanol Brownish black
Semisolid
500 62.7 12.54
5.1.2. Qualitative analysis of phytochemicals
The preliminary phytochemical investigations of crude EEBS were carried out
and the results confirmed the presence of carbohydrates, alkaloids, steroids, saponins,
proteins, aminoacids, falvonoids, tannins, phenolic compounds and fixed oils. The details
of phytochemical investigations are demonstrated in table 9.
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Table 9: Preliminary phytochemical investigation of  EEBS
Sl.No. Phytochemical constituents Phytochemical tests EEBS
1 Carbohydrate Molisch’s +ve
Fehling’s +ve
Benedict’s +ve
Barfoed’s -ve
Tollen’s -ve
Seliwanoff’S +ve
Bromine water -ve
2 Alkaloids Mayer’s +ve
Dragendorff’s +ve
Wagner’s +ve
Hagner’s +ve
Tannic acid +ve
3 Saponin Foam +ve
Hemolytic +ve
Lead acetate +ve
4 Flavonoids Shinoda’s +ve
Alkaline reagent +ve
Lead acetate +ve
Sulphuric acid +ve
5 Phenolic compounds Ferric chloride +ve
Lead acetate +ve
6 Tannins Ferric chloride +ve
Gelatin +ve
Lead acetate +ve
7 Glycoside Keller-killiani -ve
Baljet -ve
Legal’s -ve
Borntrager’s -ve
8 Steroids Libermann-Burchard’s +ve
Salkowsky’s +ve
9 Protein Biuret +ve
Ninhydrin +ve
Xanthoprotein -ve
Million’s +ve
Lead acetate -ve
10 Terpenoid Hirschonn reaction -ve
Knoller’s -ve
11 Fixed oil
Spot +ve
Saponificaton +ve
Solubility +ve
+ve - present, -ve - absent
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5.2. Quantitative estimation of phytoconstituents present in EEBS
Major  phytoconstituents contributing to antioxidant activity includes total
phenolic compounds and total flavonoid compounds.  Calibration curve for the
determination of total phenolic content and flavonoid content of EEBS are illustrated in
figure 4 and 5.
5.2.1. Total phenolic content of EEBS
Total phenolic content of EEBS were expressed in terms of gallic acid
equivalents. The concentration of total phenolic content is expressed as mg/g of gallic
acid equivalent. Absorbance increases as concentration of phenolic compounds increases.
The total phenolic content in the extract of B. sensitivum were 53.55 mg/g of gallic acid
equivalents (figure 4).
Figure 4: Calibration curve of gallic acid showing linearity over
concentration range of 10-100 µg/mL
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5.2.2. Total flavonoid content of EEBS
Total flavonoid content of EEBS were expressed in terms of rutin equivalents.
The concentrations of total flavonoids were expressed as mg/g of rutin equivalents.
Maximum absorption depends on the concentration of flavonoids. The total flavonoid
content in the extract of B. sensitivum were 153.08 mg/g of rutin equivalents (figure 5).
Figure 5: Calibration curve of rutin showing linearity over
concentration range of 10-100 µg/mL
5.3. In vitro antioxidant and free radical scavenging activity of EEBS
5.3.1. DPPH radical scavenging activity
Radical scavenging activity of extract was observed from decrease in absorbance
of DPPH with increase in concentration. Absorbance value of EEBS had shown as 1.52,
1.19, 0.98, 0.72, 0.45 and 0.34 and standard ascorbic acid exhibited as 1.28, 0.78, 0.30,
0.07, 0.04 and 0.03 at 10, 20, 40, 60, 80 and 100 µg/mL respectively. EEBS at a
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concentration of 10-100 µg/mL inhibited production of DPPH radical by 17-81% and
showed significant (P<0.05) scavenging effects on DPPH radical compared to standard
ascorbic acid which exhibited 41-99% of inhibition. IC50 value of EEBS was found to be
46.34 µg/mL and that of ascorbic acid (standard) was 14.12 µg/mL. This  result
indicated that EEBS contained sufficient phytochemical constituents capable to donate
‘H’ for the conversion of free radical DPPH to non-free radical DPPH-H (figure 6).
Figure 6: Percentage inhibition of DPPH radical scavenging activity of EEBS, in
comparison to standard ascorbic acid
5.3.2. Ferric reducing antioxidant power (FRAP Assay)
The trend for ferric ion reducing activities of EEBS and standard had shown in
figure 7. Ferric reducing antioxidant power was determined according to the ability of
sample to reduce Fe3+ to Fe2+ ions. Increased absorbance of reaction mixture indicates
increase in reducing power. Absorbance value of EEBS at 10, 20, 40, 60, 80 and 100
µg/mL had shown as 0.32, 0.33, 0.40, 0.56, 0.82 and 0.99 respectively. Ascorbic acid at
the same concentration range (10-100 µg/mL)  exhibited absorbance value as 0.55, 0.76,
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0.81, 1.10, 1.30 and 1.54 respectively. This result indicated that EEBS exhibited ferric
reducing ability in a concentration dependent manner and was significant with that of
standard (p<0.01). The ferric reducing antioxidant powers of EEBS are depicted in figure
7.
Figure 7: Absorbance of ferric reducing ability of EEBS,
in comparison to standard ascorbic acid.
5.3.3. ABTS radical scavenging activity
Radical scavenging activity of EEBS was determined by comparing with ascorbic
acid standard reference. Absorbance value of EEBS had shown as 0.26, 0.24, 0.19, 0.09,
0.06 and 0.02 and standard ascorbic acid exhibited as 0.32, 0.30, 0.26, 0.23, 0.20 and
0.09  at 10, 20, 40, 60, 80 and 100 µg/mL respectively. EEBS inhibited production of
ABTS radical by 33-95%, where as ascorbic acid showed 48-84% of inhibition. EEBS
scavenged ABTS radical in a concentration dependent manner and was comparable with
that of ascorbic acid. The concentration of extract needed to produce 50% inhibiton on
ABTS production was found to   be 42.01 µg/mL, where as 18.43 µg/mL was needed for
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ascorbic acid.  Scavenging effect of extract was found to be less compared to reference
compound. This antioxidant activity reflects free radical scavenging capacity of EEBS,
by donating electron or hydrogen atom to inactivate this radical cation (fig 8).
Figure 8: Percentage inhibition of ABTS radical scavenging activity of EEBS,
in comparison to standard ascorbic acid.
5.3.4. Hydroxyl radical scavenging activity
The extract inhibited hydroxyl radical induced deoxyribose degradation in a
concentration dependent manner and maximum inhibition at concentration  of 100 µg/mL
was found to be 53%, whereas ascorbic acid (standard) had shown as 57%. Absorbance
value of EEBS had shown as 0.215, 0.201, 0.194, 0.185, 0.181 and 0.172 and standard
ascorbic acid exhibited as 0.161, 0.155, 0.148, 0.141, 0.136 and 0.120 at 10, 20, 40, 60,
80 and 100 µg/mL respectively. The extract showed hydroxyl radical scavenging activity
with an IC50 value of 94.42 µg/mL in comparison to that of ascorbic acid (60.31 µg/mL).
These results indicated that EEBS can act as a hydroxyl radical scavenger and also inhibit
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lipid peroxidation. The hydroxyl radical scavenging activity of EEBS are presented in
figure 9.
Figure 9: Percentage inhibition of hydroxyl radical scavenging activity of EEBS,
in comparison to standard ascorbic acid
5.3.5. Superoxide radical scavenging activity
Superoxide radical scavenging activity of EEBS was compared with the same
dose of ascorbic acid ranging from 10-100 µg/mL. Absorbance value of EEBS had
shown as 0.178, 0.169, 0.167, 0.159, 0.158 and 0.146 and standard ascorbic acid
exhibited as 0.434, 0.420, 0.343, 0.311, 0.312 and 0.242 at 10, 20,40,60,80 and 100
µg/mL respectively. Ic50 value of ascorbic acid and EEBS were found to be 23.64 µg/mL
and 72.12 µg/mL respectively. Radical scavenging effect of extract was found to be
significantly (p<0.01) less compared to reference compound. EEBS inhibited production
of superoxide anion radical by 40-52% whereas reference compound had shown 46-70%
of inhibition. The super oxide radical scavenging activities of EEBS are presented in
figure 10.
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Figure 10: Percentage inhibition of superoxide radical scavenging activity of EEBS,
in comparison to standard ascorbic acid
5.3.6. Nitric oxide radical scavenging activity
Absorbance value of EEBS had shown as 0.56, 0.48, 0.43, 0.40, 0.38 and 0.31 and
standard ascorbic acid exhibited as 0.65, 0.60, 0.45, 0.43, 0.21 and 0.13 at 10, 20, 40, 60,
80 and 100 µg/mL respectively. IC50 value of EEBS was found to be 90.12 µg/mL and
that of ascorbic acid (standard) was 37.23 µg/mL. Result indicated that EEBS had
significant scavenging effect on nitric oxide radicals in a concentration dependent
manner. Standard ascorbic acid at a concentration of 10-100 µg/mL inhibited production
of nitric oxide radical by 29-86% whereas EEBS inhibited nitric oxide radical generation
by 20-56%, thereby exhibited radical scavenging activity. Nitric oxide radical scavenging
assay are depicted in figure 11.
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Figure 11: Percentage inhibition of nitric oxide radical scavenging activity of EEBS,
in comparison to standard ascorbic acid
5.3.7. Reducing power
Reducing power of extract increased with increase in the concentration and it was
found to be 0.46, 0.57, 0.74, 0.97, 1.16 and 1.56 at 10, 20, 40, 60, 80 and 100 µg/mL
respectively. Ascorbic acid at same concentration exhibited absorbance value as 0.62,
0.80, 0.82, 1.00, 1.10 and 1.40 respectively. EEBS at 80 µg/mL and 100 µg/mL showed
higher reducing activities than standard and differences were comparable (figure 12).
Figure 12: Absorbance of reducing ability of EEBS, in comparison to ascorbic acid
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5.4. In vitro antiurolithic activity of EEBS.
Small particle size of stone forming constituents in urine reduces the possibility of
nucleation, aggregation and retention in the urinary tract. In this study inhibition capacity
of plant extract on calcium oxalate (CaOx) crystallization were determined using
nucleation, aggregation and microscopic assay.
5.4.1. Nucleation assay
The percentage inhibition of extract on nucleation of CaOx crystals were found to
be 18-66%, whereas with Cystone (standard) it was 15-83%.  IC50 value of the EEBS was
68.82 mg/mL, compared with 52.41 mg/mL for Cystone. Absorbance value of EEBS at
10, 20, 40, 60, 80 and 100 mg/mL had shown as 0.76, 0.63, 0.52, 0.49, 0.42 and 0.31
respectively. Cystone (standard) at same concentration (10-100 mg/mL) exhibited
absorbance value as 0.81, 0.69, 0.58, 0.32, 0.22 and 0.16 respectively. Inhibition on
nucleation of CaOx crystals increased with increasing concentration of the extract and
was comparable with that of Cystone (table 10, figure 13).
Table 10: Percentage inhibition capacity of EEBS and Cystone on nucleation of
CaOx crystals
Sl.No.
Concentration
(mg/mL)
Percentage inhibition
Cystone*
Percentage inhibition
EEBS*
1 10 15±0.020 18±0.001
2 20 27±0.001 32±0.008
3 40 39±0.000 43±0. 006
4 60 66±0.006 47±0.000
5 80 76±0.001 54±0.005
6 100 83±0.105 66±0.006
Ic50 values Ic50= 52.41 mg/mL Ic50= 68.82 mg/mL
*Values are obtained from average of 6 determinants. EEBS-ethanol extract of
B.sensitivum
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Figure 13: Percentage inhibition of EEBS on nucleation of CaOx crystals,
in comparison to Cystone (standard)
5.4.2. Aggregation assay
Percentage inhibition of EEBS was found to be 11-78% whereas with Cystone it
was 13-82%. IC50 of the plant extract was 52.39 mg/mL and for Cystone it was found to
be 41.62 mg/mL. Absorbance  value  of  EEBS at 10, 20, 40, 60, 80 and 100 mg/mL had
shown as 0.65, 0.45, 0.36, 0.27, 0.19  and 0.12 respectively. Cystone at same
concentration (10-100 mg/mL) exhibited absorbance value as 0.74, 0.52, 0.49, 0.35, 0.26
and 0.18 respectively. EEBS showed a significant dose-dependent inhibition on the
aggregation of CaOx crystals. Higher concentrations of EEBS indicated lower
aggregation. The rate of inhibition capacity of various concentration of EEBS and
Cystone (standard) on CaOx aggregation are depicted in table 11 and figure 14.
0
10
20
30
40
50
60
70
80
90
10 20 40 60 80 100
Pe
rc
en
ta
ge
 
In
hi
bi
tio
n
 
(%
)
Concentration (µg/mL)
Standard Extract
Nucleation Assay
Result
Page 86
Table 11: Percentage inhibition capacity of EEBS and Cystone on aggregation of
CaOx crystals
Sl.No. Concentration
(mg/mL)
Percentage inhibition
Cystone*
Percentage inhibition
EEBS*
1 10 13±0.005 11±0.003
2 20 35 ±0.002 38± 0.003
3 40 48 ±0.000 41 ±0.001
4 60 61±0.005 57 ±0.002
5 80 72 ±0.001 69 ±0.001
6 100 82±0.005 78±0.003
Ic50 values Ic50= 41.62 mg/mL Ic50= 52.39 mg/mL
*Values are obtained from average of 6 determinants. EEBS-ethanol extract of
B.sensitivum
Figure 14: Percentage inhibition of EEBS on aggregarion of CaOx crystals
comparison to Cystone (standard)
5.4.3. Image analysis of calcium oxalate (CaOx) crystal morphology (Microscopic
assay)
In microphotographic study, incubation of metastable solutions of calcium
chloride and sodium oxalate resulted in the formation of CaOx crystals. The
corresponding size of CaOx crystals treated with control and various concentration of
EEBS are illustrated in figure 15-19.  Addition of EEBS at various concentration  of  20,
40, 80, 160 µg/mL had reduced crystal size as 1275.49 µm, 1080.73 µm, 905.23 µm and
0
10
20
30
40
50
60
70
80
90
10 20 40 60 80 100
Pe
rc
en
ta
ge
 
In
hi
bi
tio
n
 
(%
)
Concentration (µg/ml)
Standard Extract
Aggregation  Assay
Result
Page 87
812.68 µm respectively. CaOx  crystal size treated with control was 1398.05 µm (figure
15-19).
Figure 15-19: The size of CaOx crystals, observed under microscope (4X), in the
absence of plant extract (control) and in presence of EEBS at concentration of 20,
40, 80 and 160 µg/mL
Figure 15: CaOx crystal treated with control Figure 16:CaOx crystal treated with EEBS
(20 µg/mL)
Figure 17: CaOx crystal treated with EEBS Figure 18: CaOx crystal treated with EEBS
(40 µg/mL) (80 µg/mL)
Figure 19: CaOx crystal treated with EEBS (160 µg/mL)
Result
Page 88
5.5. Pharmacological studies
5.5.1. Cytotoxic activity of EEBS on kidney cell lines
5.5.1.1. Trypan blue exclusion assay
In trypan blue exclusion method, treatment with EBBS reduced cell viability of
human embryonic kidney 293 (HEK 293) cells in a dose-dependent manner as compared
to cells treated with control which exhibited 100% viability. EBBS at lower dose of 12.5
μg/mL showed 98.34% of cell viability, whereas dose at which 25 μg/mL showed
97.02% viability. Exposure of cells to EEBS at dose of 50 μg/mL exhibited 95.40% of
cell viability. EEBS at 100 μg/mL and 200 µg/mL showed significant (p<0.01) reduction
in the number of viable cells compared to control and the percentage of inhibition was
higher 92.20% and 88.07% respectively. The percentage cell viability of various
concentration of EEBS are illustrated in table 12 and figure 20.
Figure 20: Cytotoxic effect of EEBS against HEK-293 cell line
by trypan blue exclusion assay
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Table 12: Percentage of viable cell determination by trypan blue exclusion method
Name of test
sample
Test Conc.
(µg/mL)
µg/mL
No.  of viable cells No of dead cells Cell viability*
(%)
EEBS
12.5 99.66±0.332 1.66±0.310 98.34±0.326
25 97.66±0.320 3.00±0.577 97.02±0.548
50 96.66±0.811 4.66±0.333 95.40±0.321
100 90.66±0.310 7.66±0.333 92.20±0.260
200 88.00±0.577 12.00±1.15 88.07±0.981
*Values are obtained from average of 3 determinants. EEBS-ethanol extract of
B. sensitivum
5.5.1.2. MTT cell viability assay
Cytotoxicity  activity  of various concentration of EEBS against human
embryonic kidney 293 (HEK 293) cell lines were determined. Cells treated with control
showed 100% cell viability. EBBS at dose of 12.5, 25, 50, 100, 200 µg/mL showed
99.39%, 99.16%, 96.59%, 94.40%, 86.34% of cell growth respectively. Significant (P<
0.01) cell growth inhibition was observed only on cells which were treated with higher
concentration of EBBS, compared to control. Graph plotted with percentage of viable
cells against the concentration showed a significant dose-dependent inhibition on cell
growth (table 13, figure 21).
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Table 13: Percentage of viable cell determination by MTT assay method
Name of test sample Test Conc. (µg/mL) Absorbance value Cell growth* (%)
EEBS
12.5 0.319±0.005 99.395±1.76
25 0.319 ±0.004 99.162±0.36
50 0.310±0.008 96.593±2.93
100 0.303±0.004 94.402±1.63
200 0.274±0.003 86.34±1.45
*Values are obtained from average of 3 determinants. EEBS-ethanol extract of B.
sensitivum
Figure 21: Cytotoxic effect of EEBS against HEK-293 cell line by MTT assay
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5.5.1.3. Lactate dehydrogenase (LDH) assay
EEBS at different concentrations (5, 10, 20, 40, 80, 160, 320 µg/mL) were
screened for its cytotoxic activity against A498 cell lines by lactate dehydrogenase assay.
Cell lines treated with control showed no significant difference with that of mild
concentration of EEBS (5, 10, 20, 40 and 80 µg/mL). EEBS treated cells at higher
concentration (160 & 320 µg/mL) showed significant (P<0.01) increase in release of
LDH. Release of lactate dehydrogenase due to the effect of different concentration of
EEBS and control were shown in table 14 and figure 22.
Table 14: Cytotoxic effect of EEBS against A498 cell line
by lactate dehydrogenase assay
Name of test
sample
Test Conc.
(µg/mL)
Absorbance value LDH activity (U/L)*
EEBS
Control 0.2015±0.001 3230.05
5 0.2125±0.024 3406.38
10 0.2207±1.433 3537.82
20 0.2215±3.333 3550.65
40 0.2296±1.006 3680.49
80 0.2357±2.432 3778.27
160 0.2728±4.231 4372.98
320 0.2935±0.008 4704.81
*Values are obtained from average of 3 determinants. EEBS-ethanol extract of
B.sensitivum; LDH- lactate dehydrogenase
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Figure 22: Cytotoxic effect of EEBS against A498 cell line by lactate dehydrogenase
assay
5.5.1.4. DNA fragmentation assay
DNA fragmentation was analyzed by gel electrophoresis. DNA laddering was
observed when A498 cells were incubated with 160 and 320 µg/mL of EEBS for 24 hrs.
(Lane 1, 2 and 3 stands for control, 160 µg/mL, and 320 µg/mL respectively.  Lanes 4
stands for 100 bp DNA Marker). The figure depicted, EEBS treated A498 cells showing
significant DNA damage that was observed as a ladder pattern by agarose gel
electrophoresis. More evident DNA fragmentation was seen on A498 cells treated with
EEBS at 320 µg/mL concentration when compared to control (culture without  EEBS
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treatment). DNA fragmentation on A498 cells treated with 160 µg/mL of  EEBS was
found to be less. Thus the result suggested that higher concentration of EEBS induces
DNA fragmentation and persuades significant apoptotic activity (figure 23).
Figure 23: Agarose gel electrophoresis of the chromosomal DNA of A498 cells.
1 2 3 4
5.6. In vivo pharmacological studies
Nephroprotective activity of EEBS at concentration of 250 mg/kg (low dose) and
500 mg/kg  (high dose) were investigated using  various  general, urinary, blood, serum
and kidney homogenate parameters against gentamicin-induced nephrotoxicity in Wistar
albino rats.
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5.6.1. Gentamicin (GM)-induced nephrotoxicity
5.6.1.1. Effect of EEBS on general parameters in control and experimental animals
Table 15 illustrated the effect of EEBS on general parameters of GM-induced
nephrotoxicity in control and experimental animals that were obtained at the end of the
experiment in each group. Body weight was recorded before commencing the
experiment. This results revealed that body weight of animals in group II were
significantly (p<0.01) reduced after treatment, compared to control group, where as body
weight of animals in group III (p<0.001), group IV (p<0.01) and group V (p<0.01) were
significantly increased compared to animas in toxic control group. In GM-treated group,
the kidney weight was found to be significantly increased (p<0.001) compared to normal
control group. Significant reduction in kidney weight were observed in animals co-treated
with low dose of EEBS (p<0.01), high dose of EEBS (p<0.001) and quercetin (p<0.001).
24-hr urine volume in the GM-treated group were found to be significantly (p<0.01)
reduced in comparison to control group. Supplementation of quercetin, low dose of EEBS
(p<0.01) and high dose of EEBS (p<0.001) to GM-treated rats increased urine output.
However, water intake was significantly (p<0.05) increased only in animals co-
administered with 500 mg/kg of EEBS. Urinary pH in GM-treated group was found to be
6.6±0.04 which revealed no significant (p>0.05) changes in urinary pH compared to
animals co-treated with extract/standard.
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Table 15: Effect of EEBS on general parameters in
GM-induced nephrotoxicity in rats
Parameters
Studied
(Unit)
Group I
Normal
control
Group II
GM
100 mg/kg
Group III
GM+QTN
50 mg/kg
Group IV
GM+EEBS
250 mg/kg
Group V
GM+EEBS
500 mg/kg
Change in
body wt. (g)
3.06±0.23 1.50±0.11**a 3.38± 0.14***b 2.58± 0.17**b 2.52± 0.22**b
Kidney wt. (g) 0.64±0.00 0.97±0.05***a 0.70±0.08***b 0.73±0.00**b 0.71±0.00***b
Water intake
(mL/24 hr)
12.35±0.57 14.53±0.76ns 17.35±0.82ns 17.35± 0.82ns 17.87±0.86*b
Urine volume
(mL/24 hr)
7.73±0.14 5.74± 0.20**a 7.62±0.29**b 7.24±0.15**b 7.88± 0.08***b
Urine pH 6.8±0.05 6.6±0.04ns 6.8±0.01ns 6.7±0.06 ns 6.8±0.06 ns
Ethanol extract of B. sensitivum, GM: gentamicin, QTN: quercetin. Values are expressed
in mean ± standard error of mean  (n=6), *p<0.05, **p<0.01, ***p<0.001 a significant
compared o control group (group I), bsignificant compared with GM-induced group
(group II), ns not significant.
5.6.1.2. Effect of EEBS on urinary total protein and albumin levels in experimental
rats
GM-treated rats showed a marked increase in urinary protein and albumin
excretion (p<0.01). Animals co-treated with EEBS/quercetin significantly (P<0.01)
reduced the incidence of proteinuria, however, significant (P<0.01) reduction in
albuminuria were observed only in rats co-treated with quercetin or high dose of EEBS,
compared to group II rats (table 16).
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Table 16: Effect of EEBS on urinary total protein and albumin levels in GM-
induced nephrotoxicity in rats
Urinary parameters
(Unit)
Group I
Normal
control
Group II
GM
100 mg/kg
Group III
GM+QTN
50 mg/kg
Group IV
GM+EEBS
250 mg/kg
Group V
GM+EEBS
500 mg/kg
Total protein (g/dL) 3.65 ±0.01 4.52±0.02**a 3.55±0.01**b 4.05±0.04**b 3.53±0.05**b
Albumin (g/dL) 0.77±0.01 0.84±0.06**a 0.63±0.01**b 0.81±0.08ns 0.71±0.00**b
EEBS: Ethanol extract of B. sensitivum, GM: gentamicin, QTN: quercetin. Values are
expressed in mean ± standard error of mean  (n=6), *p<0.05, **p<0.01, ***p<0.001 a
significant compared with control group (group I), bsignificant compared with GM-
induced group (group II), ns not significant
5.6.1.3. Effect of EEBS on urinary electrolyte levels in experimental rats
Urinary excretion of calcium and magnesium were found to be much higher
(p<0.01) in group II animals, compared to control group. Co-treatment with EEBS at 250
mg/kg (p<0.01), quercetin (p<0.001) and EEBS at 500 mg/kg (p<0.001) significantly
decreased urinary calcium excretion compared to GM-treated animals. Urinary
magnesium excretion were significantly (p<0.01) lowered in animals co-administered
with standard/ extract. However, significant differences were not observed in sodium and
potassium levels among animals in different groups (table 17).
Table 17: Effect of EEBS on urinary electrolyte levels in GM-induced nephrotoxicity
Urinary parameters
(Unit)
Group I
Normal
control
Group II
GM
100 mg/kg
Group III
GM+QTN
50 mg/kg
Group IV
GM+EEBS
250 mg/kg
Group V
GM+EEBS
500 mg/kg
Sodium (mmol/L) 74.16±1.86 75.16±1.87ns 71.66±0.33ns 74.33±1.92ns 74.30±1.49 ns
Potassium (mmol/L) 3.20±0.02 3.21±0.02ns 3.20±0.02ns 3.14±0.01ns 3.21±0.02ns
Calcium (mg/dL) 8.93±0.01 10.90± 0.01**a 6.47±0.02***b 8.05±0.05**b 7.81±0.06***b
Magnesium (mg/dL) 0.78±0.01 0.83±0.07**a 0.76±0.04**b 0.79±0.05**b 0.77±0.06**b
EEBS: Ethanol extract of B. sensitivum, GM: gentamicin, QTN: quercetin.Values are
expressed in mean ± standard error of mean (n=6), *p<0.05, **p<0.01, ***p<0.001
asignificant compared with control group, bsignificant compared with GM-induced group,
nsnot significant.
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5.6.1.4. Effect of EEBS on hematological parameters in experimental rats
Table 18 demonstrated that hemoglobin (Hb), packed cell volume (p<0.001), red
blood cells (RBCs) and mean corpuscular hemoglobin (MCH) levels were significantly
(p<0.01) lowered in rats treated with GM than those in the control group. White blood
corpuscles (p<0.01) and polymorphs (p<0.001) were found to be significantly elevated in
rats in group II, compared to animals in group I. Results revealed that the animals co-
treated with standard/extract caused a significant (p<0.01) increase in RBCs,
haemoglobin and MCH level. Packed cell volume (PCV) were found to be increased
only in animals treated with quercetin/high dose of EEBS (p<0.01). Total WBC and
polymorphs were found to be significantly reduced in animals co-treated with standard/
extract (p<0.01).
Table 18: Effect of EEBS on hematological parameters in GM-induced nephrotoxicity
Parameters studied
(Unit)
Group I
Normal
control
Group II
GM
100 mg/kg
Group III
GM+QTN
50 mg/kg
Group IV
GM+EEBS
250 mg/kg
Group V
GM+EEBS
500 mg/kg
RBC (million/mm3) 7.35±0.14 6.81±0.31**a 7.22±0.21**b 6.85±0.31**b 7.10±0.43**b
HB (g/dL) 14.11± 0.28 11.76± 0.58***a 14.02±0.13**b 13.96±0.21**b 13.83±0.31**b
PCV (%) 43.66±0.52 38.27±0.81***a 39.58±0.61**b 38.29±0.42ns 38.53±0.20**b
MCH  (pg) 20.67±0.12 20.19±0.69**a 20.84±0.27**b 20.45±0.49**b 20.67±0.51**b
WBC (1X103/mm3) 8.22± 0.41 8.43±0.33**a 8.21±0.41**b 8.24±0.21**b 8.15±0.10**b
Lymphocytes (%) 60.05± 0.01 59.96 ±0.08 ns 59.97±0.01 ns 59.96±0.02ns 59. 96±0.05 ns
Monocytes (%) 4.97±0.00 5.00±0. 01 ns 4.96±0.01 ns 4.97± 0.06 ns 4.96±0.06 ns
Polymorphs (%) 12.22±0.21 15.84 ±0.11***a 14.65±0.32**b 14.19±0.20**b 14.05±0.11**b
Eosinophils (%) 1.93±0.01 2.02±0.01 ns 1.97±0.08 ns 1.97±0.02 ns 1.96±0.01 ns
EEBS: Ethanol extract of B. sensitivum, GM: gentamicin, QTN: quercetin. Values are
expressed in mean ± standard error of mean (n=6), *p<0.05, **p<0.01, ***p<0.001,
asignificant compared with control group, bsignificant compared with GM-induced group,
nsnot significant.
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5.6.1.5. Effect of EEBS on serum total protein and albumin levels in experimental
rats
Serum total protein and albumin level (p<0.05), were found to be significantly
decreased in GM-treated animals, compared to rats in group I. However, significant
differences (p>0.05), were not observed on p.o. administration of 250 and 500 mg/kg of
EEBS in group IV & V, whereas rats in group III showed significant change in total
protein (p<0.05) and albumin (p<0.01) level, compared to the animals in group II (table
19).
Table 19: Effect of EEBS on serum total protein and albumin levels in
GM-induced nephrotoxicity in rats
Serum parameters
(Unit)
Group I
Normal
control
Group II
GM
100 mg/kg
Group III
GM+QTN
50 mg/kg
Group IV
GM+EEBS
250 mg/kg
Group V
GM+EEBS
500 mg/kg
Total protein (g/dL) 7.18±0.01 7.14±0.05*a 7.18±0. 09*b 7.16±0.09ns 7.17±0.07ns
Albumin (g/dL) 4.36±0.00 4.33±0.04*a 4.37±0.00**b 4.34±0.00ns 4.35±0.03ns
EEBS: Ethanol extract of B. sensitivum, GM: gentamicin, QTN: quercetin. Values are
expressed in mean ± standard error of mean  (n=6), *p<0.05, **p<0.01, ***p<0.001 a
significant compared with control group (group I), bsignificant compared with GM-
induced group (group II), ns not significant
5.6.1.6. Effect of EEBS on serum electrolyte levels in experimental rats
Sodium, magnesium (p<0.01) and calcium (p<0.001) levels were found to be
significantly decreased in GM-treated animals, compared to group 1 animals. Co-
administration of standard/ extract significantly attenuated (p<0.01) changes in calcium
and magnesium levels, however, no significant differences (p>0.05) were observed in
sodium and potassium levels, compared to group II rats (table 20).
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Table 20:  Effect of EEBS on serum electrolyte levels in GM-induced nephrotoxicity in rats
Serum parameters
(Unit)
Group I
Normal
control
Group II
GM
100 mg/kg
Group III
GM+QTN
50 mg/kg
Group IV
GM+EEBS
250 mg/kg
Group V
GM+EEBS
500 mg/kg
Sodium (mmol/L) 138.7±0.07 138.1±0.05**a 138.5±0.15ns 138.3±0.11ns 138.5±0.14ns
Potassium(mmol/L) 5.75±0.00 5.75±0.07 5.73±0.07ns 5.76±0.01ns 5.78±0.01ns
Calcium (mg/dL) 10.60±0.13 8.17±0.00***a 9.04±0.00**b 9.25±0.08**b 9.43±0.06**b
Magnesium(mg/dL) 2.44±0.01 2.23±0.02**a 2.54±0.01**b 2.34±0.09**b 2.44±0.01**b
EEBS: Ethanol extract of B. sensitivum, GM: gentamicin, QTN: quercetin. Values are
expressed in mean ± standard error of mean (n=6), *p<0.05, **p<0.01, ***p<0.001 a
significant compared with control group (group I), bsignificant compared with GM-
induced group (group II), ns not significant.
5.6.1.7. Effect of EEBS on serum BUN, creatinine and uric acid levels in rats
Group II animals treated with GM demonstrated a significant (p<0.001) elevation
in the serum levels of creatinine, uric acid and blood urea nitrogen (BUN). Co-treatment
with quercetin significantly (p<0.001) decreased creatinine, uric acid and BUN,
compared to group II rats.  Animals co-administered with extract significantly (p<0.01)
decreased creatinine, and uric acid. BUN levels were significantly lowered in animals co-
treated with extract at low concentration (p<0.01) and high concentration (P<0.001),
compared to toxic control group (table 21).
Table 21:  Effect of EEBS on serum BUN, creatinine and uric acid levels in GM-
induced nephrotoxicity in rats
Serum Parameters
(Unit)
Group I
Normal
control
Group II
GM
100 mg/kg
Group III
GM+QTN
50 mg/kg
Group IV
GM+EEBS
250 mg/kg
Group V
GM+EEBS
500 mg/kg
BUN (mg/dL) 15.83±0.19 28.89±0.02***a 12.13±0.02***b 18.92±0.01**b 14.74±0.04***b
Creatinine (mg/dL) 0.68±0.00 1.98±0.02***a 0.81±0.00***b 1.51±0.01**b 0.94±0.01**b
Uric acid (mg/dL) 2.13±0.08 3.22±0.01***a 2.03±0.01***b 3.04±0.08**b 2.95±0.05**b
EEBS: Ethanol extract of B. sensitivum, GM: gentamicin, QTN: quercetin, BUN: blood
urea nitrogen. Values are expressed in mean ± standard error of mean (n=6), *p<0.05,
**p<0.01, ***p<0.001 a significant compared with control group (group I), bsignificant
compared with GM-induced group (group II), ns not significant.
Result
Page 100
5.6.1.8. Effect of EEBS on markers of oxidation in control and experimental animals
This study also revealed the association of GM-induced oxidative stress and
nephrotoxicity. Antioxidant status in rats exposed to GM showed a significant diminution
of activity of superoxide dismutase (SOD), catalase (p<0.01), reduced glutathione (GSH)
and glutathione peroxidise (p<0.001), compared to group I animals. Co-administration of
quercetin to group III rats showed a significant  elevation  of SOD, CAT, GPx (p<0.01)
and GSH (p<0.001) activity. EEBS at dose level of 250 mg/kg to group IV and dose
level of 500 mg/kg to group V significantly increased the SOD (p<0.01) and catalase
(p<0.001). GSH level were significantly increased only in rats co-administerd with high
dose of extract, however,  no significant differences were observed in GPx activity in
animals co-treated with extract, compared to animals in group II. A significant (p<0.01)
increase in production of malondialdehyde (MDA) levels were observed in group II toxic
control animals compared to group I rats. Co-administration of quercetin/EEBS
significantly (p<0.01) decreased MDA levels (figure 24 & 25).
Figure 24: Effect of EBS on lipid peroxidation in GM-induced nephrotoxicity
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EEBS: Ethanol extract of B. sensitivum, GM: gentamicin, QTN: quercetin. Units: LPO
(nmol of MDA formed/ mg protein). Values are expressed in mean ± standard error of
mean (n=6), p<0.05, **p<0.01, ***p<0.001 a significant compared with control group
(group I), bsignificant compared with GM-induced group (group II), ns not significant.
Figure 25: Effect of EEBS on oxidative stress parameters in GM-induced
nephrotoxicity in rats
EEBS: Ethanol extract of B. sensitivum, GM: gentamicin, QTN: quercetin. a) superoxide
dismutase b) catalase  c) glutathione peroxidase  d) reduced glutathione.; Values are
expressed in mean ± standard error of mean  (n=6), p<0.05, **p<0.01, ***p<0.001 a
significant compared with control group (group I), bsignificant  compared with GM-
induced group (group II), ns not significant
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5.6.2. Cisplatin (CDDP)-induced nephrotoxicity
Renoprotective  activity  of EEBS at concentration of 250 and 500 mg/kg were
determined using different general, urinary, blood, serum and kidney homogenate
parameters against cisplatin- induced nephrotoxicity in Wistar albino rats.
5.6.2.1. Effect of EEBS on general parameters in control and experimental animals
Table 22 illustrated the effect of EEBS on general parameters of CDPP-induced
nephrotoxicity in control and experimental animals that were obtained at the end of the
experiment. Body weight was recorded before starting the experiment. After treatment
period, body weight was significantly reduced in rats in CDDP-treated group (p<0.001),
compared to animals in control group. Significant weight gain was observed in animals
co-treated with quercetin (p<0.001), high dose of EEBS (p<0.001) and low dose of EEBS
(p<0.01) compared to animals in the CDDP-treated group. Kidney weight was
significantly increased in CDDP-treated group (p<0.05) compared to normal control
group. Significant reduction in kidney weight were observed  in animals in group III
(p<0.01), group  IV (p<0.05) and group V (p<0.01), compared to rats in group II. 24 hr
urine volume were measured in the CDDP-treated group and found to be significantly
(p<0.01) increased in comparison to control group.  However, there were no significant
(p>0.05) change in water intake and urine volume in groups supplemented  with
quercetin /EEBS, compared to group II animals. This result also revealed a significant
change in urine pH in rats co-treated with extract (p<0.01) or standard (p<0.001),
compared to rats in CDDP-treated group.
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Table 22: Effect of EEBS on general parameters in
CDDP-induced nephrotoxicity in rats
Parameters
Studied
(Unit)
Group I
Normal
control
Group II
CDDP
8 mg/kg
Group III
CDDP+QTN
50 mg/kg
Group IV
CDDP+EEBS
250 mg/kg
Group V
CDDP+EEBS
500 mg/kg
Change in body
wt.(g) 3.56±0.98 1.92±0.87
***a 3.74±3.44***b 3.34±2.50**b 3.72±2.16***b
Kidney wt.(g) 0.85±0.01 0.89±0.01*a 0.76±0.01**b 0. 83±0.00*b 0.81±0.01**b
Water intake
(mL/24 hr) 10.54±0.45 11.00±0.21
ns 10.56±0.29ns 10.78±0.22ns 10.76±0.07ns
Urine volume
(mL/24 hr) 7.82±0.25 8.84± 0.09
**a 8.40±0.30ns 8.35±0.14ns 8.23± 0.13ns
Urine pH 6.80± 0.10 5.93±0.12**a 6.95±0.05***b 6.80±0.081**b 6.86±0.088**b
EEBS: Ethanol extract of B. sensitivum, CDDP: cisplatin, QTN: quercetin. Values are
expressed in mean ± standard error of mean (n=6), *p<0.05, **p<0.01, ***p<0.001 a
significant compared with control group (group I), b significant compared with CDDP-
induced group (group II), ns not significant.
5.6.2.2. Effect of EEBS on urinary total protein and albumin levels in experimental
rats
CDDP-treated rats showed a marked increase in urinary total protein excretion
(p<0.05). Concurrent administration of EEBS (500 mg/kg)/ standard significantly
(p<0.01) reduced the incidence of proteinuria. Lowering of albumiuria were observed in
rats co-treated with high dose of EEBS/quercetin (p<0.05), compared to CDDP-treated
rats (table 23).
Table 23: Effect of EEBS on urinary total protein and albumin levels in
CDDP-induced nephrotoxicity in rats
Urinary parameters
(Unit)
Group I
Normal
control
Group II
CDDP
8 mg/kg
Group III
CDDP+QTN
50 mg/kg
Group IV
CDDP+EEBS
250 mg/kg
Group V
CDDP+EEBS
500 mg/kg
Total protein (g/dL) 1.41±0.02 1.79±0.12*a 1.13±0.05**b 1.50±0.10ns 1.16±0.10**b
Albumin (g/dL) 0.39±0.01 0.40±0.07ns 0.37±0.02*b 0.39±0.05ns 0.38±0.03*b
EEBS: Ethanol extract of B. sensitivum, CDDP: cisplatin, QTN: quercetin. Values are
expressed in mean ± standard error of mean (n=6), *p<0.05, **p<0.01, ***p<0.001 a
significant compared with control group (group I), bsignificant compared with CDDP-
induced group (group II), ns not significant.
Result
Page 104
5.6.2.3. Effect of EEBS on urinary electrolyte levels in experimental rats
Urinary excretion of calcium (p<0.001), magnesium (p<0.05) and potassium
(p<0.01) levels were found to be significantly higher in group II animals compared to
control group. Significant (p<0.01) reduction in urinary excretion of electrolyte levels
were observed in group treated with quercetin. Concurrent administration with extract
significantly (P<0.01) lowered urinary calcium excretion, however, there were no
significant (P>0.05) differences in urinary excretion of sodium, potassium and
magnesium levels, compared to nephrotoxic control group (table 24).
Table 24: Effect of EEBS on urinary electrolyte levels in
CDDP-induced nephrotoxicity
Urinary parameters
(Unit)
Group I
Normal
control
Group II
CDDP
8 mg/kg
Group III
CDDP+QTN
50 mg/kg
Group IV
CDDP+EEBS
250 mg/kg
Group V
CDDP+EEBS
500 mg/kg
Sodium (mmol/L) 51.28±0.02 51.34±0.01ns 50.75±0.02**b 51.29±0.02ns 51.31±0.02ns
Potassium (mmol/L) 3.20±0.00 3.26±0.01**a 3.13±0.00**b 3.23±0.07ns 3.22±0.01ns
Calcium (mg/dL) 15.53±0.03 25.16± 0.01***a 18.18±0.02**b 18.94±0.01**b 18.78±0.24**b
Magnesium (mg/dL) 1.34±0.01 1.36±0.00*a 1.33±0.09**b 1.34±0.08ns 1.34±0.08ns
EEBS: Ethanol extract of B. sensitivum, CDDP: cisplatin, QTN: quercetin. Values are
expressed in mean ± standard error of mean (n=6), *p<0.05, **p<0.01, ***p<0.001 a
significant compared with control group (group I), bsignificant compared with CDDP-
induced group (group II), ns not significant.
5.6.2.4. Effect of EEBS on hematological parameters in experimental rats
Table 25 illustrated the effect of EEBS on haematological parameters in control
and experimental animals. Total white blood cells (WBC), monocytes and polymorphs
were significantly (p<0.01) elevated in CDDP-treated animals compared to control group.
Co-treatment with quercetin/EEBS significantly (p<0.01) decreased total WBC.
Polymorphs level were significantly reduced only in animals treated with standard
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(p<0.01) or high dose of extract (p<0.05). Significant reduction in total red blood cells
(RBCs), hemoglobin (Hb), mean corpuscular hemoglobin (p<0.01), packed cell volume
(PCV), lymphocytes (p<0.001) levels were observed in animals treated with CDDP, in
comparison with control group. Animals co-administered with quercetin/ EEBS
significantly increased total RBC, PCV and Hb levels (p<0.01), however, MCH levels
were elevated only in animals in group III and V (p<0.01), compared to toxic control
animals (table 25).
Table 25: Effect of EEBS on hematological parameters in
CDDP-induced nephrotoxicity
Parameters Studied
(Unit)
Group I
Normal
control
Group II
CDDP
8 mg/kg
Group III
CDDP+QTN
50 mg/kg
Group IV
CDDP+EEBS
250 mg/kg
Group V
CDDP+EEBS
500 mg/kg
RBC (million/mm3) 6.81±0.27 5.89±0.32**a 6.56±0.22**b 6.85±0.41** b 6.86±0.12** b
HB (g/dL) 12.22± 0.49 11.61± 0.12**a 13.25±1.08** b 13.77±0.45** b 13.62±0.31** b
PCV (%) 44.38±0.62 32.38± 0.48*** a 39.51±0.37** b 38.29±0.31** b 38.22±0.52** b
MCH (pg) 23.62±0.12 22.85±0.13** a 23.79±0.09** b 22.64±0.08ns 23.82±0.09** b
WBC (1X103/mm3) 10.46± 0.33 10.69±0.31**a 10.46±0.32** b 10.25±0.52** b 10.08±0.51** b
Lymphocytes (%) 81.02± 0.42 75.32±0.31*** a 77.32±0.32** b 75.37±0.24 ns 75.33±0.42 ns
Monocytes (%) 5.89±0.03 5.98±0.03** a 5.91±0.01** b 5.95±0.01 ns 5.94±0.02 ns
Polymorphs (%) 12.82±0.22 12.92 ±0.11**a 12.22±0.30** b 12.86±0.11ns 12.85±0.21* b
Eosinophils (%) 2.33±0.01 2.38±0.00 ns 2.31±0.01* b 2.32±0.02 ns 2.33±0.01 ns
EEBS: Ethanol extract of B. sensitivum, CDDP: cisplatin, QTN: quercetin. Values are
expressed in mean ± standard error of mean  (n=6), *p<0.05, **p<0.01, ***p<0.001 a
significant compared with control group (group I), bsignificant compared with CDDP-
induced group (group II), ns not significant.
5.6.2.5. Effect of EEBS on serum total protein and albumin levels
Significant difference in protein and albumin levels were not observed in
animals in CDDP-treated group in comparison with the control group. However,
concurrent administration of quercetin /high dose of EEBS (p<0.05) showed signifnicant
elevation in serum total protein level. Marked elevation in albumin levels were observed
in rats treated with standard (p<0.01), but not in animals treated with EEBS, compared to
toxicity induced rats in group II (table 26).
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Table 26: Effect of EEBS on serum total protein and albumin levels in
CDDP-induced nephrotoxicity in rats
Serum parameters
(Unit)
Group I
Normal
control
Group II
CDDP
8 mg/kg
Group III
CDDP+QTN
50 mg/kg
Group IV
CDDP+EEBS
250 mg/kg
Group V
CDDP+EEBS
500 mg/kg
Total protein (g/dL) 3.39±0.01 3.38±0.01ns 3.41±0.08*b 3.40±0.07ns 3.42±0.07*b
Albumin (g/dL) 1.38±0.00 1.37±0.00 ns 1.41±0.01**b 1.38±0.04 ns 1.39±0.04 ns
EEBS: Ethanol extract of B. sensitivum, CDDP: cisplatin, QTN: quercetin. Values are
expressed in mean ± standard error of mean (n=6), *p<0.05, **p<0.01, ***p<0.001 a
significant compared with control group (group I), bsignificant compared with CDDP-
induced group (group II), ns not significant.
5.6.2.6. Effect of EEBS on serum electrolyte levels in experimental rats
Sodium, potassium, and calcium levels (p<0.01) were found to be significantly
decreased in CDDP-treated animals. Co-administration of quercetin, significantly
increased serum electrolyte levels except magnesium level. Significant (p<0.01) change
in calcium levels were observed in group IV and V animals, whereas serum sodium
levels were found to be significantly (p<0.01)   increased in rats co-treated with 500
mg/kg of EEBS. No significant differences (p>0.05)  were observed in potassium and
magnesium levels in group IV and V rats, compared to animals in group II (table 27).
Table 27: Effect of EEBS on serum electrolyte levels in
CDDP-induced nephrotoxicity
Serum parameters
(Unit)
Group I
Normal
control
Group II
CDDP
8 mg/kg
Group III
CDDP+QTN
50 mg/kg
Group IV
CDDP+EEBS
250 mg/kg
Group V
CDDP+EEBS
500 mg/kg
Sodium (mmol/L) 125.58±1.67 106.05±2.06**a 125.84±1.5***b 109.06±1.37ns 120.80±1.48**b
Potassium (mmol/L) 7.18±0.01 6.12±0.05**a 6.48±0.02**b 6.09±0.08 ns 6.13±0.07ns
Calcium (mg/dL) 17.20±0.00 12.61± 0.01**a 15.70±0.01**b 15.03±0.01**b 15.84±0.04**b
Magnesium (mg/dL) 4.35±0.05 4.35±0.01 4.38±0.09 4.36±0.09ns 4.38±0.04ns
EEBS: Ethanol extract of B. sensitivum, CDDP: cisplatin, QTN: quercetin. Values are
expressed in mean ± standard error of mean  (n=6), *p<0.05, **p<0.01, ***p<0.001 a
significant compared with control group (group I), bsignificant compared with CDDP-
induced group (group II), ns not significant.
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5.6.2.7. Effect of EEBS on serum BUN, creatinine and uric acid levels in
experimental rats
Group II animals treated with CDDP, demonstrated a significant elevation in the
serum levels of creatinine, uric acid (p<0.01) and BUN (p<0.001). Co-treatment with
quercetin/extract (group III, IV, &V) significantly (p<0.01) decreased BUN and
creatinine levels. However, significant decrease in uric acid levels were observed only in
group co-treated with quercetin (p<0.01), compared to animals in group II (table 28).
Table 28: Effect of EEBS on serum levels of BUN, creatinine and uric acid in
CDDP-induced nephrotoxicity in rats
Serum Parameters
(Unit)
Group I
Normal
control
Group II
CDDP
8 mg/kg
Group III
CDDP+QTN
50 mg/kg
Group IV
CDDP+EEBS
250 mg/kg
Group V
CDDP+EEBS
500 mg/kg
BUN (mg/dL) 30.54±0.01 39.97±0.00***a 35.53±0.02**b 38.69±0.00**b 37.92±0.07**b
Creatinine (mg/dL) 1.04±0.01 2.55±0.01**a 1.09±0.007*b 0.96±0.01**b 0.93±0.08**b
Uric acid (mg/dL) 2.31±0.02 3.15±0.01**a 2.36±0.01**b 3.13±0.01 ns 3.15±0.02 ns
EEBS: Ethanol extract of B. sensitivum, CDDP: cisplatin, QTN: quercetin, BUN: blood
urea nitrogen. Values are expressed in mean ± standard error of mean (n=6), *p<0.05,
**p<0.01, ***p<0.001 a significant compared with control group (group I), bsignificant
compared with CDDP-induced group (group II), ns not significant.
5.6.2.8. Effect of EEBS on markers of oxidation in control and experimental animals
This result also confirmed the link between CDDP- induced oxidative stress and
nephrotoxicity. Antioxidant status in rats exposed to CDDP showed a significant
diminution of activity of SOD, CAT (p<0.01), GSH and GPx (p<0.001), compared to
group I animals. Administration of EEBS to animals induced with nephrotoxicity
significantly increased SOD activity (p<0.01). Evaluation of catalase activity revealed
that rats co-treated with low dose of extract (p<0.01) and high dose of extract (p<0.001)
presented significant elevation, however, significant (p<0.01) improvement in GPx levels
were observed only in rats co-treated with high dose of extract. GSH levels were also
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significantly improved in rats co-administered with 250 mg/kg of extract (p<0.05) and
500 mg/kg of extract (p<0.01). Rats co-administered with standard significantly restored
depleted levels of SOD (p<0.001), CAT, GSH and GPx (p<0.01). A significant
(p<0.001) increase in production of MDA were observed in group II toxic control
animals compared to group I normal animals. Co-administration with standard to group
III, EEBS to group IV and group V animals significantly (p<0.01) decreased MDA levels
(figure 26 &27).
Figure 26: Effect of EEBS on lipid peroxidation in
CDDP-induced nephrotoxicity in rats
EEBS: Ethanol extract of B. sensitivum, CDDP: cisplatin, QTN: quercetin. Units: LPO
(nmol of MDA formed/ mg protein).Values are expressed in mean ± standard error of
mean  (n=6), p<0.05, **p<0.01, ***p<0.001 a significant compared with control group
(group I), bsignificant compared with CDDP-induced group (group II), ns not significant
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Figure 27: Effect of EEBS on oxidative stress parameters in CDDP-induced
nephrotoxicity in rats
EEBS: Ethanol extract of B. sensitivum, CDDP: cisplatin, QTN: quercetin. a) superoxide
dismutase b) catalase  c) glutathione peroxidase  d) reduced glutathione. Values are
expressed in mean ± standard error of mean  (n=6), p<0.05, **p<0.01, ***p<0.001 a
significant compared with control group (group I), bsignificant compared with CDDP-
induced group (group II), ns not significant
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5.6.3. Ethylene glycol (EG)-induced urolithiasis
Antiurolithic activity of EEBS at concentration of 250 and 500 mg/kg, were
determined using different general, urinary, blood, serum and kidney homogenate
parameters against ethylene glycol-induced urolithiais in Wistar albino rats.
5.6.3.1. Effect of EEBS on general parameters in control and experimental animals
Table 29 depicted the effect of EEBS on general parameters of EG-induced
urolithiasis in control and experimental animals that were obtained at the end of the
experiment in each group. Body weight was measured before starting the experiment and
other general parameters were recorded on 28th day during the experimental period.
Significant (P<0.001) weight reduction were observed in group II animals (toxic control)
compared to control group. This results confirmed that there was significant (P< 0.001)
gain in body weight in animals treated with EG+Cystone (group III), EG+ EEBS (group
IV and V), compared to calculi-induced group. Kidney weight was significantly
increased in group II rats (p<0.001) compared to normal control group. Significant
kidney weight reduction were observed in animals in group III, IV (p<0.01) and V
(p<0.001), compared to group II rats. Water intake and urine output in EG-treated group
were significantly (p<0.01) reduced. Urine volume was significantly higher in group co-
treated with standard, low dose of EEBS, (P<0.01) or high dose of EEBS (P< 0.001). No
significant  (p>0.05) change in water intake were observed in rats treated with extract,
however significant (P<0.01) improvement was observed in rats co-treated with
standard, compared to animals in group II. Urine pH was significantly (P<0.01) elevated
in calculi-induced rats, compared to animals in group I. The urine pH were reduced
significantly (p<0.01) in extract/Cystone-treated rats in comparison with group II rats.
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Table 29: Effect of EEBS on general parameters in EG-induced urolithiasis in rats
Parameters
studied
(Unit)
Group I
Normal
control
Group II
EG
0.75% v/v
Group III
EG+Cystone
750 mg/kg
Group IV
EG+EEBS
250 mg/kg
Group V
EG+EEBS
500 mg/kg
Change in body
wt. (g)
5.50±1.02 2.60±0.87***a 5.25±2.94***b 4.81±1.26***b 4.90±1.92***b
Kidney wt. (g) 0.63±0.01 1.06±0.01***a 0.71±0.00**b 0.82±0.00**b 0.69±0.02***b
Water intake
(mL/24 hr)
17.67±0.02 17.22±0.01**a 18.62±0.16**b 17.45± 0.04ns 17.50±0.01ns
Urine volume
(mL/24 hr)
17.83±0.00 10.83± 0.08 **a 16.40±0.00**b 17.98±0.00**b 21.85±0.08***b
Urine pH 6.8±0.05 8.2±0.11**a 6.86±0.11**b 7.10±0.05**b 6.90±0.10**b
EEBS: Ethanol extract of B. sensitivum, EG: ethylene glycol.  Values are expressed in
mean ± standard error of mean (n=6), *p<0.05, **p<0.01, ***p<0.001 asignificant
compared with control group (group I), bsignificant compared with EG-induced group
(group II), nsnot significant.
5.6.3.2. Effect of EEBS on urinary total protein and albumin levels in experimental
rats
Total protein content in urine increased significantly (p<0.001) in EG-induced
group, compared to animals in control group. Oral administration of 250 and 500 mg/kg
of EEBS (p<0.01) and cystone (p<0.001) attenuated changes in proteinuria. However,
there were no significant (p>0.05) change in urinary albumin levels among animals
treated with EG, EG+Cystone or EG+EEBS (table 30).
Table 30: Effect of EEBS on urinary total protein and albumin levels in
EG-induced urolithiasis in rats
Urinary parameter
(Unit)
Group I
Normal
control
Group II
EG
0.75% v/v
GroupIII
EG+Cystone
750 mg/kg
Group IV
EG+EEBS
250 mg/kg
Group V
EG+EEBS
500 mg/kg
Total protein (g/dL) 2.02±0.07 5.13±0.08***a 2.45±0.01***b 3.38±0.00**b 3.03±0.00**b
Albumin (g/dL) 1.02±0.00 1.01±0.07ns 1.04±0.00ns 1.01±0.01ns 1.02±0.02ns
EEBS: Ethanol extract of B. sensitivum, EG: ethylene glycol.  Values are expressed in
mean ± standard error of mean (n=6), *p<0.05, **p<0.01, ***p<0.001 a significant
compared with control group (group I), bsignificant compared with EG-induced group
(group II), ns not significant.
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5.6.3.3. Effect of EEBS on urinary electrolyte levels in experimental rats
Urinary calcium and phosphate excretion were significantly (p<0.001) elevated in
EG-induced group compared to control. Phosphate levels (p<0.01) were found to be
increased only in group III rats, whereas, concurrent administration with Cystone /extract
(p<0.01) attenuated changes in calcium levels. Magnesium excretion were significantly
(p<0.05) reduced in EG-treated group compared to control group. Co-treatment with
Cystone at the dose of 750 mg/kg (p<0.01)/ EEBS at 500 mg/kg (p<0.001) significantly
increased magnesium excretion, compared to lithiatic control group (table 31).
Table 31: Effect of EEBS on urinary electrolyte levels in
EG-induced urolithiasis in rats
Urinary parameters
(Unit)
Group I
Normal
control
Group II
EG
0.75% v/v
Group III
EG+Cystone
750 mg/kg
Group IV
EG+EEBS
250 mg/kg
Group V
EG+EEBS
500 mg/kg
Calcium (mg/dL) 8.02±0.00 14.68±0.03***a 12.02±0.07**b 11.93±0.06**b 10.23±0.03**b
Phosphate (mg/dL) 3.23±0.01 5.46±0.01***a 4.12±0.07**b 5.40±0.03 ns 5.39±0.01 ns
Magnesium (mg/dL) 2.17±0.01 2.04± 0.01*a 2.43±0.04**b 2.06±0.05ns 2.66±0.06***b
EEBS: Ethanol extract of B. sensitivum, EG: ethylene glycol.  Values are expressed in
mean ± standard error of mean  (n=6), *p<0.05, **p<0.01, ***p<0.001 a significant
compared with control group (group I), bsignificant compared with EG-induced group
(group II), ns not significant.
5.6.3.4. Effect of EEBS on hematological parameters in experimental rats
Significant reduction in total red blood cells (RBCs), lymphocytes (p<0.001),
hemoglobin (Hb), packed cell volume (PCV) and mean corpuscular hemoglobin (MCH)
levels (p<0.01) were observed in calculi-induced animals compared to control group.
Animals co-administered with Cystone/ EEBS significantly increased levels of total RBC
(p<0.001), MCH, lymphocytes, and Hb (p<0.01), compared to toxic control animals.
PCV levels were significantly  (p<0.01) improved in animals co-treated with Cystone but
not in animals co-administered with extract (p>0.05). Total WBCs, polymorphs
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(p<0.001) and eosinophils (p<0.01) were significantly elevated in EG-treated animals
compared to control group. Co-treatment with quercetin/EEBS significantly (p<0.001)
decreased total WBC compared to lithiatic control rats. No significant differences were
observed in eosinophil level, however, polymorphs levels were significantly elevated
only in rats co-treated with standard Cystone (p<0. 01), compared to calculi-induced rats
(table 32).
Table 32: Effect of EEBS on hematological parameters in
EG-induced urolithiasis in rats
Parameters Studied
(Unit)
Group I
Normal
control
Group II
EG
0.75% v/v
GroupIII
EG+Cystone
750 mg/kg
Group IV
EG+EEBS
250 mg/kg
Group V
EG+EEBS
500 mg/kg
RBC(million/mm3) 6.12±0.10 3.92±0.42***a 6.95±0.23***b 6. 70±0.42*** b 6.87±0.52*** b
HB ( g/dl) 10.47±0.46 8.23±0.36** a 10.82±0.24**b 10.08±0.23** b 10.94±0.42** b
PCV (%) 37.26±0.24 35.15±0.34** a 37.20±0.33** b 35.01±0.36ns 35.19±0.42ns
MCH  (pg) 21.61±0.13 20.94±0.12** a 22.72±0.09** b 21.64±0.08** b 22.79±0.13** b
WBC (1X103/mm3) 8.87±0.12 9.91±0.22*** a 8.27±0.34*** b 9.12±0.33*** b 9.19±0.12*** b
Lymphocytes (%) 86.21±0.12 78.94±0.34*** a 83.22±0.28** b 81.19±0.44** b 82.41±0.46** b
Monocytes (%) 3.55± 0.02 3.54±0.13 ns 3.52±0.02 ns 3.49±0.02 ns 3.48±0.11 ns
Polymorphs (%) 12.28±0.53 18.27±0.24*** a 13.66±0.14*** b 18.25±0.13ns 18.26±0.09ns
Eosinophils (%) 3.03±0.02 3.30±0. 01** a 3.28±0.02ns 3.24±0.03 ns 3.23±0.00 ns
EEBS: Ethanol extract of B. sensitivum, EG: ethylene glycol.  Values are expressed in
mean ± standard error of mean (n=6), *p<0.05, **p<0.01, ***p<0.001 a significant
compared with control group (group I), bsignificant compared with EG-induced group
(group II), nsnot significant.
5.6.3.5. Effect of EEBS on serum total protein and albumin levels in experimental
rats
Table 33 illustrated the effect of EEBS on serum total protein and albumin levels
in control and experimental animals in each group. Serum total protein levels were
significantly lowered (p<0.001) in calculi-induced rats in comparison with group I rats.
However, significant elevation in serum levels of total protein were observed in animals
in group III (p<0.01), group IV and V (p<0.001), compared to group II rats. Significant
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change in serum albumin levels were not observed among animals co-treated with
standard/extract, compared to group II rats (p>0.05).
Table 33: Effect of EEBS on serum total protein and albumin levels in
EG-induced urolithiasis in rats
Serum parameters
(Unit)
Group I
Normal
control
Group II
EG
0.75% v/v
Group III
EG+Cystone
750 mg/kg
Group IV
EG+EEBS
250 mg/kg
Group V
EG+EEBS
500 mg/kg
Total protein (g/dL) 7.46±0.02 5.76±0.03***a 7.20±0.01**b 7.43±0.01***b 7.86±0.07***b
Albumin (g/dL) 4.32±0.00 4.31±0.00ns 4.32±0.00ns 4.29±0.03ns 4.30±0.00ns
EEBS: Ethanol extract of B. sensitivum, EG: ethylene glycol.  Values are expressed in
mean± standard error of mean (n=6), *p<0.05, **p<0.01, ***p<0.001 a significant
compared with control group (group I), bsignificant compared with EG-induced group
(group II), nsnot significant.
5.6.3.6. Effect of EEBS on serum electrolyte levels in experimental rats
The serum levels of calcium, phosphate (p<0.01) and magnesium (p<0.05) were
significantly elevated in calculi-induced animals compared to control group, indicating
impaired renal function. Co-therapy with Cystone/extract significantly (p<0.01)
decreased calcium level.  However, significant  reduction in serum  phosphate levels
were observed only in  animals co-treated with Cystone (p<0.01)/high dose of EEBS
(p<0.05). Animals administered with EG+standard (group III), attenuated changes in
magnesium level (p<0.01), but not in animals co-treated with EEBS (p>0.05), compared
to group II rats (table 34).
Table 34: Effect of EEBS on serum electrolyte levels in
EG-induced urolithiasis in rats
Serum parameters
(Unit)
Group I
Normal
control
Group II
EG
0.75% v/v
GroupIII
EG+Cystone
750 mg/kg
Group IV
EG+EEBS
250 mg/kg
Group V
EG+EEBS
500 mg/kg
Calcium (mg/dL) 9.29±0.07 11.16±0.01**a 9.39±0.02**b 10.42±0.00**b 9.15±0.01**b
Phosphate (mg/dL) 6.58±0.06 8.06±0.01**a 7.18±0.01**b 8.02±0.01ns 8.00±0.01*b
Magnesium (mg/dL) 2.30±0.00 2.33±0.00*a 2.51±0.00**b 2.31±0.00ns 2.32±0.00ns
EEBS: Ethanol extract of B. sensitivum, EG: ethylene glycol.  Values are expressed in
mean± standard error of mean  (n=6), *p<0.05, **p<0.01, ***p<0.001 a significant
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compared with control group (group I), bsignificant compared with EG-induced group
(group II), ns not significant.
5.6.3.7. Effect of EEBS on serum BUN, creatinine and uric acid levels in
experimental rats
The serum levels of creatinine, uric acid (p<0.01) and BUN (p<0.001) were
significantly elevated in calculi-induced animals compared to control group, indicating
impaired renal function. . Animals co-treated with EEBS 250 mg/kg (curative regimen)
or EEBS 500 mg/kg (preventive regimen) exhibited significant reduction on BUN,
creatinine (p<0.001) and uric acid (p<0.01) levels. Animals treated with standard also
showed significant reduction on BUN (p<0.001), creatinine and uric acid level (p<0.01),
compared to calculi-induced group (table 35).
Table 35: Effect of EEBS on serum BUN, creatinine and uric acid levels in
EG-induced  urolithiasis in rats
Parameters Studied
(Unit)
Group I
Normal
control
Group II
EG
0.75% v/v
Group III
EG+Cystone
750 mg/kg
Group IV
EG+EEBS
250 mg/kg
Group V
EG+EEBS
500 mg/kg
BUN (mg/dL) 36.09 ±0.01 58.53±0.01***a 34.51±0.00***b 41.75±0.01***b 39.87±0.03***b
Creatinine (mg/dL) 0.57±0.00 0.88±0.00**a 0.60±0.01**b 0.49±0.00***b 0.46±0.00***b
Uric acid (mg/dL) 2.75±0.01 3.91±0.00**a 3.34±0.01**b 3.66±0.27**b 3.68±0.01**b
EEBS: Ethanol extract of B. sensitivum, EG: ethylene glycol, BUN: blood urea nitrogen.
Values are expressed in mean± standard error of mean (n=6), *p<0.05, **p<0.01,
***p<0.001 a significant compared with control group (group I), bsignificant compared
with EG-induced group (group II), ns not significant.
5.6.3.8. Effect of EEBS on markers of oxidation in control and experimental animals
The effect of EEBS on lipid peroxidation and antioxidant status in rats exposed to
EG-induced urolithiasis showed a significant decrease of SOD, CAT, GSH and GPx
(p<0.01) activity, compared to group I normal animals. Co-administration of standard
(cystone) to group III rats, EEBS (250 mg/kg) to group IV rats and EEBS (500 mg/kg)
to group V rats, significantly increased SOD levels (p<0.01). GPx activity was found to
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be increased in rats co-treated with standard/ high dose of extract (p<0.01), however, no
significant differences were observed in catalase and GSH activity in animals co-treated
with low/ high dose of extract, compared to calculi-induced rats. A significant (p<0.01)
increase in production of MDA were observed in group II toxic control animals
compared to group I normal animals. Co-administration of cystone to group III, EEBS to
group IV rats and group V rats significantly (p<0.01) decreased MDA levels, compared
to calculi-induced rats (figure 28, 29).
Figure 28:  Effect of EEBS on lipid peroxidation in EG-induced urolithiasis in rats
EEBS: Ethanol extract of B. sensitivum, EG: ethylene glycol. Units: LPO (nmol of MDA
formed/ mg protein). Values are expressed in mean ± standard error of mean  (n=6),
p<0.05, **p<0.01, ***p<0.001 a significant compared with control group (group I),
bsignificant compared with EG-induced group (group II), ns not significant.
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Figure 29: Effect of EEBS on oxidative stress parameters in
EG-induced urolithiasis in rats
EEBS: Ethanol extract of B. sensitivum, EG: ethylene glycol. a) superoxide dismutase b)
catalase  c) glutathione peroxidase  d) reduced glutathione. Values are expressed in mean
± standard error of mean  (n=6), p<0.05, **p<0.01, ***p<0.001 a significant compared
with control group (group I), bsignificant compared with EG-induced group (group II), ns
not significant
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5.7. Histopathological studies
5.7.1.Histopathological studies of EEBS on gentamicin (GM)-induced nephrotoxicity
Histopathological analysis of kidney in group I rats revealed normal morphology
of glomeruli, tubules, blood vessels and interstitium. Rats administered with GM (100
mg/kg; for 8 days; i.p.) caused acute renal damages which were evident by marked
mesangial hypercellularity in glomerulus, tubular necrosis, tubular degeneration and
blood vessel congestion. Rats administered with GM+low dose of EEBS (250 mg/kg)
also showed mesangial hypercellularity and cytoplasmic vacuolation in the proximal
tubules. These changes were reduced in rats co-treated with high dose of EEBS (500
mg/kg) which were evident only by mild epithelial vacuolation in the proximal tubules,
thus showing protective effect of extract on drug-induced nephrotoxicity.
Histopathological presentation of kidney in normal, toxic, standard and extract treated
animals are presented in figure 30-34.
Figure 30: Histopathology results of kidney of normal rats (control) in
GM-induced nephrotoxicity model
(A) 10X shows  normal cortex and medulla;  (B) 40X shows normal glomeruli; (C)
40X shows normal tubule; (D) 40X shows normal interstitium.
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Figure 31: Histopathology results of kidney in GM-treated rats (toxic control)
A) 40X  shows  cortex and medulla; (B) 40X shows marked mesangial hypercellularity in
glomeruli;  (C) 40X shows  focal tubular epithelial loss; (D) 40X shows blood vessel
congestion.
Figure 32: Histopathology results of kidney in GM+quercetin-treated rats
(A) 40X shows  normal cortex and medulla;   (B) 40 X shows mild mesangial
hypercellularity  in glomeruli; (C)  40X shows  normal tubules; (D) 40X shows mild
blood vessel congestion.
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Figure 33: Histopathology results of kidney in GM+EEBS (250 mg/kg)-treated rats
(A) 10X shows cortex and medulla with mild mesangial  hypercellularity; (B) 40X shows
cortex and medulla with mild mesangial  hypercellularity; (C) 40X shows tubular
degeneration, cytoplasmic vacuolation in the proximal tubules; (D) 40X shows normal
interstitium.
Figure 34: Histopathology results of kidney in GM+EEBS (500 mg/kg)-treated rats
(A) 40X shows normal glomeruli with tubules;  (B) 40X shows normal glomeruli; (C)
40X shows mild cytoplasmic vacuolation in tubules; (D) 40X shows normal interstitium.
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5.7.2. Histopathological studies of EEBS on cisplatin (CDDP)-induced
nephrotoxicity
Histopathological analysis of kidney section of animals in control group revealed
normal morphology of glomeruli, tubules, blood vessels and interstitium . Treatment
with CDDP caused acute renal damages which were evident by mild mesangial
hypercellularity in glomerulus, tubular casts, mild interstitial inflammation, cytoplasmic
vacuolations and swelling in glomerulus, as compared to control. Animals co-
administered with low dose of EEBS (250 mg/kg) revealed mild mesangial
hypercellularity and matrix expansion in glomerulus, focal nuclear loss and epithelial
thinning in tubular region.  These changes were reduced in group V animals co-
administered with high dose of EEBS (500 mg/kg) thus showing nephroprotective effect
of drug. Histopathological presentation of kidney in normal, toxic, standard and extract
treated animals are presented in figure (35-39).
Figure 35: Histopathology results of kidney of normal rats (control) in CDDP-
Induced nephrotoxicity model
(A) 10X shows  normal cortex and medulla; (B) 40X shows normal glomeruli; (C) 40X
shows  normal tubule; (D ) 40X shows normal interstitium.
Result
Page 122
Figure 36: Histopathology results of kidney in  CDDP-treated  rats (toxic control)
(A) 40X shows marked mesangial hypercellularity in glomeruli; (B) 40X shows casts in
tubules;  ( C) 10X shows  mild inflammatory infilterate in interstitium; (D) 40X shows
mild inflammatory infilterate and cytoplasmic vacuolation in interstitium.
Figure 37: Histopathology results of kidney in CDDP+quercetin-treated rats
(A) 10X shows  normal cortex and medulla;   (B)  40X shows normal glomeruli; (C) 40X
shows normal glomeruli and tubule; (D ) 40X shows normal interstitium.
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Figure 38: Histopathology results of kidney in CDDP+EEBS (250 mg/kg)-treated
rats
(A) 40X shows mild mesangial  hypercellularity and matrix expansion in glomerulus;
(B) 10X shows  mild mesangial  hypercellularity and matrix expansion in glomerulus;
(C) 40X shows focal nuclear loss and epithelial thinning; D) 40X shows normal
interstitium.
Figure 39: Histopathology results of kidney in CDDP+ EEBS (500 mg/kg)-treated
rats
(A) 40X shows normal glomeruli; (B) 40X shows normal glomeruli and tubules; (C)
40X shows normal tubules; (D) 40X shows normal interstitium.
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5.7.3. Histopathological studies of EEBS on ethylene glycol (EG)-induced
urolithiasis
Histopathological analysis of kidney section of glomeruli, tubules, blood vessels
and interstitium  in control group rats revealed normal morphology. There were no
abnormalities or calcium oxalate deposits inside tubles. Rats in toxic control (group II)
exhibited mesangial hypercellularity in glomerulus, interstitial inflammation, mild
congestion in blood vessels, tubular epithelial loss, vacuolation and  dilation (features of
acute tubular necrosis), along with crystal deposits. Animals co-administered with low
dose of EEBS (250 mg/kg) revealed tubular epithelial loss, vacuolization and dilation,
along with crystal deposits.  These changes were reduced in group V animals co-
administered with high dose of EEBS (500 mg/kg) thus showing antiurolithic effect of
drug. Histopathological presentation of kidney in normal, toxic, standard and extract
treated animals are presented in figure 40-44.
Figure 40: Histopathology results of kidney of normal rats (control) in EG-induced
urolithiasis model
(A) 10X  shows  normal cortex and medulla;  (B) 40X shows normal glomeruli; (C)
40X shows  normal tubule;  (D ) 40X shows normal interstitium.
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Figure 41: Histopathology results of kidney in EG-induced urolithic rats (toxic
control)
(A) 40X shows marked mesangial hypercellularity in glomeruli; (B) 40X shows proximal
tubular dilation along with crystal;  (C)  40X shows  tubular loss, vacuolation and
necrosis; D ) 40X shows interstitial inflammation.
Figure 42: Histopathology results of kidney in EG+ cystone-treated rats
(A) 10X shows  normal cortex and medulla;   (B) 10X shows normal glomeruli; (C)
40X shows focal dilatation of the tubules; (D ) 40x shows normal interstitium.
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Figure 43: Histopathology results of kidney in EG+EEBS (250 mg/kg)-treated rats
(A) 40X shows normal glomerulus; (B) 10X shows tubular dilation with crystal deposit;
(C) 40X shows tubular  epithelial loss and vacuolation; (D) 10X shows normal
interstitium.
Figure 44: Histopathology results of kidney in EG+EEBS (500 mg/kg) -treated rats
(A) 10X shows normal cortex and medulla;  (B) 40X shows normal glomeruli;  (C ) 40X
shows mild tubular dilation; (D) 10X shows normal interstitium2
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6. DISCUSSION (Inferences)
The term herbalism, herbology or phytotherapy refers to the use and importance
of herbal plants based on their therapeutic values. Medicinal plants are the oldest form of
health care, ever since the birth of mankind. In prehistoric period, the primitive men
depended only on natural resources (plants and animals) for curing their ailments. They
started observing the relationship between life, disease and plants and found that large
number of plants possess therapeutic activities.169 The collected knowledge acquired
through their experiences about medicinal value of herbal plants were transferred from
generation to generation.  The world health organisation (WHO) has recorded about
21,000 medicinal plants all over the world, out of which 2500 species are from India,
therefore India is known as the botanical garden of the world.170 Herbal drugs constitutes
the major biosource for use as food supplements, folk medicines, modern medicine,
pharmaceutical aids, nutraceuticals and chemical entities for synthetic drugs. It is also
recorded that about one fourth of prescribed drugs contain active ingredients derived
from medicinal plants. Previous research studies reported that the curative property of
medicinal plants for various ailments are perhaps  due to the presence of secondary
metabolites including alkaloids, phenols, flavonoids, glycosides, tannins, saponins and
terpenoids.171
Globally, renotoxicity remains  a common challenging side effect of various classes
of drug and and exerts substantial  burden to the society.1 Hence, there is an urgent need for
providing safe and successful treatment to prevent drug-induced renal complications. Large
volume of research works with different medicinal plants were performed to prove their
claimed effects on drug induced nephrotxicity or urolithiasis. Several studies have proved
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that co-therapy with nephroprotective medicinal plants along with different nephrotoxic
agents minimized its toxicity.2 Several chemical and natural substances with antioxidant
activity also enhanced the therapeutic efficacy of drug having nephrotoxic potential.3
Therefore, investigating new pharmacological agents from plant source with different
phytoconstituents may provide  safe and effective treatment for drug induced
nephrotoxicity.
The whole plant B. sensitivum is a well-known auspicious medicinal plant used in
the Indian medicine for treating several diseases. This plant was evaluated for various
pharmacological activities which included antioxidant, antibacterial, antidiabetic,
antitumour, immunomodulation, radioprotective, anti-inflammatory, cardioprotective and
many more. In this current study, the investigation covered phytochemical, cytoprotective,
antioxidant, nephroprotective and antiurolithic activities of whole plant B. sensitivum.
6.1. Phytochemistry
6.1.1. Collection, identification and preliminary phytochemical studies
In the present study, the shade dried whole plant B. sensitivum were subjected to
size reduction by passing through sieve No. 40. The uniformly powdered plant material
were then subjected to solvent extraction process using petroleum ether for defatting the
drug and then with 70% ethanol. Shade drying of plant material protects phytoconstituents
so that therapeutic properties would not be destroyed. Extraction of plant material is the
initial process used for screening, isolation and standardization of  phytoconstituents
present in the plant material. Solvent extractions are widely accepted procedure due to their
efficiency, availability, applicability and ease of use. The yield of extractable compound
depends on various factors including temperature, solvent polarity, duration, sample
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characteristics, ratio of sample and solvent. 70% ethanol is generally considered as safe and
better solvent for extraction. In this study, percentage yield of extraction were found to be
12.54% w/w with ethanol extract and 4.92% w/w with petroleum ether extract of B.
sensitivum (Table 8).  Highest amount of total extractable compounds were obtained with
70% ethanol in comparison with petroleum ether.
Preliminary phytochemical analysis would be useful in the identification of
chemical constituents with therapeutic potential and their subsequent use in drug
development and discovery. Phytochemical screening results of our study have confirmed
that whole plant of B. sensitivum contains carbohydrates, alkaloids, steroids, saponins,
proteins, aminoacids, falvonoids, tannins, phenolic compounds and fixed oils (Table 9).
Previous research studies have reported that bioflavonoid, the primary antioxidant and free
radical scavenger  are responsible for wide range of therapeutic activities mainly
antioxidant, anti-inflammatory and anticancer properties.100,104,108,110 Our phytochemical
screening result s were in agreement with the earlier findings by Uma et al., 172 but lacked
the presence of steroids. Findings of Shibila et al.,173 showed the presence of steroids. In
contrast to our findings, Uma et al.,172 also reported the presence of cardiac glycoside in
EEBS. These secondary metabolites perhaps are responsible for the pharmacological
activities of plant extract.
6.2. Quantitative estimation of total phenolic content and flavonoids
Polyphenols are the large and diverse class of compounds which occur naturally
in wide range of plants. Among polyphenols, phenolic compounds and flavonoids are the
best studied aromatic compounds which protect organism from damage caused by free
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radical induced oxidative stress. Polyphenols  possess diverse therapeutic activities
including antioxidant, anti-mutagenic, anti-carcinogenic and anti-inflammatory effects.
6.2.1. Total phenolic content
Several methods have been used for the estimation of total phenolic contents.
Among all, Folin-Ciocalteu assay are most widely used method, which was preferred in
the present study for the estimation of total phenolics due to its sensitivity and speed. The
Folin-Ciocalteu assay relies on the ability of phenolic compounds to transfer reducing
equivalents (electrons), to phosphomolybdic/phosphotungstic acid complexes in the
alkaline medium, resulted in the formation of blue colour complexes and absorbance was
measured at 725 nm.125 In this study, total phenolic content in EEBS were 53.55 mg/g of
gallic acid equivalents.
6.2.2. Total flavonoid content
Flavonoids are large sub groups of plant phenolics which were estimated using
colorimetric method based on the ability of aluminium chloride to form acid stable
complexes with C-4 ketogroups, either with the C-3 or C-5 hydroxyl group of flavones
and flavonols, or acid labile complexes with orthodihydroxyl groups in the A-or B-ring of
flavonoids.126 Absorbance was measured at 415 nm. Result of this study demonstrated
that EEBS posessed highest flavonoid content i.e. 153.08 mg/g of rutin eqiuvalents. Our
findings were consistent with the result of study performed by Sulaiman CT &
Balachandran I.174
6.3. In vitro antioxidant and free radical scavenging activities of EEBS
Free radicals are highly reactive and chemically unstable atoms or molecules
capable of initiating oxidative reactions due to the presence of unpaired electrons in
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outermost orbital. Accumulation of free radicals are responsible for about 95% of
pathologies in people above 35 years of age.175 Overwhelming research reports suggest
that ample generation of reactive oxygen species in any biogenic redox process may leads
to pairing of free radicals by interacting with specific biomolecules in the body such as
cell protein, lipid, carbohydrate, lipoprotein and eventually cause induction of lipid
peroxidation, cell damage or cell death. In biochemical reaction, oxygen and hydrogen
peroxide react together to form hydroxyl radical which is the most reactive free radical
known to initiate lipid peroxidation and DNA fragmentation. Nitric oxide react with
superoxide radical and form highly reactive peroxy nitrite. Excessive generation of free
radicals has also been implicated in development of several chronic diseases.176-181
Antioxidants, containing one or more free electrons are capable of neutralizing
reactive oxygen species (ROS) and convert them into less harmful or harmless species.
Endogenous antioxidant defense system generally provide insufficient protection against
ROS, hence antioxidants are needed to supplement from external source. At present,
there has been a great interest on naturally occurring antioxidant owing to harmful side
effects of most extensively used commercially available synthetic antioxidants. Several
experimental data indicates there is a close association between consumption of
antioxidant rich food and prevention of diseases.
Various in vitro methods have been developed to measure the antioxidant
potential of pure compounds or plant extracts.  Ferric reducing antioxidant power
(FRAP), α, α-diphenyl-β-picryl-hydrazyl radical scavenging assay (DPPH), superoxide
anion radical scavenging assay, hydroxyl radical scavenging assay, nitric oxide radical
scavenging assay and total phenol assay  are most widely used in vitro methods182 due to
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their sensitivity and speed. The concentration of antioxidants needed to decrease free
radical concentration by 50% (IC50) is a parameter widely used to measure the
antioxidant activity. Lower IC50 value indicates a higher antioxidant power or excellent
free radical scavenging activity.
In this current study, we have determined the antioxidant or free radical
scavenging activity of EEBS using different in vitro models which included ferric
reducing antioxidant power assay, reducing power assay, 1,1-Diphenyl-2-picryl
hydrazine (DPPH) radical scavenging assay, ABTS radical scavenging assay,  hydroxyl
radical scavenging assay, superoxide radical scavenging assay and  nitric oxide radical
scavenging assay.
6.3.1. DPPH (1, 1-Diphenyl-2-picryl hydrazine) radical scavenging activity
DPPH radical scavenging assay is widely used method183 based on the reduction
of DPPH, a stable organic nitrogen radical to non-radical form DPPH-H. It is rapid,
simple, reliable, inexpensive and reproducible type of assay. The dose dependent
inhibition of DPPH radical indicated that odd electron of nitrogen atom in DPPH is
reduced by receiving a hydrogen atom from phenolic OH group of antioxidant to
corresponding hydrazine. In this study EEBS exhibited significant scavenging effect on
the DPPH radical in comparison to standard ascorbic acid and suggested that the
phytochemical constituents present in this extract are capable to prevent oxidative injury
to tissues. Our findings were similar to the report of Sreena R et al.184
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6.3.2. Ferric reducing antioxidant power (FRAP) assay
FRAP assay was employed to estimate the reducing ability of antioxidants in vitro
against oxidative effects of reactive oxygen species. This assay method is based on the
reduction of ferric tripyridyl triazine (Fe III TPTZ) complex to form ferrous at low pH
which produce intense blue colour. This reaction can be monitored by measuring the
change in absorption which is directly related to the reducing power of antioxidants
present in the reaction mixture. They exert their action by donating a hydrogen atom after
breaking the free radical chain. Ferrous sulphate is used for calibration. Butylated
hydroxyanisole, butylated hydroxytoluene, ascorbic acid, quercetin, catechin and trolox
can be used as positive control.128 Reducing ability of extract might be due to the
presence of flavonoids or polyphenolic compounds. Our findings were correlated with the
result of Pal TP et al.185
6.3.3. ABTS [2, 2’-azino-bis (ethylbenzthiazoline-6-sulphonic acid)] radical
scavenging activity
ABTS radical decolorization study is an excellent method to measure the
antioxidant activity of phenolic compounds. This assay is based on the ability of sample
to scavenge 2, 2’-azino-bis (ethylbenzthiazoline-6-sulphonic acid) or ABTS radical.129
Blue coloured ABTS radical generated in presence of free radical inducer was quenched
by EEBS and demonstrated oxygen radical absorbance capacity in a concentration
dependent manner. EEBS possessed good hydrogen-donating capacity, as evidenced by
its IC50 value (42.01 μg/mL).
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6.3.4. Hydroxyl radical scavenging activity
Hydroxyl radical is the most potent reactive oxygen species which react with
lipid, polypeptides, proteins, DNA and are capable of initiation of lipid peroxidation by
extracting hydrogen atoms from unsaturated fatty acid.130 Hydroxyl radical scavenging
activity was quantified based upon the competition between deoxy ribose and antioxidant
component in the plant extract for hydroxyl radicals generated by Fe3+-ascorbate, EDTA-
hydrogen peroxide system (Fenton) system. Hydroxyl radicals formed in free solution or
in presence of transition metal ions such as iron causes degradation of sugar into
malondialdehyde which form a pink chromogen on heating with thiobarbituric acid.186
Effect of EEBS on hydroxyl radicals scavenging activity was measured by determining
the degree of deoxyribose degradation, an indicator of thiobarbituric acid-malonaldehyde
(TBA-MDA) adduct formation. Absorbance value decreases with increase in hydroxyl
scavenging activity. In this study, polyphenolic compounds present in EEBS may be
performed as metal chelators or hydrogen donors which inhibit complexing of hydroxyl
radical with deoxy ribose, thereby demonstrated hydroxyl radical scavenging activity.
Our results were consistent with the findings of Guruvayoorappan C et al.108
6.3.5. Superoxide radical scavenging activity
Superoxide anion (O2-) is one electron reduced form of molecular oxygen. This
free radical generates under condition of oxidative stress have potential of reacting with
biological macromolecules. Superoxide anion also promote generation of powerful and
dangerous hydroxyl radicals and singlet oxygen which play an important role in
contributing oxidative stress.187 Recent studies have shown that phenolic compounds
particularily flavonoids are important superoxide anion scavengers. Superoxide anion
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derived from dissolved oxygen by phenazine methosulfate/reduced nicotinamide adenine
dinucleotide (PMS/NADH) coupling reaction reduces nitroblue tetrazoliumchloride
(NBT) resulting in the formation of blue formazan. The intensity of colour decreases
proportional to the superoxide radical scavenging activity of extract.131 Decrease of
absorbance at 560 nm indicated the consumption of superoxide anion in the reaction
mixture.188 Hence, from the result it can be concluded that the extract possessed
significant superoxide scavenging activity and this ability depends on the concentration
of phenolic compounds, number of hyrdroxyl group in aromatic ring. Our findings were
consistent with the report of Guruvayoorappan C et al.108
6.3.6. Nitric oxide radical scavenging activity
Nitric oxide is an important reactive oxygen species generated by endothelial
cells, macrophages, stress, toxins etc and have been implicated in various diseases.
Excess nitric oxide reacts with oxygen and generates stable nitrate and peroxy nitrite ions
under aerobic condition. The method used for the determination of nitric oxide is based
upon the inhibition of nitric oxide radical generated from sodium nitroprusside in
aqueous solution at physiological pH. The inhibitory potentials of EEBS against this
highly reactive compound may be attributed to their ability to compete with oxygen for
nitric oxide leading to reduced production of nitrite ions, thereby demonstrated its
protective role against oxidative stress. Nitric oxide scavenging activity exhibited by
EEBS was found to be less compared to standard ascorbic acid. Our findings were in
accordance with the report of Guruvayoorappan C et al.108
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6.3.7. Reducing power activity
Previous research reports have revealed that there is a direct correlation exist
between antioxidant activities and reducing power of certain plant extracts.189 Antioxidant
having reduction potential react with potassium ferricyanide (Fe3+) to form potassium
ferrocyanide(Fe2+), further react with ferric chloride to form ferric ferrous complex and
can be monitered by measuring the absorbance at 700 nm. The change in absorbance is
directly related to total reducing power of the electron donating antioxidants present in
the reaction mixture. Phytoconstituents with reducing power, serving as primary and
secondary antioxidants can oxidize intermediates of lipid peroxidation processes.190 In
this study, EEBS at concentration of 80 and 100 µg/mL showed reducing capacity higher
than that of standard ascorbic acid, indicating its potency to donate electron to reactive
free radicals and converting them into more stable non-reactive species. This result also
implies that poly phenolic compounds present in EEBS may be the contributing factor
towards antioxidant activity or quenching ability of free radicals in a dose dependent
manner.
Previous studies have reported the antioxidant properties of medicinal plants or
foods which are rich in phenolic compounds.191 However, it is required to depend more
than one antioxidant assay when plant extracts are being evaluated for their antioxidant
potential because of the complex nature of phytochemicals.192 In this study ability of
EEBS to scavenge free radicals  were found to be different in different testing system.
Overall, the present in vitro antioxidant and free radical scavenging assay indicated that
the whole plant B. sensitivum are potential source of bioactive compounds which exhibits
excellent antioxidant and free radical scavenging activity.
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6.4. In vitro antiurolithic activity of EEBS.
Related to urinary tract diseases, renal calculi is the third most common affliction,
which is exceeded by the urinary tract infections and prostate diseases.193 Urolithiasis
begins with urinary super saturation of solid crystalline particles followed by nucleation,
growth, aggregation and retention within the kidneys. Calcium oxalate monohydrate ,
calcium oxalate dihydrate and basic calcium phosphate are the most commonly occurring
stones. Accumulation of thermodynamically stable calcium monohydrate promotes stone
formation in kidney than calcium dihydrate form. 194 Crystal size is a limiting factor in
stone formers as large particle occludes, less likely to pass through urinary tract and
subsequently induce injury on urinary tract.  Therefore, antiurolithic activity is mainly
associated with the dissolution of kidney stones or calcium oxalate crystals which
further prevent kidney stone formation and its recurrence. Previous clinical and
preclinical studies reported that the formation of urinary stones leads to oxidative stress
in patients.195,196 Ureteric calculus disappeared within 55 days of treatment with
‘Cystone’ a herbo-mineral composition mainly by inducing diuresis.197 In this current
study, we have determined the antiurolithic activity of EEBS using in vitro models such
as nucleation, aggregation and microscopic assay.
6.4.1. Nucleation assay
In this study, the in vitro inhibitory effect of EEBS and Cystone (standard) on
calcium oxalate (CaOx) crystallisation were determined at various concentrations (10-
100 mg/mL) and compared it with control. The findings of the present study exhibited
dose dependent inhibitory effect of EEBS on nucleation of crystals.
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6.4.2. Aggregation assay
In the aggregation assay, EEBS at various concentration (10-100 mg/mL) showed
a significant dose-dependent inhibition on aggregation of crystals (11-78%). Cystone
showed inhibitory activity on crystal aggregation more potent than the plant extract at the
same concentration range (13-82%).
6.4.3. Microscopic assay
EEBS  at different concentrations  were applied directly on the crystals. This
process resulted in  number and size reduction of crystals in concentration dependent
manner, which showed the ability of EEBS to prevent super saturation and precipitation
of the CaOx crystal.
These results further confirming that EEBS might contain some phytochemicals
that inhibit nucleation, aggregation or growth of CaOx crystal. EEBS promoted
dispersion of particles in solution  which  favour excretion from the kidney and thereby
reducing the chance of retention in the urinary tract. Previous research studies mentioned
the significance of polyphenols and flavonoids in the antioxidant and antiurolithic
activity of different plant extracts.198,199 Several clinical and preclinical studies were also
confirmed that the flavonoids present in medicinal plants inhibit calcium oxalate  and
crystal deposition in human urine as well as in animal models.200, 201 Herniaria hirsuta, a
plant rich with saponin, disaggregate the suspension of mucoproteins, which promote
crystallization.136 The present findings revealed similar inhibition on formation of
kidney stones as reported for Adiantum capillus,202 Terminalia arjuna,203 Phyllanthus
niruri 204. Overall, in vitro antiurolithic activity of EEBS indicated that the
phytoconstituents especially phenolic compounds, flavonoids and saponin  present in the
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whole plant B. sensitivum might inhibit nucleation, aggregation and growth of  CaOx
crystals, thereby reducing the possibility of kidney stone formation and  injury.
6.5. Cytoprotective activity of EEBS
Ethnomedical usefulness of herbal drugs for various ailments were normally
based on accidental discovery. Hence cell viability or cytotoxic testing with medicinal
plant extracts is vital for safety evaluation. Several mechanisms are responsible for
cytotoxicity including oxidative stress, inflammation, fibrogenesis and apoptosis. Lipid
peroxidation mediated by reactive oxygen species inhibit DNA inter-strand and intra-
strand cross-linking process which subsequently leads to cell death.205 Cytotoxic
compounds often compromise cell membrane integrity. Hence assessing cell membrane
integrity is one of the most common ways to measure cytotoxic effects.
Trypan blue exclusion method, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay and lactate dehydrogenase (LDH) assays are
well-established methods to determine the percentage cell viability, mitochondrial
competence, cell membrane integrity respectively which provide an indirect
measurement of cell death.206 Apoptosis or necrosis compromise cell membrane integrity,
hence additionally DNA fragmentation assay (biochemical hallmark of apoptosis) was
performed.
In this study, cell protective activity of  EEBS were evaluated using Trypan blue
exclusion and MTT assay method on human embryonic kidney 293 (HEK 293) cell lines.
These methods are highly popular, simple and convenient way of determining cell
viability. HEK 293 cells are preferred in cell biology research for many years, because of
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their reliable growth and propensity for transfection.207 Lactate dehydrogenase assay was
also carried out to determine cytoprotective activity of extract using A498 cell lines.
A498 cells are widely used in cytotoxic research. DNA laddering assay was performed in
A498 cell lines for further evaluating the nature of cell death.
6.5.1. Trypan blue exclusion assay
Dye exclusion assays are based on the exclusion of certain dyes by intact cell
membrane. Cell suspension is mixed with the dye and visually examined to determine
whether cells take up or exclude. Dye penetrates when membrane integrity of the cells is
compromised.  Affinity of trypan blue is increased for basic proteins as it is a weak acid,
hence its nuclei uptake is generally high due to the presence of histones.  Therefore viable
cells remain unstained  with clear cytoplasm and a refractile ring around them where as
nonviable cells appear as dark blue color with no refractile ring around them.208 In this
study, cell lines treated with  different concentration of EEBS (12.5-200 μg/mL),
demonstrated that the percentage cell viability decreases as concentration of EEBS
increases. Our findings were in accordance with the study done by Jetva K et al.209
6.5.2. MTT assay
MTT is a colorimetric assay that measures the reduction of yellow 3-(4, 5
dimethylthiazol-2-yl) -2, 5-diphenyltetrazolium bromide (MTT), a water soluble
tetrazolium salt. The MTT enters the cells and passes into the mitochondria where it is
reduced to an insoluble dark purple colored formazan product by mitochondrial enzyme
succinate-dehydrogenase.The  amount of formazan produced is directly proportional to
the number of viable cells, as cleavage of the tetrazolium ring of MTT can only occur in
metabolically active cells. It was clear from our study that MTT assay method produced
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almost similar results as that of trypan blue dye exclusion method.  EEBS exhibited
cytotoxic effects only at high concentration (100 & 200 μg/mL) and percentage  cell
viability was decreasing in dose dependant  manner in both assay method. Our findings
were correlated with the report of Sreena R et al.,184 Guruvayorappan C and Girija K.109
6.5.3. Lactate dehydrogenase assay
Lactate dehydrogenase is an oxidative enzyme widely concentrated in cell
membranes and cytoplasm and plays an important step in energy production in cells.
When cell membrane ruptures, lactate dehydrogenase release and catalyse the conversion
of pyruvate to lactate. This is a simple, reliable and fast cytotoxicity assay based on the
level of lactate dehydrogenase (LDH) in the extracellular medium. This cytoplasmic
enzyme level indicating cytotoxicity was measured by assessing nicotinamide adenine
dinucleotide (NADH) that remained in mixture.210 Result clearly indicated that the
volume of enzyme activity measured in this assay had progressed in a dose-dependent
manner. However, significant LDH release was observed only in cell lines treated  with
EEBS at dose level of 160 µg/mL and 320 µg/mL, compared to untreated cells indicating
irreversible cell death. Apoptosis  or necrosis process may compromise cell membrane
integrity that resulted in the release of LDH into the medium. Our findings were in
accordance with the study done by Gayathri G et al.,211 Kangas L et al. 212
6.5.4. DNA fragmentation assay
Cell membrane injury is milder incase of apoptosis, compared to necrosis. Hence
DNA laddering was done for determining the nature of cell death. The conventional
agarose gel electrophoresis was performed on A498 cell lines by treating with the 160
Discussion
Page 142
and 320 µg/mL of EEBS for 48 hrs. Apoptotic DNA fragmentation is a natural
fragmentation of cell or programmed cell death, characterized by cytoplasmic
condensation, plasma membrane blebbing, nuclear pyknosis, leading to nuclear DNA
breakdown into multiple fragments. In dying cells, DNA is cleaved by endonuclease that
fragments the chromatin into nucleosomal units, which are multiples of about 180 bp
(base pair) oligomers and appear as a DNA ladder when run on an agarose gel. This
study result revealed the degradation of chromosomal DNA into smaller
internucleosomal fragments and produced a ladder pattern. 213 Evident DNA
fragmentation was seen on A498 cells treated with EEBS at 320 µg/mL concentration
indicating apoptosis, however, at 160 µg/mL lesser fragmentation was observed. Our
findings were correlated with the report of Guruvayoorappan C et al.117
Overall, this result suggested that the EEBS at lower concentration did not show
any cytotoxic effect. Phytoconstituents present in this plant especially phenolic
compounds  and flavonoids  may be attributed to its cell protective activity. However,
EEBS at higher concentration demonstrated cytotoxic and apoptotic effect.
6.6. In vivo pharmacological studies
Nephrotoxicity is the most common kidney problem generally observed among
people who widely use potent therapeutic drugs cisplatin (chemotherapeutic agent) and
aminoglycoside antibiotics. However, these drugs still widely used in clinical practice
because of its low cost and efficacy. In preclinical studies, gentamicin or cisplatin-
induced nephrotoxicity are widely used experimental models. Hence the present study
has been undertaken to determine nephroprotective activity of EEBS by selecting these
experimental models. Nephroprotective effect of EEBS were determined by assessing
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various general, hematological, urinary and serum parameters. In vivo antioxidant
enzyme levels in kidney homogenate were also determined. In present study, EEBS at
concentration of 250 mg/kg (low dose) and 500 mg/kg (high dose) were selected to
investigate the nephroprotective activity based on the study report of Anidya et al.112
Natural flavonoid, quercetin (50 mg/kg) was used as standard. Large amount of this
flavonoid present in various fruits and vegetables exhibited excellent antioxidant,
cytoprotective and nephroprotective effects.214, 215
6.6.1. Gentamicin-induced nephrotoxicity
Gentamicin (GM), is an aminoglycoside antibiotic widely used in the treatment of
gram-negative infections. However, its clinical use is highly constrained due to its
adverse effects, mainly nephrotoxicity and ototoxicity.216 Poon et al., have reported that
GM at dose level of 100 mg/kg/bw is nephrotoxic to experimental animals.217
In this sudy, progressive weight loss of animals were observed in the negative
control group treated with GM (100 mg/kg;i.p.) and this might be associated with
increased catabolism, physiological imbalance, mental stress, poor food or water intake.
Co-administration with EEBS/quercetin (standard) promoted food intake and cause
subsequent increase in body weight. Nairuti et al.,218 demonstrated  significant reduction
in body weight, urine volume and increase in  kidney weight in animals treated with GM.
In current study, significant weight reduction of kidney was observed in animals co-
treated with EEBS/quercetin compared to rats in toxic control group and this might be
due to its potential to reduce inflammation. Urine output was markedly reduced in
animals in toxic control compared to animals in normal group. This might be due to the
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drug-induced change in release of antidiuretic hormone or thirst center activity in the
cerebral cortex.219 Supplementation of EEBS to GM-treated animals significantly
improved water intake and urine output. Our findings were consisitent with the study of
Nairuti et al.218 Usually urinary pH value decreases consistently with degree of kidney
injury.220 However, in our findings there were no significant difference in urinary pH
among animals in toxic control group, standard/extract-treated rats. In contrast to our
findings, Aparna RM et al.,221 reported that elevated urinary pH value observed in GM-
treated group were significantly lowered in animals co-administered with ethanolic
extract of Annona reticulata.
Incidence of elevated levels of urinary excretion of total protein and albumin have
been suggested as an index of renal damage and proximal tubular dysfunction..222 In this
study, proteinuria and albuminuria observed in animals in toxic control group were
significantly reduced in EEBS/quercetin-treated rats. These observations indicated
protective role of EEBS against GM-induced nephrotoxicity. The results obtained were
consistent with the findings of Anitha T and Mohan DS,223 based on  the investigation of
nephroprotective activity of Morinda citrifolia extract against GM-induced renal damage
in rats.
Drug induced nephrotoxicity has been associated with fall in glomerular filtration
rate. Drug induced rise in urinary excretion of sodium, potassium, calcium and
magnesium have been reported previously.224,  225 In this study urinary excretion of
calcium and magnesium levels were significantly increased. Hypermagnesiuria and
hypercalciuria reveal specific membrane or transport system abnormality.226, 227 In current
study, no significant changes were observed in urinary excretion of sodium and
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potassium levels among animals treated with GM, standard or extract. However, co-
administration  of  EEBS/quercetin showed a significant change in elevated urinary level
of  calcium and magnesium observed in GM-treated animals. Thus, prevention of
hypercalciuric  and  hypermagnesuric effect may probably be attributed to the protective
effect of EEBS in GM-induced nephrotoxicity. Previous findings of Anitha T and Mohan
DS,223 confirmed that administration of Morinda citrifolia reverted the urinary excretion
of these biochemical constituents to near normal suggesting nephroprotective activity of
this plant extract.
Determination of haematological parameters are considered as earliest indicator
of deleterious effect produced by the nephrotoxic drug and its metabolite. 228 Exposure of
human body  to  toxic substances  may affect multiple organ systems and cause
morphological, biochemical and physiological changes, including impaired kidney
function and hematological disorders.229-231 Hematopoietic system is the main target of
some drug which adversely affects heme synthesis enzymes, normal production rate of
erythropoietin, normal range, morphology and distribution of various blood cells.232, 233
Toxic drugs damage erythrocyte and affect its oxygen carrying capacity thereby increase
risk of developing hypertension and cardiac arrest.234 Factors contributing to
pathogenesis of anaemia include, shortened RBC survival, marrow suppression by
uraemic toxins, iron or folate deficiency. Damage of peritubular cells especially due to
the exposure to toxins resulted in inadequate secretion of erythropoietin. In this study, it
was observed that haematological parameters were significantly affected due to the
administrtion of GM. Fall in the hemoglobin content, red blood cells counts count,
packed cell volume, mean corpuscular hemoglobin level and elevation of white blood
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cells count and polymorphs were observed in animals in toxic control group. These
effects may cause defective hematopoiesis, anemia and weakness in experimental rats.
Overall, results of this study suggested that the animals co-administered with
standard/extract showed significant reversal in the hematological parameters that
observed in animals in toxic control group and showed an improvement in hematological
status. Ebtihal et al.,235 narrated that that concurrent administration of Acacia senegal
with GM reversed reduction in haemoglobin, red blood cells count,  packed cell volume
that  observed in toxic control animals.
This study further demonstrated significant elevation of serum levels of
creatinine, uric acid, blood urea nitrogen (BUN) and lowering of serum level of total
protein, albumin, sodium, calcium and magnesium in GM-treated rats compared to
animals in control group. This result revealed failure of kidney’s ability to filter waste
products or to conserve cations adequately.  Preclinical studies in agreement with the
present findings, Chatterjee et al.,236 Qadir et al.,237 Vidya et al.,7 reported significant
elevation of serum creatinine, BUN, uric acid levels in animals in  toxic control group.
Drug induced nephrotoxicity associates with decreased activity of sodium-potassium-
ATPase and disturbances in the electrolytes which are manifested by hyponatremia,
hypomagnesaemia, hypocalcaemia and hypokalemia. Drug induced nephrotoxicity
induces destruction of proximal and distal tubules leading to decreased reabsorption,
increased vascular resistance and this caused the elevation in BUN, uric acid and
creatinine levels.238 In current study significant  change in serum total protein and
albumin levels were not observed in GM+EEBS-treated group, however co-therapy with
quercetin exhibited significant elevation, compared to the rats in toxic control group. In
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contrast to our findings, elevated level of serum total protein and albumin in GM-treated
group were reduced significantly in animals treated with aqueous extract of Khaya
senegalensis.239 In this study significant changes in serum level of sodium and potassium
were not observed in EEBS/quercetin-treated group, compared to animals in toxic
control. These findings were similar to the study conducted by Cekmen M et al.240 Co-
therapy with EEBS/quercetin in GM-treated animals restored the elevated serum level of
BUN, creatinine, uric acid and diminished calcium and magnesium levels. These results
confirmed that EEBS possessed significant protective effect against drug induced
nephrotoxicity in a dose dependent manner. Co-administration of M. piperita with
gentamicin successfully elevated serum calcium level compared to GM-treated
animals.241 Vamsi et al.,242 reported that GM intoxication resulted in elevated serum
urea, BUN, uric acid, and creatinine levels which was found to be significantly lowered
in dose-dependent manner in groups received Daucus carota L extract.
Gentamicin is highly charged and water soluble at physiological pH and hence,
exhibits less penetration through biological membranes.39 This leads to the accumulation
of drug in proximal tubules and enhance hydrogen peroxide production. This causes
release of iron from mitochondria membranes and promote complex formation with
gentamicin which further hasten the production of reactive oxygen products.42 This
further resulted in lipid peroxidation and decrease in antioxidant enzyme levels.243
Endogenous antioxidative enzymes like superoxide dismutase, catalase, glutathione
peroxidase and reduced glutathione possess excellent antioxidant activity by neutralizing
or scavenging various free radicals. Decrease in these enzyme activities cause
accumulation of lipid peroxides and induce oxidative stress.244-246
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Superoxide dismutase associate with the convertion of superoxide radicals to
oxygen and hydrogen peroxide and considered as a major defense against reactive
oxygen species.247 Catalase involved in the conversion of hydrogen peroxide to water
and oxygen.248 Soluble tripeptide  reduced glutathione  (GSH) acts as an antioxidant and
a redox buffer.249 Drug induced nephrotoxicity induce oxidative degradation of lipids
which leads to a process called lipid peroxidation.250 The extend of  lipid peroxidation
can be measured based upon the  amount of malondialdehyde (MDA) formed. MDA
level increases with degradation of lipid.  In this study, it was observed that co-therapy
with EEBS in GM-treated animals significantly restored the level of SOD, CAT, GSH
and  MDA, thereby inhibited the changes associated with oxidative stress.   The results of
our study demonstrated that EEBS exhibited significant antioxidant activity in both in
vitro and in vivo studies. Our results were in accordance with the previous studies of
Guruvayoorappan et al. 108
6.6.2. Cisplatin-induced nephrotoxicity
Renotoxicity is a common adverse effect of chemotherapy and degree of toxicity
depends on accumulation and binding of the substance in kidney. Nephrotoxicty is a
common complication of cisplatin (CDDP), a platinum compound used to treat cancer.
Inhibition of protein synthesis, DNA damage, mitochondrial injury, inflammation,
oxidative stress and apoptosis are the major mechanism associated with CDDP-induced
nephrotoxicity.
In this sudy, statistically  significant decrease in body weight and an increase in
kidney weight were observed in the negative control group treated with single dose of
CDDP (8 mg/kg;i.p.). Weight loss of animals  might be closely related with poor food
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intake, stress,  increased catabolism or physiological imbalance. Rats co-treated with
EEBS/quercetin demonstrated subsequent increase in body weight. The increase in
kidney weight of animals in negative control group treated with CDDP may be associated
with inflammation or edema due to drug induced nephrotoxicity. Significant weight
reduction of kidney was observed in animals co-treated with EEBS/ standard which
might be due to its anti-inflammatory action. Our findings were consistent with the report
of Fatemeh M et al.,251 during the investigation of nephroprotective activity of
Pomegranate flower extract against CDDP-induced nephrotoxicity.
In our study, animals treated with CDDP showed a significant increase in urine
output. This study result revealed CDDP-induced non-oliguric acute renal failure and this
effect perhaps due to reduction in the gene expression of aquaporines and their density in
the proximal tubule.252 Administration of the EEBS and quercetin to  CDDP-treated rats
for nine days caused reduction in urine volume, but statistically not significant. Our
findings were similar to the report of Md-Azmat et al.,253 during the investigation of
nephroprotective activity of  etahnolic extract of Bauhinia purpurea extract against
CDDP-induced nephrotoxicity.
In this study urinary pH value was markedly lowered (5.93±0.12) in animals
treated with CDDP. Urinary pH value decreases with increase in degree of kidney injury.
In our study significant change in urine pH were observed among animals co-
supplemented with extract/ standard, compared to group II animals.  Ashish M and
Ashutosh P,254 reported that urine pH was higher in CDDP-treated group and rats treated
with extract of Ocimum sanctum showed significant reduction in urinary pH.
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Proteinuria observed in animals treated with CDDP indicating renal damage and
proximal tubular dysfunction. 222 In current study, proteinuria and albuminuria were
significantly reduced in animals co-administered with high dose of EEBS indicating the
nephroprotective role of extract. Our findings were similar to the study report of
Kaveripakam S and Adikay S.255
Previous study reports demonstrated significant elevation in urinary excretion of
sodium, potassium, calcium and magnesium level in animals induced with
nephrotoxicity, 224, 225 however, disturbance of  this electrolyte homeostasis is less well
documented . In current study urinary electrolyte level (potassium, calcium and
magnesium) were significantly elevated in animals treated with CDDP, revealing specific
membrane or transport system abnormality.226, 227 Concurrent administration of EEBS
with CDDP showed a significant reduction in calcium excretion. Thus, prevention of
hypercalciuria may probably be attributed to the protective effect of EEBS in CDDP-
induced nephrotoxicity. Hassan et al., reported that pretreatment with grape seed extract
and fish oil significantly decreased CDDP-induced elevation of urinary excretion of
sodium, potassium and calcium levels in urine.256
In our study, total WBCs and polymorphs were significantly (p<0.01) elevated in
CDDP-treated animals indicating infections in the body due to kidney injury. The
elevation of WBC and polymorphs level may be due to its adverse effects on
haemopoietic system.257 Co-treatment with quercetin/EEBS significantly (p<0.01)
decreased total WBC and polymorphs level. Lowering level of red blood cells (RBC),
hemoglobin (Hb), mean corpuscular haemoglobin (MCH), packed cell volume (PCV),
lymphocytes in rats treated with nephrotoxic drug may be due to the imbalance between
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the rate of normal production of erythropoietin and their catabolism/ destruction.
Lowering of RBC count indicated that these nephrotoxic drug might induce direct toxic
effect on red blood cells thereby, reducing its life span. These deleterious effects perhaps
as  consequence of  generation of reactive oxygen species. However animals co-
administerd with  EEBS/standard  mitigated toxic effect of drugs by protecting the
hemopoietic stem cells from oxidative damage, thereby restored  fuctional capacity of
blood. EEBS treatment produced a significant reversal in the haematological parameters
exhibited by toxic control animals in group II, which   signify the protective activity of
extract.  These effects on haematology may be attributed to the antioxidant activities of
the phytochemicals, mainly phenolic compound and flavonoids present in EEBS. Present
study results were consistent with the results of Shelkea T et al.,258 in which oral
treatment with Crataeva nurvula reversed the lowering level of  Hb, RBC and PCV
recorded in CDDP-induced hematotoxicity.
In this  study, we found that a single dose of CDDP administration caused
significant elevation in serum levels  of creatinine, uric acid and BUN and lowering of
serum concentration of sodium, potassium and calcium compared to control group,
indicating  renal dysfunction. This toxic effects of CDDP in our study were consisitent
with the study of Badary et al.,259 showing significant elevation in urea and creatinine
levels in CDDP-treated rats, compared to control group. We confirmed that co-
administration of EEBS had beneficial effect on kidney as it restored the elevated serum
level of BUN, creatinine and diminished total protein, calcium and sodium levels. These
findings were in accordance with the results described previously by Kusumoto.260
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Oxidative stress is the major mechanism involved in CDDP-induced
nephrotoxicity through elevation of reactive oxygen species and reduction of the
antioxidant defense system.261, 262 Previous research  studies proved  that CDDP
administrations resulted in  increased formation of free radicals, and heavy oxidative
stress.263-265 As a marker of oxidative stress and lipid peroxidation we evaluated
superoxidedismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), reduced
glutathione (GSH) and malondialdehyde (MDA) levels in kidney homogenate. In this
study, it was observed that treatment with EEBS in CDDP-induced animals significantly
restored the levels of SOD, CAT, GPx, GST and MDA, thereby inhibited the changes
associated with oxidative stress. Our findings were in accordance with the results
demonstrated previously by Yogesh CY et al.266
6.6.3. Ethylene-glycol induced nephrotoxicity
Urolithiasis is a painful disease that afflicts human population since ancient times
and still remain a common problem globally.  Relapse rate is high and more prevalent in
age between 20-40 in both sexes. Kidney stone is a hard mass composed of inorganic and
organic crystals amalgamated with proteins. Stone forming minerals and chemicals that
are excreted in the urine sometimes combine and grow to form very small invisible sized
to large sized crystals. If stone size is small, it will flush out and leave the body through
the urine stream without causing symptoms. If stones grow to sufficient size (at least 3
millimeters) causes obstruction to the ureter. Ureteral obstruction causes post renal
azotemia, hydronephrosis, spasm of the ureter and renal colic. Renal colic is associated
with nausea, vomiting, fever, hematuria, pyuria, and painful urination. Urolithiasis also
induce free radical production and decrease in antioxidant status followed by cell injury
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and cell death. Ethylene glycol, sodium oxalate, ammonium oxalate, glyolic acid are
common agents used for inducing urolithiasis. 267 In this study, male albino rats were
used for inducing urolithiasis, as the urinary system of this experimental animals
resembles that of human. 268 In our study, ethylene glycol (EG) was used to induce renal
stone formation. Accumulation of glycolic acid, a metabolite of EG in kidney is
responsible for toxicity.269 Cystone, a herbomineral formulation, favourably reported as
an effective drug for the treatment of  urolithiasis, crystalluria, urinary tract infections
and edema. It acts on the mucin that binds the stone forming components  together. It
relaxes the smooth muscles of the ureter and the urinary tract and  enables easy passage
of small calculi. It has no toxic effect and also relieves the pain. Previous studies have
proven that this drug is significantly effective in  80%  patients with   urolithiasis.270
Hence cystone was selected as standard drug in this study.
In this study, decreased quantity and frequency of food or water intake were
found to be the major factors involved in weight loss of animals in calculi-induced group.
Physiological imbalance and/or mental stress may be the other factors influencing weight
reduction.271 Co-administration of EEBS/Cystone (standard) improved diet (frequency
and quantity), water intake and this cause subsequent increase in body weight. Kidney
weight was significantly increased in calculi-induced group compared to normal control
group. Significant weight reduction of kidney was observed in animals co-treated with
EEBS/Cystone, which might be due to the increased excretion of stone forming
chemicals or due to the anti-inflammatory action. Decreased urine output plays a
prominent role in inducing urolithiasis. 272 In current study, rats co-administered with
curative dose of EEBS (250 mg/kg;from 15th day till 28th day; p.o.), preventive dose  of
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EEBS (500 mg/kg; from 1st day till 28th day; p.o.) and Cystone (standard) increased urine
output in a dose dependent manner along with normalization of pH. Effect of EEBS in
experimental animals confirmed that the diuretic activity promotes flushing out of
deposits thereby inhibiting saturation and precipitation of stone forming constituents. The
results obtained were consistent with the findings of Aseesh KG et al.,273 during the
evaluation of antiurolithic potential of Kigelia africana fruits. Nucleation and aggregation
of crystals in urine is pH dependent. Acidic urine favours uric acid stones formation,
whereas calcium oxalate and calcium phosphate stones occur in highly alkaline urine.274,
275 In this study, pH of urine was found to be 8.2±0.11 in EG-treated animals, which
favoured formation of kidney stones. Treatment with plant extracts (EEBS 500 mg/kg)
significantly reduced urine pH to 6.9±0.10. Our results obtained were similar to the study
done by  Lulat SI et al.,276 during the evaluation of lithocare against ethylene glycol
induced urolithiasis.
Proteinuria observed in our study indicates renal tubular dysfunction. Total protein levels
were significantly reduced in animals treated with EEBS/Cystone, however no statistical
differences were observed in albumin level among rats treated with extract/ standard,
compared to rats in calculi-induced group. Sharma I et al.,277 also demonstrated that
albuminuria observed in calculi-induced rats were not  significantly lowered  in
experimental rats treated with  aqueous extract of Bergenia ligulata, as compared to
toxic control rats.
28 days of ethylene glycol (0.75% v/v) treatment, increased the risk of kidney
stone formation by raising the level of stone forming chemicals in urine. High level of
stone forming constituentss in the urine induce toxic effects on the renal epithelial cells
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leading to alteration in membrane integrity, generation of reactive oxygen species,
development of oxidative stress, lipid peroxidation and depleted source of antioxidant
enzymes.278 Renal epithelial injury exposed to a variety of crystal adhesion molecules
further promotes retention of stone forming constituents. High concentration of urinary
calcium promotes nucleation, aggregation or retention of calcium oxalate or calcium
phosphate.279 Recurrent kidney stone formation have been prevented in patients treated
with potassium magnesium citrate. Magnesium deficiency promote the nucleation and
retention of renal tubular calcium.  High magnesium level favours binding with oxalate to
form soluble complex, and reduce the availability  of oxalate to form precipitate with
calcium oxalate.280 Excess urinary excretion of calcium and phosphate observed in calculi
induced group in our study indicating an environment appropriate for calcium phosphate
crystals formation. Supplementation with Cystone, EEBS (500 mg/kg) served as
preventive regimen and EEBS (250 mg/kg) served as the curative regimen, significantly
restored the alteration in the level of urinary calcium. Magnesium levels were increased
in animal group treated with high dose of extract, thereby clearly indicated antiurolithic
activity of EEBS. Lulat SI et al.,276 demonstrated that the treatment with lithocare showed
a significant decrease in elevated urinary calcium and phosphate level observed in EG-
treated rats and similar to our study significant improvement in magnesium levels were
also observed.
Haematological parameters were significantly affected by the administration of
EG (0.75% v/v) for 28 days. In present study, lowering of red blood cells count (RBC),
haemoglobin (Hb),  packed cell volume (PCV), lymohocytes and mean corpuscular
hemoglobim (MCH) levels were more pronounced in ethylene glycol induced urolithiasis
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rats, indicating anaemia. WBC and polymorphs were increased showing that the immune
system of animal is affected which might be due to the presence of infections associated
with kidney injury. Animals co-administerd with EEBS showed significant reverseal in
the haematological parameters (RBC, Hb, MCH, lymphocytes and WBC)  that observed
in animals in urolithiasis control group,  signifying  the protective activity of extract. Our
results were consisitent with the study report of Badrinathan S et al.281
Hypoalbuminemia and hypoproteinemia represent nephrotic syndrome, in which
protein is lost through urine due to kidney injury.282 In our findings, decreased serum
total protein level  observed in urolithiais control rats  were significantly elevated in rats
treated with standard/ extract, where as significant change in albumin level were  not
observed among animals in toxic control, standard or extract-treated rats . Sharma I et
al.,277 demonstrated that significant changes were not observed in total protein level in
calculi-induced rats, compared to rats in normal control group. However, elevated serum
albumin level observed in urolithiasis rats were reduced in experimental animals treated
with aqueous extract of Bergenia ligulata.
Glomerular filtration rate decreases due to the obstruction of urine outflow by
stones in the urinary system or due to the injury of renal parenchyma. This promotes
accumulation of the waste products, particularly nitrogenous substances such as urea,
creatinine, and uric acid in the blood.283 This result also confirmed a significant increase
in serum levels of uric acid, creatinine, blood urea nitrogen, calcium, magnesium and
phosphate in animals treated with EG, compared to animals in normal control. These
nitrogenous substances and serum biochemicals (calcium, phosphate) levels were found
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to be lowered following treatment with EEBS in dose dependent manner. Our findings
were consistent with the study of Shah JG et al.,284 Hussain G et al.285
Previous research study have confirmed enhanced lipid peroxidation and lowering
levels of antioxidant potential in rats supplemented with a calculi-producing diet.286 In
this study EEBS treated animals served both as preventive and curative regimens,
significantly decreased malondialdehyde levels and increased activity of antioxidant
enzyme level of superoxide dismutase  and glutathione peroxidase in comparison with
animals in calculi-induced group, thereby inhibiting the changes associated with
oxidative stress. The results obtained were consisitent with the findings of Dixit P et al.287
6.7. Histopathological studies
Histopathological examination of kidneys substantiated the results obtained from
in vivo evaluation of antiurolithic and  nephroprotective activity in animals. Renotoxicity
in preclinical study can be confirmed by determining the pathological symptoms such as
tubular degeneration, desquamation, necrosis, intertubular hemorrhage, presence of
hyaline casts in tubules, congestion and swelling in glomerulus.288 In this study,
administration of GM (100 mg/kg) and single dose of cisplatin (8 mg/kg) caused acute
kidney injury which were evident by marked  mesangial hypercellularity in glomerulus,
tubular necrosis, tubular degeneration, cytoplasmic vacuolation in the proximal tubules,
intertubular hemorrhage and  swelling in glomerulus, as compared to animals in  control
group.` These pathological symptoms were lowered in EEBS-treated groups which were
evident from mild epithelial vacuolation in the proximal tubules and  mild blood vessels
congestion, thus showing protective effect of drug. It was observed that, amelioration of
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GM/CDDP-induced renal injury was more insightful in rats treated with 500 mg/kg of
EEBS. Our histopathological findings were correlated with those of Sahar M et al.289
Microphotographic analysis of animals treated with EG for 28 days resulted in
dilation of renal tubule, glomerular injury which might be due to the presence of crystals
which causes obstruction in tubular blood flow. Preclinical studies have reported that 28
days of EG (0.75%, v/v) administration in rats resulted in the formation of renal
calculi.290 Group V animals co- administered with EEBS at a dose of 500 mg/kg,
markedly decreased crystal deposition in renal tubules with mild tubular dilation and
blood vessel congestion. Our histopathological results were correlated with those of
Gilhotra U et al.291
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7. SUMMARY AND CONCLUSION
Kidney performs various essential functions in the body including metabolism
and excretion of  exogenously administered  drugs, chemicals and their metabolites.
Hence kidney is considered as a major organ vulnerable to develop various forms of toxic
effects due to drug administration. Today, people have more comorbidties and are
exposed more to therapeutic and diagnostic procedures having nephrotoxic potential.
Therefore, incidence of drug induced kidney injury is dramatically increasing worldwide
and present even among young children and exerts substantial burden to the people.
Urolithiasis is a painful disorder and also leads to morbidities and end stage renal failure.
Several mechanisms are involved in developing drug induced kidney injury including
oxidative stress, inflammation, fibrogenesis and apoptosis. Reactive oxygen species are
considered as the important mediators in drug induced nephrotoxicity. Previous research
studies also reported that formation of urinary stones leads to oxidative stress in patients.
Endogenous antioxidant defense system often produce insufficient protection against free
radicals, hence it is required to supplement antioxidants from external source.
Drug induced kidney injury is a multifactorial process, hence indigenous system
of medicine and traditional herbal remedies  focusing on multiple targets are considered
as effective and safe with minimal side effects.   Various herbal medicines are esteemed
all over the world as a source of therapeutic agent for prevention and treatment of
nephrotoxicity and urolithiasis.  Clinical and preclinical reports indicated that flavonoids
inhibit calcium oxalate and crystal deposition in urine. Polyphenols especially phenolic
and flavonoids are aromatic compounds which possess excellent free radical scavenging
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activity. Plants rich with saponin, disaggregate the suspension of mucoproteins, which
promote crystallization.
In this present study, we have evaluated the nephroprotective and antiurolithic
activity of ethanol extract of whole plant B. sensitivum by selecting experimental models
which included gentamicin-induced nephrotoxicty,  cisplatin-induced nephrotoxicity and
ethylene glycol-induced urolithiasis in rats.
Phytochemical screening indicated the presences of carbohydrates, alkaloids,
steroids, saponins, proteins, aminoacids, falvonoids, tannins, phenolic compounds and
fixed oils in ethanol extract  of B. sensitivum.
Our study also proved that this drug possess considerable amount of flavonoid
and phenolic compounds. In vitro antioxidant and antiurolithic study illustrated that
EEBS possessed significant free radical scavenging activity and excellent inhibiton on
nucleation and aggregation of stone forming constituents in urine, thereby confirming its
lithotriptic effect. Image analysis of  CaOx crystals using microscopic assay, further
confirmed  its lithotriptic activity. Our study also demonstrated cytoprotective activity of
EEBS. Cytotoxicity and DNA fragmentation were observed only at high concentration.
Supplementation of EEBS to drug induced nephrotoxic and urolithiasis rats significantly
restored changes in body weight, kidney weight, urine pH, indicating its nephroprotective
and antiurolithic activity. Diuretic effects were observed in gentamicin-induced
nephrotoxicity and ethylene glycol-induced urolithiasis model. Increased urine output
promotes flushing out of stone forming constituents through urine. Prevention of
proteinuria, albuminuria and hypercalciuria in gentamicin and cisplatin-treated rats,
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hypermagnesuria in gentamicin-treated rats, indicating its nephroprotective activity.
Hypocalciuric and hypermagnesuric effect observed in the ethylene+EEBS-treated
animals, clearly indicating its antiurolithic activity.
Co-therapy with EEBS showed significant reversal in the hematological
parameters that  observed in animals in toxic control group and exhibited  improvement
in hematological status. Treatment with EEBS in GM-induced rats restored the elevated
serum level of nitrogenous waste products and diminished calcium and magnesium
levels. CDDP-treated animals restored the elevated serum level of BUN, creatinine and
diminished total protein, calcium and sodium level. In urolithiasis induced animals,
serum level of calcium, phosphate and nitrogenous substances were lowered, where as
total protein levels were increased in animals co-administered with EEBS. Effect of B.
sensitivum on oxidative stress were evaluated using estimation of enzymatic (superoxide
dismutase, catalase, and glutathione peroxidase) and non enzymatic (lipid peroxidation
and reduced glutathione) constituents in kidney homogenate. Co-treatment with EEBS
significantly restored the level of enzymatic and nonenzymatic antioxidants, thereby
inhibited the changes associated with oxidative stress. Histopathological examination of
kidneys from toxicity induced animals substantiated the results obtained from in vivo
evaluation of nephroprotective, antiurolithic and antioxidant activity.
Thus the results obtained from nephroprotective and antiurolithic investigation
provided sufficient scientific evidences about the use of B. sensitivum for the treatment of
drug induced kidney injury. These activities attributed to the presence of
phytoconstituents present in B. sensitivum.
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Hence, we may conclude that the whole plant B. sensitivum used alone or in
combination with other herbal or synthetic drugs may have promising nephroprotective
and antiurolithic effect.
Impact of the Study
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8. IMPACT OF THE STUDY
Current study highlighted the nephroprotective activity of ethanol extract of B.
sensitivum in gentamicin and cisplatin-induced nephrotoxicity and antiurolithic effect in
ethylene glycol-induced urolithiasis in rats.  These activities of EEBS can be confirmed
further by doing research works using different toxic agents or solvent extracts.
Our findings warrant advanced analytical research on isolation, identification and
purification of phytoconstituents present in B. sensitivum responsible for the
nephroprotective and antiurolithic activity.
We also recommend to evaluate pharmacological studies, molecular mechanism
of action and potential usefulness of B. sensitivum as an alternative nephroprotective and
antiurolithic agent.
Further pharmacokinetic, toxicological studies and clinical evaluation are needed
before usage in human.
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